Indirect T Cell Allorecognition and Alloantibody-Mediated Rejection of MHC Class I-Disparate Heart Grafts by Pettigrew, Gavin J
INDIRECT T CELL ALLORECOGNITION AND ALLOANTIBODY-
MEDIATED REJECTION OF MHC CLASS I-DISPARATE HEART
GRAFTS.
By
Gavin J. Pettigrew
A thesis submitted to the University of Glasgow towards the degree of Doctor of
Medicine
Transplantation Laboratories,
Department of Surgery,
44, Church Street,
Western Infirmary,
Glasgow, G11 6NT.
© Gavin J. Pettigrew, 2001.
ProQuest Number: 13833993
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13833993
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Indirect T cell allorecognition and alloantibody-mediated rejection of MHC 
class I-disparate heart grafts.
Gavin J. Pettigrew 
Abstract
The T cell allorecognition pathways responsible for the rejection of MHC class I 
disparate allografts remain poorly defined. The respective contributions o f the 
‘direct’ recognition of the allogeneic class I molecule by recipient CD8 T cells, and 
the ‘indirect’ recognition of processed allo-class I MHC peptide fragments by 
recipient CD4 T cells, requires clarification. Recent studies in the rat have 
established a role for T cell dependent antibody. MHC class I disparate PVG.R8 
(RT1.A3) heart grafts are rejected acutely in naive, and hyperacutely in sensitised, 
PVG.RT1U recipients by CD4 T cell dependent alloantibody. This thesis explores 
the T cell allorecognition pathways responsible and demonstrates that direct 
injection of plasmid DNA encoding a truncated, water-soluble sequence o f the 
RT1.A3 heavy chain (pcmu-tAa) results in accelerated rejection of PVG.R8 heart 
grafts (MST 2 days). Pcmu-tA3 injection did not generate of an allocytotoxic T cell 
response, but an anti-A3 IgG2b cytotoxic alloantibody response developed. That T 
cell recognition of the class I MHC alloantigen was restricted to the indirect 
pathway was confirmed by CD4 T cell depletion, which abrogated the alloantibody 
response and resulted in prolonged graft survival, rather than accelerated rejection. 
By comparison CD8 T cell depletion had no discernible effect. Priming CD4 T cells 
for indirect allorecogntion by the administration of synthetic 15-mer allopeptides 
spanning the a l  and a2  domains of the RT1.A3 antigen did not stimulate an 
alloantibody response against the intact A3 antigen but the antibody response to a 
subsequent PVG.R8 heart graft was accelerated. Graft rejection was, however, only 
modestly accelerated (MST 4 days). These results suggest that soluble class I MHC 
and allopeptides are equally efficient at priming CD4 T cells by the indirect 
pathway, but that soluble class I MHC is a more effective immunogen, not because 
it activates an additional subset of directly restricted T cells, but because its tertiary 
protein structure provides the appropriate B cell epitopes for the development of 
humoral immunity against the graft. This is analogous to the provision of cytotoxic 
T cell help by indirectly restricted T cells and the confirmation that the indirect
pathway may be responsible for the development of effector mechanisms directed 
against intact MHC on donor cells provides the first demonstration of its role in 
effecting accelerated rejection. These results further imply that the potentially 
tolerogenic effects conferred by the ability of soluble donor class I MHC to induce 
apoptosis in the alloreactive CD8 cytotoxic T cell population may be masked by a 
detrimental indirect CD4 T cell response.
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CHAPTER ONE
INTRODUCTION
1.1 Overview
This thesis’ principal experiment involves the transfer o f DNA encoding a major 
histocompatibility complex (MHC) class I alloantigen in a model of rat allograft 
rejection. This experimental system was designed to examine several aspects of 
the alloimmune response; the possible tolerogenic effect of soluble allo-MHC, the 
significance of the alloantibody response, and chiefly, the role of the ‘indirect’ 
pathway of allorecognition in initiating accelerated graft rejection.
The differences between the indirect pathway of allorecognition and the 
conventional ‘direct’ pathway pertain to the critical initial stages of the 
alloimmune response. T cell activation through the two pathways may occur 
simultaneously, and elucidating their respective contributions to graft rejection is 
obviously important, particularly with regards the design of future tolerogenic 
strategies. The principles of direct allorecognition were perceived in the 1950s, for 
they are simply an extension of the seminal experiments that established graft 
rejection as an immunological process. Indirect allorecognition has, by contrast, 
become prominent only over the last decade. In order to directly compare the two 
pathways of alloantigen presentation, one has to consider not only the historical 
data concerning the elucidation of the cellular basis of graft rejection, but also the 
subsequent discoveries of the structure of MHC, and of the nature of antigen 
processing and presentation, which were fundamental to the development of the 
concepts of indirect allorecognition.
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1.2 Historical Perspective
1.2.1 The Discovery o f  the Major Histocompatibility Antigens
The elucidation of the nature of the major histocompatibility complex (MHC) was 
initiated by Gorer’s observation that the serological reaction between the red cells 
of different mouse strains could be mapped to a single dominant gene (1). He 
subsequently demonstrated that the product of this gene, ‘antigen II’, was equally 
critical for tumour graft rejection; the eventual loss of a ‘Strong A ’ strain’s 
susceptibility td a sarcoma cell-line, upon repeated back-crossing with a resistant 
C57 strain, correlated with the acquisition o f the C57 allele for antigen II (2). In 
conjunction with Snell, Gorer was able to extend these observations by studying 
newly developed ‘congenic’ strains, which had been established using 
backcrossing techniques. They found in all the strains studied that a similar 
antigenic locus was responsible for tumour cell rejection, but that each strain 
exhibited a different allele at this locus (3). They thus established the first major 
histocompatibility complex, now known as MHC class I, and presciently 
suggested that it possessed a Tong series of alleles’.
It took over 20 years to establish that another group of ‘lymphocyte-defined’ 
antigens were largely responsible for stimulating proliferation in mixed leukocyte 
culture (4-6). These antigens mapped to the Ir region and were subsequently 
established as a second form of MHC antigen, the MHC class II antigens (7, 8).
1.2.2 The Elucidation o f  the Effector Mechanisms o f Graft Rejection
Tumour cell rejection in Gorer’s experiments was associated with the 
development of antibody against the tumour cell (2). This antibody was able to 
agglutinate or lyse other cells in vitro that displayed the same ‘antigen II’ 
haplotype as the tumour cells and Gorer’s experiments therefore provided a 
mechanism through which the recognition of a histocompatibility antigen could 
result in rejection. This humoral effector mechanism was uncontested for a decade 
until Medawar, as a result of studying the rejection of skin grafts in humans (9), 
and outbred rabbits (10-12) illustrated two principles that have governed 
transplant immunology to this day:
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1. Allograft rejection is an actively acquired immunological phenomenon, with 
second set skin grafts of the same phenotype as the donor undergoing 
significantly more rapid lymphocyte infiltration and rejection.
2. A cellular, rather than humoral effector mechanism governs graft rejection.
The latter statement was initially based on the observation that rejection correlated 
with lymphocyte infiltration into the graft, rather than the presence of anti-donor 
antibodies. The importance of cellular over humoral mechanisms of graft rejection 
was confirmed by the demonstration that immunity could be adoptively 
transferred into naive animals by transferring lymphocytes from animals primed 
with donor antigen.
It has since become appreciated that the small lymphocyte can effect graft 
rejection through two mechanisms. Firstly, by infiltrating the graft, small 
lymphocytes can release the necessary inflammatory mediators responsible for the 
recruitment and activation of an effector macrophage population which, as noted 
by Brent, is analogous to a delayed type hypersensitivity (DTH) response. He was 
able to reproduce its typical features of neutrophil and monocyte infiltration, by 
the subcutaneous injection of donor spleen cells into animals previously primed 
with a donor skin graft (13, 14). A second cellular effector mechanism was 
proposed upon the observation that lymphocytes recovered from recipients that 
had already rejected a graft were able to directly lyse donor cells in vitro (15-17). 
This effect could not be reproduced using lymphocytes from naive donors, 
suggesting that these cytotoxic lymphocytes developed in vivo and as such, 
represented a powerful mechanism by which graft cells could be destroyed.
The development of the mixed leukocyte culture to enable the generation of 
cytotoxic lymphocytes has also provided an in vitro model for dissecting the 
mechanics of alloreactivity. The demonstration of cognate interactions between 
cultured cells (18) and of the intrinsic involvement of the H-2 complex in this 
interaction (19), resulted in the eventual elucidation of the nature of antigen 
presenting cells (APCs) (20), and also of MHC-restriction (21-23). In short, the 
use of mixed leukocyte culture clarified the integral components of the allo-
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immune response; that graft rejection was initiated as a result of recipient T cell 
recognition of allo-MHC on the surface of donor APCs.
By the 1970s it had been established that an allogeneic graft was destroyed 
through a combination of three basic mechanisms:
1. A cytotoxic T cell response.
2. A DTH-like response due to the activation of recipient T cells within the graft.
3. An antibody-mediated response.
The earlier concept of alloantibody-mediated graft destruction had been largely 
discounted following the elucidation of the cellular mechanisms of graft rejection 
and the demonstration that alloantibody could enhance graft survival (24). 
However, alloantibody regained prominence upon the demonstration that the 
presence of alloantibody correlated with the development of hyperacute rejection 
(25).
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1.3 The Major Histocompatibility Complex
1.3.1 Class I  and Class II MHC Structure
Klein (26) proposed the general categorisation of MHC into class I and class II 
antigens upon the discovery that MHC could be structurally separated into two 
forms, and that this division correlated with the previous functional definition into 
either serologically-defined or lymphocyte-defined antigens. Class I and class II 
MHC molecules are members of the immunoglobulin (Ig) superfamily (see (27) 
for review). They are membrane glycoproteins, which have evolved by mutation 
and tandem duplication of the Ig domain gene and have similar structures. Both 
have four surface Ig domains, a transmembrane domain, and a cytoplasmic 
domain (28) (see Figure 1.1). Of the four surface Ig domains, the pair adjacent to 
the cell membrane are typical V-region-like Ig domains. In comparison, the 
outermost pair have a sheet and helical structure, such that, of seven p □ strands, 
the first four fold to form a p-pleated sheet and the remaining three form a long a- 
helix. The two membrane distal domains are aligned face to face, resulting in the 
sheet strands forming a single continuous anti-parallel P-pleated sheet.
The structural components of the extracellular domains differ in the MHC class I 
and class II antigens. In MHC class I antigens, the a l  and a2 domains of the 
44kDa a  chain form the membrane-distal domains. The a-chain also contains a 
third domain, a3, which forms one of the membrane-proximal domains. A smaller 
12kDa conserved molecule, p2 -microglobulin, forms the final membrane-proximal 
domain (see Figure 1.1B). The class II structure is assembled from a pair o f non­
identical protein chains, a 32kDa a  chain and a 28kDa p chain. Each of these 
chains is composed of two domains; a membrane proximal Ig-like domain and a 
membrane distal domain that has a P-pleated sheet and a-helical-like structure. 
Both the a  and p chains of MHC class II molecules contain transmembrane and 
cytoplasmic domains, whereas these are present in only the a  chain of an MHC 
class I molecule (see Figure 1.1 A)
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p a
a-helix
P-pleated sheet 
Ig domain
Transm em brane domain
Figure 1.1 Schematic representation of the MHC structure.
A) MHC class II.
B) MHC class I.
p 2 represents the p 2 -microglobulin light chain. Adapted from Halloran (28).
Although it was appreciated that the MHC was responsible for presenting peptides 
(29, 30), Bjorkm an’s crystallographic elucidation o f  the fine three-dimensional 
structure o f  MHC class I (31, 32) established that the a l  and a 2  domains were 
arranged such that they formed a groove for peptide binding, with the p-pleated 
sheets contributing the floor, and the a-helices the side walls, o f  the groove. More 
recently, the crystallographic structure o f  MHC class II antigens has also been 
established (33, 34). Class II antigens have a generally similar three-dimensional 
structure to class I antigens, with the peptide binding groove formed as an 
interchain dimer o f  the a l  and pi domains in an analogous fashion to the a l  and 
a 2  domains o f  the class I structure. In contrast to the MHC class I structure, the 
peptide-binding cleft o f  class II antigens is open at either end. This difference is 
due to the nature o f  the amino acids found at either end o f  the peptide binding 
cleft. Class I antigens tend to have bulky amino acids, such as tryptophan in these 
positions, whereas the corresponding amino acids in class II structures are 
commonly those with smaller side chains, such as asparagine, which do not block
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the ends of the cleft. These differences account for the ability of MHC class II 
molecules to bind longer peptides than class I molecules, as peptides are able to 
protrude from either end of the cleft.
1.3.2 Organisation o f  the Rat MHC (RT1)
The rat MHC, RT1, is approximately 3200 kilobases (3 centimorgans) long and is 
located on the short arm of chromosome 20 (35). Figure 1.2A depicts the genetic 
map as deduced through serological, biochemical and phenotypical analysis. 
Figure 1.2B represents the physical map of RT1, as obtained by using sequencing 
and restriction fragment length polymorphism (RFLP). (36). The MHC can be 
broadly divided into three sequential regions, I, II and III. The murine MHC 
differs from other species studied, in that it has undergone a major translocation 
event, which has resulted in the class II and class III loci being located between 
the major class I loci.
1.3.2.1 Class I  MHC loci
Classical class I MHC antigens (la) are characterised by their polymorphism, their 
capture and binding of peptide, and their ability to elicit an allo-cytotoxic and an 
allo-humoral response. Other class I loci, the so-called non-classical, or lb 
antigens, have been recognised and their products are frequently serologically 
undetectable (see (37, 38) for review). Those that are expressed are generally 
monomorphic and these antigens do not appear to have strong antigen presenting 
functions.
Classical MHC Class I  Antigens (la)
The functional la antigens of the rat MHC are located in the RT1.A region. The 
degree of polymorphism in this region is much less marked than in other species. 
This is due to the presence of only one locus for the classical antigens within this 
region (39-41), in comparison to other species that usually express between two 
and four loci. The number of alleles within this locus is similarly reduced and has 
been estimated serologically at twelve (42, 43).
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Figure 1.2 The current status of the genetic and physical maps of the rat 
major histocompatibility complex.
The genetic map (A) is based on data from serological, biochemical and 
phenotypical studies. The physical map (B) is based upon sequencing and RFLP 
data. The symbols E'(4) and C'(4) indicate four E-like and four C-like loci, 
respectively. Abridged from Gill (36)
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To date nine alleles have been sequenced; RT1.A3 (39), RTl.A n (44, 45), R T l.A b 
(46), RT1.AU (41), RT1.A1 (47, 48), RT1.AC (40), and more recently, RT1.A0, 
R Tl.A f, and R Tl.A g (45). The RT1.AC (40), RT1.A0 and R Tl.A f (45) haplotypes 
are unusual, as sequencing reveals that each contains two distinct class I antigens, 
presumably because a second class I locus is present within the RT1.A region, as 
is the case for example with RT1 .A° (RT1 .A lc and RT1 .A2C) (40).
Although other la loci are present within the rat MHC, they do not appear to have 
a strong function as antigen presenting molecules and are frequently mono- or 
oligo-morphic. They behave, at most, as minor transplantation antigens. For 
example, the classical MHC class I region additionally contains the antigens 
RT1.K (Pa) and RT1.F. Only one serotype of the Pa antigen has been sequenced
(49), but three different alleles are responsible for differing levels of its expression
(50), and these are inherited according to simple Mendelian genetics (51). Pa is 
thought to function as an immunoglobulin transporter during pregnancy. The 
RT1.F antigen is similarly monomorphic (52), but its function is unknown.
Non-Classical MHC Class I Antigens (lb)
The remainder of the class I genes, which have been estimated to be as many as 
60 in the rat (53), map to the RT1.E/C/M, non-classical region. They perform a 
wide range of functions. Many are simply pseudogenes without an identifiable 
gene product, and either provide a reservoir of class I-like genes for the 
diversification of the classical class I products through recombinant events (54), 
or perhaps represent classical antigens which have been superseded during the 
evolution of the MHC. Non-classical antigens are unable to bind as wide a 
diversity of peptides as the classical antigens. Several have been identified in 
humans and the mice that can bind specific ligands. They may be pivotal in the 
response against certain bacteria, viruses and heat shock proteins (hsp) (55, 56). 
Functional, non-classical class I antigens may however be more revalent in the rat 
as a means of compensating for the otherwise limited polymorphism at the 
classical locus. Leong et al (57), for example, have recently described an RT1.U 
antigen which maps to the RT1.E/C/M region and is closely related 
phylogenetically to the classical antigens. It is serologically detectable, elicits a
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cytotoxic T cell response, and possesses typical residues at the conserved sites 
required for peptide binding.
1.3.2.2 Class II MHC loci
The gene density within the MHC class II region is relatively low, approximately 
one gene per 40 kilobases, and large stretches have been sequenced without 
detecting recognisable genes. Recombination events within such low-density areas 
are relatively rare, and mapping has confirmed the strikingly similar basic 
organisation o f the region in the human, mouse, and rat (58) (see Figure 1.3). The 
rat has two functional classical class II loci, RT1.B and RT1.D, which correspond 
to the human DQ and DR antigens respectively. The DR antigen is amongst the 
most polymorphic of the human MHC antigens. In comparison, the rat B and D 
antigens apparently exhibit limited polymorphism, in that there are only eleven 
serologically defined class II antigens (a-d, f, h, k-n, and u) (59). Nucleotide 
sequencing of the D locus confirms the presence of relatively few alleles; the 
R T l.D a locus carries a virtually identical allele for every rat strain studied, and 
only 6 different alleles have been discovered for the RT1.DP locus (60). However, 
genetic sequencing suggests that the RT1.B region is more polymorphic, with at 
least nine RTl.Bp alleles (61) and six R T l.B a alleles (62) identified. This 
discrepancy in the degree of polymorphism as established by genetic, compared to 
serological techniques has yet to be reconciled. Only one pair of functional a  and 
(3 genes are expressed at the B and D loci, and this again contrasts with the human 
DR antigen, which can have as many as four functional P chains (63). In humans, 
a third class II locus, DP, exists. The equivalent loci in the rat and in the mouse, 
RT1.H and H-2P respectively, do not express functional antigens as their p chain 
components are pseudogenes (64-67).
Within the RT1 class II region, additional sequences code for two non-classical 
antigens. The DM antigen, which is similarly placed in the human (named HLA- 
DM) and mouse genome (named H-2M), appears to have a universal role in the 
exchange of the CLIP peptide for antigenic peptide (68). RT1.DO is also a non- 
classical, monomorphic class II antigen (69). It was initially discovered in the 
HLA as an a-chain gene DN and a P chain gene DO. Subsequent studies on the
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LMP D° bDOa DM
H-2
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DP DN DM DRTap DO DOLMP _  J L h
Figure 1.3 Comparative organisation of the class II major 
histocompatibility region of the rat (RT1), mouse (H-2), and 
human (HLA).
Classical class II loci 
Pseudogenes 
Non-classical loci
analogous mouse antigen, H-20, revealed that these chains could combine into a 
functional protein (70, 71), although tissue distribution is restricted to B cells and 
epithelial cells of the thymic medulla (72). The DO antigen modulates peptide 
loading of class II molecules in the endocytic pathway (see section 1.4.3.5). The 
DOa and DOb alleles are separated by sequences for TAP-A and TAP-B, and 
LMP-2 and LMP-7 (73) whose products are integral components of the class I 
antigen processing pathway.
13
1.3.2.3 Class III MHC loci
Unlike the class I and class II regions, the products of the class III loci do not 
appear to have a common evolutionary origin. They consequently perform an 
eclectic range of functions, but these are generally connected with the immune 
response. It may be that mutation to incorporate their genetic sequences into the 
MHC was associated with an evolutionary advantage. Products identified to date 
include the complement factors, C2, C4, B f (74, 75) and several soluble proteins 
such as TNF-a and hsp70 (76, 77).
1.3 3 Genetic Organisation o f  the Rat Class I  and Class II MHC Antigens.
For eukaryotic genes, the genetic coding sequence is divided into a series of 
sections known as exons, which are separated by non-coding sequences called 
introns. The boundaries between introns and exons are marked by specific 
nucleotide sequences, frequently AGGTAAGT and TCNCAGG. For members of 
the Ig superfamily, exons generally correspond to the domains of the protein. The 
first exon contains the message for the leader sequence, including the signal 
peptide. This guides the nascent peptide through the endoplasmic reticulum and is 
cleaved before final maturation.
SS otl cx2 a3 TM Cyt 3'UT
SS p TM 3'UT
Figure 1.4 Exon-intron organisation of the heavy and light chains of class I 
MHC genes.
A) a-heavy chain of a class I MHC gene
B) P2 -microglobulin light chain.
SS -signal sequence 
TM -transmembrane domain 
Cyt -cytoplasmic tail 
3'UT - 3 'untranslated region
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MHC class I genes typically span 4000 to 5000 bases and contain eight exons 
(Figure 1.4A), with two exons coding for the cytoplasmic tail, and the final eighth 
exon untranslated. The gene for the non-polymorphic p2 -microglobulin molecule 
is composed of four exons, although the majority of the actual coding sequences 
originate from the second exon (Figure 1.4B). MHC class II genes are similarly 
arranged. Only one exon, however, codes for the a  chain transmembrane and 
cytoplasmic domains, whereas separate exons code for each in the p chain gene. 
There is an additional, non-expressed p chain gene at each of the major class II 
loci, which is located to the left of the B region and in the middle of the D region 
(78) (Figure 1.5).
Bp2 Bp Ba Dp Dp2 Da
RT1.B RT1.D
Figure 1.5 Genomic organisation of the class II alleles of the rat MHC.
Arrows indicate the direction of transcription.
a  alleles 
P alleles 
Pseudogenes
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1.3.4 MHC Gene Transcription
1.3.4.1 Transcription Machinery
As with most eukaryotic genes, MHC sequences typically contain the conserved 
TATA and CCAAT elements in their upstream promoter (Figure 1.6). The TATA 
box, which is situated approximately 30 bases upstream of the initiation of 
transcription, acts as the core promoter, to which the basal transcription initiation 
complex binds. This consists of at least five factors, and transcription is initiated 
upon binding of RNA polymerase II to these factors (see (79) for review). 
Termination of transcription occurs at a variable distance (frequently hundreds or 
thousands of bases) downstream of the termination codon. The nascent mRNA 
sequence is modified in three ways. Firstly, a methylated guanine residue is 
attached to the 5' end of the molecule, at a specific ‘cap’ site. Secondly, a poly 
adenosine tail is added to the 3' end of the molecule by a specific polymerase, 
which is triggered by the AAUAAA signal in the 3' non-coding region. The 
nascent mRNA finally undergoes endo- or exonucleotyic cleavage to remove the 
introns, followed by exon splicing to form the mature mRNA sequence.
promoter
t------K------■\
CAAT TATA
Poly(A) 
AATAA addition site
Enhancer box box ATG
^  ^  ^  Exon 2 Intron Exon 2
-100 -30
Cap
site AGGTAAGT
Termination
Py()1)NCAGG
Figure 1.6 Transcriptional machinery for a typical eukaryotic gene.
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1.3.4.2 The Regulation o f  transcription
In addition to the TATA and CCAAT elements, there are a number of cis-acting 
enhancer sequences within the upstream promoter, whose features are conserved 
and specific for each class of MHC gene. The binding of various regulatory 
proteins to these enhancers alters the rate at which the polymerase complex 
transcribes the upstream message. Four enhancer elements have been identified 
within the class I promoter region; the enhancer A element, the interferon 
stimulated response element (ISRE), site a , and the enhancer B element (Figure 
1.7A) (80). The enhancer A element is a possible ligand for the binding of the five 
proteins of the NF-kB family (81). The binding of interferon regulatory factors 
(IRF) 1 and 2 to the ISRE site results in increased and decreased rates of 
transcription respectively. This provides a mechanism by which IFN-y can 
regulate transcription, since the levels of IRF are IFN-y sensitive (82). The ligands 
for the site a  are unclear, but occupancy of this cis-acting, regulatory element 
appears to be necessary for ISRE-induced transactivation (83). Finally, the 
enhancer B element represents an inverted CCAAT box, and is an essential 
component of class I activation (84). The clustering of these enhancer areas within 
the class I promoter suggests that they act in a synergistic fashion upon class I 
transcription.
kB2 kB 1
Enhancer A ISRE Site a  Enh.B CCAAT TATA
W/S XI X2 Y CCAAT TATA
Figure 1.7 Promoter structures of MHC class I and class II genes.
A) MHC class I promoter structure.
B) MHC class II promoter structure.
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For MHC class II genes, the upstream promoter elements include W/S, X, and Y 
boxes (Figure 1.7B) (see (85) for review). The X box consists of XI and X2 
halves. Five members of the ‘RFX’ family of transcription factors (RFX1-RFX5) 
interact with the XI box, although only RFX5 has been observed to induce class 
II transcription. RFX5 binds to the box, as part of a sub-unit of an RFX complex, 
which also contains an RFX-associated protein (RFXAP) and a p41 protein, 
whose identity is unknown. Although several protein families have been identified 
that can bind to the X2 box, only the X2 binding protein (X2BP) is crucial to class 
II transactivation. The W/S box has a similar sequence to the XI box, and also 
binds the RFX complex. Precise spacing of the W/S box in relation to the X box is 
required for class II promoter activity. The Y box is an inverted CCAAT box that 
binds, amongst other proteins, NF-Y. The above proteins do not work 
independently, but collectively form a protein complex, which acts as a basic 
regulatory module on the W/S-X-Y region (86). Binding of this complex is not 
sufficient for class II transcription. This requires the additional presence of the 
class II transactivator protein (CUTA), which acts as a co-activator by binding to 
the regulatory module at the RFX5 subunit (87). CIITA is expressed constitutively 
only within antigen presenting cells.
The nucleotide sequences of the enhancer boxes are not conserved, but vary 
according to the individual MHC class II gene. Consequently, the enhancer boxes 
of different class II genes bind their respective components (RFX, X2B and NF- 
Y) of the regulatory module with different affinities. Nevertheless, as a complete 
unit the regulatory module appears to bind the class II enhancer region with a 
constant affinity as synergistic RFX-X2BP-X box complexes can be formed on 
the X-box regions of all MHC class II genes in vitro (86, 88). This permits the 
transcription of a  and p chains to be regulated in a co-ordinated fashion.
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1.4 Antigen Processing and Presentation
1.4.1 MHC Restriction and Antigen Processing
The MHC was initially discovered through its ability to initiate an alloimmune 
response. It was subsequently realised that, more importantly, the interaction of 
self-MMC with the TCR was fundamental to any specific immune response. This 
was prompted by the observation that in vitro T cell proliferative responses to 
antigen required an additional population of cells, commonly macrophages (89, 
90). Rosenthal subsequently noted that the macrophage and lymphocyte 
populations had to display the same immune response (Ir) genes (20, 91). It was 
not appreciated that this experiment demonstrated the principles of MHC- 
restriction, as at that time, the nature of the Ir genes was unknown. MHC- 
restriction was first clearly demonstrated by Zingernagel (21-23), who noted that 
virally infected fibroblasts could only be lysed by primed T cells that displayed 
the same MHC class I phenotype. Simultaneously, David and Sachs established 
that the Ir proteins represented a second class of MHC antigen (7, 92). The 
following year Erb and Kappler (93-95) reported a similar restriction phenomenon 
for MHC class II. Subsequently, Cantor demonstrated that T cells could be 
divided serologically into cytotoxic (Tc) and helper (Th) subsets (96, 97), and in 
turn, that each subset was specific for a different class of MHC. Thus the 
principles of T cell activation were established: CD4 helper T cells recognise 
antigen presented by APCs in the context of MHC class II, whereas CD8 
cytotoxic T cells respond to antigen presented by MHC class I.
Knowledge of the APC was still in its’ infancy, and a decade passed before 
Ziegler and Unanue demonstrated that disrupting the lysosomal function of APCs 
prevented MHC class II-restricted antigen presentation (98, 99). It was concluded 
that in such cells antigen was modified, or ‘processed’ before its presentation. 
Towsend et al subsequently confirmed that this also applied to MHC class I- 
restricted antigen presentation (100-102). Understanding of the class I and class II 
processing pathways has increased tremendously over the last decade.
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1.4.2 Class I  MHC antigen processing
The peptides that are ultimately presented by MHC class I molecules are 
generated in the cytosol, by a complex known as the proteosome. The association 
of peptide with nascent MHC class I heterodimers occurs in the endoplasmic 
reticulum (ER), with the transfer of peptides from the cytosol to the ER achieved 
with the aid of the transporter associated with processing (TAP).
1.4.2.1 The Proteosome Complex and Antigen Degradation
The Regulation o f  Proteolysis
Peptide fragments are continuously required to stabilise MHC class I molecules, 
and peptides eluted from surface MHC molecules are generally derived from self­
protein, rather than foreign antigen (103). The generation of self-peptides for 
MHC class I loading requires regulation, otherwise essential self-proteins would 
be needlessly destroyed. The exact mechanisms of this regulation are as yet 
unknown. Yewdell has suggested that proteins that are misfolded, due to defective 
ribosomal synthesis, are more susceptible to protease-digestion (104). Otherwise, 
certain sequences o f a protein may make it more susceptible to digestion. For 
example, the presence of either PEST regions (105) (areas rich in proline, 
glutamine, serine and threonine), or destruction boxes (106) promote degradation.
The commonest means by which proteins are targeted to the proteosome is 
through the conjugation of ubiquitin to the internal lysine residues of the proteins. 
Several enzymes catalyse this reaction and they add additional ubiquitin 
molecules to the lysine residues of already-bound ubiquitin molecules. It is 
unclear how polyubiquitination destabilises protein, but it probably unfolds the 
tertiary structure of the protein and provides a signal for uptake by the proteosome 
(107).
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The Proteosome Complex
The proteosome consists of a barrel-shaped 20s core, which lyses proteins that 
associate with class I MHC molecules (108). In simple archaebacterium, its 
crystal structure reveals a stack of four rings (109). Each ring contains seven 
subunits, which are type a  in the outer rings and p in the inner rings. The inner 
rings additionally contain the proteolytic elements. In higher eukaryotes additional 
subunits, such as a PA28 activator, a PA700 subunit (110) and a 19s ATPase 
complex (111) make up a larger 26s proteosome complex (112). The PA28 
activator is inducible by IFN-y and consists of a hexamer of ap  subunits that 
attaches as a cap to both ends of the 20s proteosome. It increases the spectrum of 
peptides that are generated, partly by increasing cleavage after hydrophobic amino 
acid residues (113), but also by rendering the substrate protein susceptible to 
protease activity at two sites concurrently, resulting in double peptide cleavage 
(114).
In higher eukaryotes only three of the p subunits in each P7 ring are active. Each 
of these possesses distinct proteolytic activities; for example P5 has a 
chymotrypsin-like activity, whereas p2 resembles trypsin. IFN-y, however, 
induces the expression of three additional p subunits, MECL-1, LMP2 and LMP7, 
which compete respectively with the constitutively expressed p2, p7 and p5 
subunits. Their incorporation results in an immuno-proteosome, which alters the 
spectrum of peptides that are generated (115-117). In particular, LMP7 increases 
cleavage after hydrophobic or basic residues, which may improve the efficiency 
with which the resulting peptides bind to nascent MHC molecules. The nucleotide 
sequence of LMP2 and LMP7 are situated within the MHC class II region of the 
genome.
It has generally been assumed that the proteosome strictly regulates proteolysis to 
ensure that the generated peptides are 8-9 amino acids in length. However, 
Kisselev recently demonstrated that the peptide products of archeabacterial 
proteosome varied widely in length with only 15% falling within the 7-9 amino 
acid residue length (118, 119). Neither is the proteosome complex indispensable.
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Mammalian cells can adapt in vitro to its loss by the over-expression of another 
large proteosome particle (120).
1.4.2.2 The TAP Transporter
Once appropriately sized peptides have been generated by the proteosome, they pass 
into the ER. This process is controlled by a heterodimeric transporter complex 
referred to as the transporter associated with processing (TAP). The TAP complex is 
comprised of two subunits, TAP-1 and TAP-2, which are encoded by genes in the 
MHC class II region. Each TAP subunit has an N-terminal hydrophobic region with 
up to eight transmembrane domains. This allows it to straddle the membrane of the 
ER. The peptide-binding site is located on the C-terminal end of the hydrophobic 
segments of both subunits, adjacent to the hydrophilic cytosolic domain (121, 122). 
It is likely that peptides are both bound by their N- and C- terminal regions, with 
looping of the central portion of the peptide (123). This permits the binding and 
transport of peptides as long as 40 amino acids across the ER membrane (124), but 
peptides of 8-13 residues generally bind most efficiently (125). Although TAP is the 
main transporter, subsidiary ones exist (126).
There are two TAP haplotypes in the rat, A and B (127-129) which demonstrate 
linkage disequilibrium with the classical class I antigen (130). The differences in the 
peptides that they transport are profound; in RT1.A3 bearing hosts that normally 
express TAP-A, the Aa antigen becomes immunogenic if it is linked instead to TAP- 
B (131). Genetic mapping and subsequent cloning of the rat transporters (130, 131) 
have identified that the type A and B haplotypes relate to the TAP-2 locus. Alleles at 
this locus exhibit polymorphism, but the alleles of one haplotype can be 
distinguished from the other on the characteristics of 25 amino acid residues in the 
N-terminal two-thirds of the chain (132, 133). TAP-2B is similar to mouse TAP-2, in 
that it has a high affinity for peptides with a hydrophobic C-terminal amino acid 
residue. In comparison, TAP-2A is akin to the human transporter and is much more 
permissive, binding peptides regardless of their C-terminal amino acid residue. It is 
unclear what evolutionary advantage the persistence of TAP-2B provides, as its 
substitution with TAP-2A does not impair peptide loading of MHC class I molecules 
(134). There is no apparent functional polymorphism present in either the mouse or 
the human (125, 135, 136).
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1.4.2.3 Assembly o f  the Peptide-MHC Class I  Complex
The stability of the MHC class I heterodimer is conferred by the bound peptide. 
Without an appropriately bound peptide, nascent MHC molecules do not reach the 
cell surface, but instead undergo degradation within the ER (137, 138). Assembly of 
the MHC-peptide complex requires a series of protein mediators, or chaperones. 
Initially, class I heavy chains associate with calnexin. This is an ER-retained 
transmembrane protein, which aids the appropriate folding and the formation of 
disulphide bonds in the heavy chains (139). [U-microglobulin then binds to the heavy 
chain, and this catalyses, at least in humans, the exchange of calnexin for its soluble 
homologue, calreticulum (140). Two further chaperones subsequently become 
incorporated into the class I complex, the recently discovered ERP57 (141-143), and 
a 48kDa protein, tapasin. Tapasin is a transmembrane protein belonging to the 
immunoglobulin superfamily, and is encoded in the human and murine class II MHC 
regions immediately centromeric to the class II region (144). There is no redundancy 
within the ER for tapasin and it has at least two important functions (145). Primarily, 
it enables the MHC complex to bind to the TAP transporter, and as many as four 
tapasin-MHC complexes can bind to one TAP dimer (146). This multimeric complex 
may enhance the efficiency of peptide loading, by increasing the availability of 
different MHC molecules. Tapasin also directly stabilises empty class I molecules, 
possibly by binding to the a l  and a2 domains of the nascent molecule. This is an 
analogous property to that of HLA-DM in MHC class II peptide loading, and is 
independent of its association with TAP (147). Upon peptide binding, all auxiliary 
molecules are released from the class I molecule and the mature class I complex is 
exported to the cell surface via the golgi and trans-golgi network, and from there 
follows the 'default' pathway of vesicular traffic to the cell surface (148).
1.4.2.4 Presentation o f Exogenous Peptide
Although, the cytosolic proteosome generally degrades endogenous proteins (either 
self or viral), it can also sample exogenous substrates. APCs in particular are able to 
transfer antigens from class II-processing organelles to the cytosol for proteosomal 
lysis (149-151). Additionally, MHC class I can either re-circulate from the cell 
surface into the phagosomal pathway, or perhaps is targeted to the endocytic 
pathway by linking to the invariant chain signal (152).
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1.4.3 MHC Class 11A ntigen Processing
The MHC class II processing pathway presents extracellularly derived antigens to 
CD4 T cells. Nascent class II heterodimers are bound to an invariant chain (Ii), 
whose signal sequence directs the class II complex from the ER to the endosomal 
compartments that process engulfed antigen. There, the Ii is lysed into smaller 
peptide fragments, and the DM antigen catalyses their exchange for antigenic 
peptide. Mature MHC class II-peptide complexes travel to the cell surface by 
mechanisms that are poorly understood.
1.4.3.1 Processing o f  Exogenous Antigen
APCs use several mechanisms to internalise extracellular antigen into their highly 
developed endosomal and lysosomal compartments; receptor mediated endocytosis 
(153), phagocytosis, and macropinocytosis. The relative contribution of each of these 
mechanisms varies according to the class of APC (154). B cells, for example, 
generally recognise antigen through its binding to the Ig surface receptors. The Ig 
receptors are associated on the cell surface with clathrin coated pits that internalise 
antigen to the endosomal pathways. Such receptor-mediated endocytosis permits B 
cells to process and present antigen, specific for their surface immunoglobulin 
receptors, at 103 to 104 times lower concentration than cells which internalise antigen 
non-specifically (155, 156).
In comparison, macrophages and dendritic cells capture antigen by either 
phagocytosis or macropinocytosis. Phagocytosis is initiated by the binding of Ig- 
derived peptides to surface receptors. This activates the cell membrane to form 
pseudopods that initially engulf the bound particle and then internalise it by 
detaching from the membrane as phagosomes. Macropinocytosis (cell drinking) 
generally occurs at clathrin coated pits, but unlike those involved in receptor- 
mediated uptake, the pits are of a larger size, which permits sampling of a greater 
volume of the extracellular milieu. The relative ability of an APC to capture antigen 
equates to the overall efficiency with which that antigen is presented (157).
APCs contain a complex arrangement of distinct endosomal compartments, through 
which internalised antigen is trafficked sequentially. The first structures receiving 
endocytosed material are early endosomes (EE). These are less acidic than later
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endosomes, which limits their proteolytic potential. EEs are specifically concerned 
with the recycling of plasma membrane proteins to the cell membrane. Transfer 
occurs via small vesicles that emanate from the EE tubule (158). Antigens that are 
not recycled are subsequently transported to late endosomes (LE). LEs 
characteristically display numerous small membrane vesicles in their lumens and 
develop from the vacuolar parts of the EE network. They gradually mature into 
lysosomes (159), by progressively accumulating internal membranes, dense waste 
material and specific cell surface markers, such as lysosome-associated membrane 
protein (LAMP).
These changes correlate with the development of protease activity. Protein antigen is 
degraded by a combination of endoproteases, which hydrolyse internal amide bonds 
of proteins, and exopeptidases, which hydrolyse one or two amino acids from either 
end of the target peptides. The enzymes are characterised according to the particular 
'active-site' amino acid residue of the target protein that they recognise. There appear 
to be three major endoproteases; the aspartate protease, cathepsin D, and the cysteine 
proteases, cathepsins L and S (160). Two further cathepsins, B and H, have limited 
endoproteolytic activity, but their function is mostly vestigial (161).
1.4.3.2 Trafficking o f Nascent MHC Class II Dimers through the Endoplasmic 
Reticulum
After translation, MHC class II molecules and the Ii are, in similar fashion to MHC 
class I molecules, co-translationally inserted into the ER, due to the presence of a C- 
terminal signal sequence (162). Chaperones such as calnexin (163, 164) retain class 
II molecules in the ER until they are properly folded and associated with the Ii. The 
association of MHC class II and the Ii occurs through the binding of the class II- 
associated invariant chain peptide (CLIP) portion of the Ii to the MHC class II 
peptide binding groove (164-168). This renders the groove inaccessible to peptides 
present within the ER (see Figure 1.8).
25
Protease inhibitor
IiP41
plO 193 256
TM CLIP Trimer
IiP33
Cytoplasm 30 60 103 163 183 Lumen
N L D Q L R M K L P K P P K P V S K M R M A T P L L M Q A L P M G A L P
Cathepsin S Cathepsin S, others
Figure 1.8 Structure of the invariant chain.
The human P31 isoform is depicted. Important structural features include a 
cytoplasmic sequence involved in endosomal trafficking (shaded), a 
transmembrane domain (TM), the class II associated invariant chain peptide 
(CLIP), and a trimerisation domain (trimer). In addition, a protease inhibitor 
domain occurs in certain isoforms, e.g. P41. Arrows designate probable 
cleavage sites of the CLIP protein by cathepsins. The amino acids in bold 
type are responsible for anchoring the invariant chain to the class II peptide- 
binding groove. Adapted from Chapman (160).
Trimerisation o f Ii chains, as a result of an interaction at the C-termini (169, 170), 
and possibly at the transmembrane trimerisation sequences (165), subsequently 
occurs, resulting in the formation of nonameric MHC class Il-Ii complexes (see 
Figures 1.8 and 1.9). Proteins within the ER are normally expressed at the cell 
surface after transfer through the golgi and trans-golgi network, but nonameric MHC 
class II complexes are diverted into the endosomal network by di-leucine based 
targeting signals in the Ii chain cytoplasmic tail (171-173). This targeting does not 
involve cell surface recycling, and trimerisation of the Ii substantially increases the 
efficacy of the signal sequence (174).
1.4.3.3 Entry into the Endosomal Pathways
In professional APCs, MHC class II accumulates in endocytic structures called MHC 
class II compartments (MIICs) (175). This is presumably their entry point into the 
endocytic pathway as the Ii, which is degraded quickly, is also first detectable in this 
compartment (176, 177). MIIC probably represent the immature LEs found in non­
professional APCs. Certainly, they contain typical lysosomal membrane proteins and
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enzymes (178), and in comparison, the transferrin receptor, whose presence 
characterises EEs, is not present. Recent immunoelectron microscopy has confirmed 
the similarities between the two types o f  vesicle (179). MIICs mature in stages, from 
a multivesicular structure, to an intermediate structure, containing both vesicles and 
membrane sheets, and finally to a multilaminar vesicle, which contains membrane 
sheets only.
Trimerisation
domain
Lumen
Membrane
Cytoplasm
Intracellular 
targeting domain
a  P Ii Nonameric «[3-Ii complex
Figure 1.9 Interaction of the invariant chain with class II MHC.
The invariant chain (shaded) associates with MHC class II a p  heterodimer 
(unshaded). The left panel shows a complex o f  one Ii molecule and a nascent class II 
molecule, whereas the right panel shows trimer association through the trimerisation 
and transmembrane domains to form nonameric complexes. Adapted from Pieters 
(180).
Mellman and others however, have proposed that class II complexes enter the 
endocytic pathway at the EE stage (163, 181, 182), and are incorporated in so-called 
class II-containing vesicles (CIIVs) (177, 181, 183. 184). The significance o f  these 
vesicles is uncertain, for they appear to be morphologically distinct from other 
endocytic compartments, in that they do not contain Ii. The class II molecules within 
these vesicles may have however entered via recycling from the cell membrane 
(185), rather than directly from the ER. Different compartments may moreover be 
more relevant in different types o f  APCs.
Whatever the exact point of entry of MHC class II molecules into the endocytic 
pathway, the associated Ii is degraded rapidly in distinct steps to generate successive 
fragments of 22, 18 and 12kDa (186, 187) (see Figure 1.8). Both cathepsins S and L 
are responsible for Ii degradation, with the former perhaps more important (188). 
Degradation begins at the lumenal C-terminal domain, and by disrupting the 
trimerisation sequence, separates the invariant chains to leave individual MHC class 
II dimer-Ii complexes. The 12kDa Ii fragment that remains after the final cleavage 
contains the CLIP peptide (see Figure 1.8).
1.4.3.4 MHC Class II Peptide Loading
The exact site of antigenic peptide exchange for the CLIP fragment is uncertain, but 
probably occurs in MIICs (177, 182, 186, 189-191). Exchange is generally 
dependent on the HLA-DM (DM) antigen (183, 192, 193) (analogous to H-2M in the 
mouse), which is found in the later MIICs (179, 184, 194-196). DM molecules reach 
this compartment independently of the Ii, as a result of a tyrosine-based signal 
sequence in the cytoplasmic tail of the p chain (194, 197), possibly by binding to the 
internal clathrin-associated adapter protein complexes, API, AP2 and AP3 (198- 
203).
The DM antigen is non-polymorphic and non-classical in that its’ peptide-binding 
groove is closed (204). Mutant human cell lines defective in HLA-DM can only 
generate MHC molecules containing CLIP peptides (205), and similar results have 
recently been obtained in vivo using H-2M-deficient mice (206-208). By binding to 
an MHC class II molecule, DM catalyses peptide exchange by stabilising empty 
MHC class II dimers, thus preventing their degradation, particularly in acidic 
compartments (209). This permits sampling of putative peptides, so that only those 
with high enough binding affinity for the class II dimers are ultimately chosen, while 
those with low affinity rapidly dissociate (193, 210-212). A single HLA-DM 
molecule facilitates serial loading of MHC class II molecules, attaining a turnover of 
3-12 CLIP complexes a minute (213).
MHC class II peptide loading can occur in the absence of DM in several situations. 
For example, certain class II antigens can release CLIP independently (214). This 
ability has been ascribed, in the case of R Tl.A k, to an extremely low affinity for the
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CLIP fragment (215). Certain compartments, notably EEs, lack the DM antigen, but 
are still able to load class II complexes with peptide, possibly because o f a reduced 
affinity for CLIP in their less acidic environment (216).
Once peptide has bound with sufficiently high affinity to a nascent MHC class II 
molecule, DM dissociates, and the mature class II complex is transported to the cell 
surface. This may occur by several mechanisms, most probably by either fusion of 
the multi vesicular MIICs with the plasma membrane (217), or via vesicles detaching 
from tubular extensions of early MIICs (218).
The class II peptide complexes that reach the cell membrane do not necessarily 
remain static, but can recycle into the EEs (185), particularly those complexes in 
which the CLIP fragment has remained bound (219). Recycled class II complexes 
return to the cell membrane directly via small vesicles emanating from the EE 
tubules (158) and do not enter the major class II loading compartments.
1.4.3.5 Regulation o f  MHC Class II Processing
The successful presentation of exogenous antigens depends upon the concurrent 
regulation of several processes. The availability of DM, the efficiency with which 
the Ii is degraded, and the ability to process antigen into suitable peptides within the 
lysosome, may all influence peptide presentation by MHC class II. DM is generally 
expressed at limiting levels within the APC (220), and nascent class II dimers may 
therefore compete for its’ binding; DM-catalysed loading of DR2-CLIP, for 
example, was considerably slowed when DR3-CLIP complexes were added (213). 
Additionally, different APCs contain different isoforms of Ii, which have different 
functions. One such isoform, IiP41 contains a 64 amino acid, cysteine-rich domain. 
This has strong homology to the repetitive segment in thyroglobulin (221, 222), and 
is expressed in 5% of B cells, and in 50% of dendritic cells (223). The additional 
domain probably acts as an inhibitor of cysteine proteases, such as cathepsin L (224, 
225), thus preventing degradation of the CLIP complex past the lOkDa stage (226) 
(see Figure 1.8). This presumably influences the spectrum of peptides that are bound 
to, and ultimately presented by, MHC class II molecules, as the ability of certain 
peptides to displace CLIP may vary depending on the extent to which CLIP has been 
degraded.
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As mentioned in section 1.3.2.2, the DO antigen is expressed in B cells and in the 
thymic medulla. It is a non-classical class II antigen, and appears to antagonise the 
function of DM, for which it has a strong binding affinity (227). It may therefore be 
an important modulator of MHC class II-restricted antigen processing.
1.4.3.6 Presentation o f Endogenously-Derived Antigens by Class II MHC
Cytosolically derived peptides (i.e. endogenous peptides) are normally processed by 
the MHC class I pathway but can, under certain conditions, enter the MHC class II 
pathway. One mechanism by which this may occur is through internalisation of 
membrane proteins into the endocytic pathway. However, although MHC class I- 
derived peptides are naturally associated with surface MHC class II (103, 228), there 
is no direct evidence that internalised membrane proteins undergo degradation (229). 
Cytosolic antigens may alternatively be sampled by the process of autophagy, 
whereby a cistema, presumably of ER origin, randomly engulfs a portion of 
cytoplasm and matures into an autophagic vacuole that subsequently fuses with the 
LE (230). Cytosolic proteins can also be translocated across the MIIC membrane by 
a receptor mediated pump requiring ATP and heat shock proteins (231).
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1.5 Allorecognition
Allograft rejection was conventionally perceived as the result of the ‘direct’ T cell 
recognition of allogeneic MHC molecules on the surface of donor cells. However, 
the realisation that MHC-restricted peptide presentation was equally relevant to the 
thymic selection of the T cell repertoire (232) resulted in the re-evaluation of the 
principles of allorecognition. Specifically, it was necessary to explain not only how 
T cells selected on the basis of self MHC-restriction were able to recognise 
allogeneic MHC, but also why such a large precursor frequency of T cells was able 
to do so. Two possible explanations have been suggested. Firstly, if  one assumes that 
an allogeneic MHC molecule mimics the complex of an antigenic peptide bound to 
self-MHC, then every allogeneic molecule on the surface of a donor antigen- 
presenting cell is a potential determinant for T cell activation. This represents a 
much higher ‘determinant density’ (233) than occurs upon the processing of nominal 
antigen, wherein only approximately 0.1 to 1% of the surface MHC molecules 
express the relevant peptide (see Figures 1.10A and 1.1 OB). An alternative 
explanation for the strength of the alloimmune response is provided by the ability of 
a single MHC molecule to bind many different peptides; each combination of the 
MHC molecule with a different peptide represents a distinct binary complex that 
may be recognised by a different T cell clone (234) (see Figure 1.10C). Experimental 
evidence suggests that the ‘high determinant density’ and ‘multiple binary complex’ 
theories both contribute to the process of allorecognition (235).
1.5.1 The Occurrence o f  Indirect Allorecognition during Graft Rejection
Elucidation o f the role of MHC molecules in the presentation of nominal antigen led 
Lechler and Bachelor (236) to question whether the self-restricted recognition of 
alloantigen could contribute to graft rejection. This was based on their observation 
that kidney allografts depleted of interstitial dendritic cells were still rejected, albeit 
more slowly than grafts with their full complement of cells. They argued that 
because dendritic cells provided additional costimulatory signals, they were uniquely 
capable of activating recipient alloreactive T cells. In their absence T cell activation 
could still occur, through a second route in which donor MHC is internalised, 
processed, and presented by recipient APCs prior to expression at the cell surface as 
peptide fragments bound to recipient MHC class II. Further evidence to support this
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'indirect pathway' was provided by Sherwood (237). She noted that mouse skin 
grafts were rejected with accelerated second-set kinetics if  recipients additionally 
received splenocytes from syngeneic animals previously primed with donor strain 
splenocytes (237). Since neither intact donor antigen nor sensitised recipient T cells 
were transferred, recognition o f  donor antigen (as presented by the transferred 
APCs) was restricted to the indirect pathway, providing in vivo functional evidence 
as to its role in effecting acute graft rejection.
A. Nominal Antigen C. Multiple Binary
Determinant Density Complexes
Figure 1.10 Proposed models of alloreactivity.
Figure A depicts the recognition o f  a self-restricted nominal antigen, which is 
generally presented by no more than 100 o f  the MF1C molecules on the surface o f  
an APC. In comparison, the allogeneic MHC molecules on the surface o f  a donor 
APC either represent a much higher frequency o f  T cell determinants (Figure B) or 
stimulate a polyclonal T cell response (Figure C).
Direct evidence for the recognition o f  processed graft antigens was provided by 
Benichou (238). He noted that 10 days after the transplantation o f  m ouse skin grafts, 
recipient T cells proliferated in vitro to the polymorphic region o f  the donor class II 
MHC' molecule (238). Similarly, 10 days after transplanting Few is (RT11) rats with 
DA (R T F 1) renal allografts, Fangmann demonstrated T cell proliferation to the 
hypervariable regions o f  the donor class I MHC, but only if  the recipients had 
additionally been primed with a donor skin graft 4-6 weeks prior to receiving the 
kidney graft (239). In a different rat strain combination, WF (R T F 1) to Lewis (R T11), 
self-restricted T cells specific for donor class II peptide were detected following 
cardiac allografting, fhese 1 cells were C D 4+ and could be detected as early as three
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days post-transplant (240, 241). Studies on human recipients of kidney grafts have 
now also revealed the presence of recipient T cells reactive against donor MHC 
peptide (242).
1.5.2 The Role o f  Indirect Allorecognition in Initiating Graft Rejection
In Sherwood’s experiments, T cells activated through indirect recognition of donor 
antigen appeared an important mediator of graft rejection since sensitising animals to 
this pathway resulted in accelerated rejection (237). However, intact donor MHC 
was detectable as part of the innoculum and it is possible that T cells were 
additionally activated via the direct pathway. An alternative approach to assess how 
the indirect pathway contributes to graft rejection is to immunise with the denatured 
chains or peptide fragments of donor MHC, so that only the indirect pathway is 
primed. Such studies have generally resulted in either no difference (243), or in only 
a slight decrease in the survival times of subsequent grafts (244-248). Thus, despite 
the evidence that indirect T cell activation occurs during allograft rejection, it may 
not actively contribute to the process of graft rejection.
In comparison, pre-immunisation with intact allo-MHC molecules on the surface of 
donor cells results in accelerated rejection with second-set rejection kinetics (245, 
246). For example, Shirwan et al (245), reported that immunisation with peptides 
derived from the hypervariable region of the donor RT1.A3 molecule, resulted in a 
minimal acceleration in the rejection of a subsequent Aa-bearing heart graft (five 
days for experimental animals compared with six days for controls). Immunisation 
with irradiated donor splenocytes however, shortened graft survival to just one day. 
He attributed the rapid rejection of the latter group to the ability of intact allo-MHC, 
as presented by donor splenocytes, to activate an additional subset of directly 
restricted T cells.
One can however argue, because priming with the intact allogeneic MHC molecule 
also provides a source for recipient APCs to generate allopeptide fragments, that the 
indirect pathway is simultaneously activated. If so, the effector mechanisms 
responsible for accelerated rejection following priming with donor cells may not be 
exclusively due to priming of the direct pathway, but rather to the synergy afforded 
by the concurrent priming of T cells through both the direct and indirect pathways.
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As to why directly and indirectly primed T cells may have a synergistic effect on 
graft rejection is perhaps explained by consideration of the nature of their respective 
target determinants. It is simple to envisage that T cells that directly recognise an 
allogeneic MHC molecule are also able to mount an efficient cytolytic response 
against donor graft cells bearing that antigen. In comparison, because indirectly 
activated T cells are restricted to processed donor peptides presented in the context 
o f self-MHC, they are unable to recognise, and consequently directly damage, graft 
cells bearing the intact allo-MHC determinants. One way they could counter this is 
by acting as helper cells for the development of effector mechanisms mediated by 
directly restricted T cells.
To establish the contribution of the indirect pathway to allograft rejection, it is 
therefore necessary to re-evaluate those effector mechanisms traditionally considered 
to be mediated by directly restricted T cells (delayed-type hypersensitivity, 
lymphocytotoxicity and alloantibody responses), to assess the extent that their 
development is influenced by T cell activation via the indirect pathway.
1.5.2.1 Delayed Type Hypersensitivity (DTH) Responses
Although the cognitive phase of a DTH response involves the specific recognition of 
foreign antigen by host T cells (usually CD4+), the effector phase represents an 
innate immune response in which activated macrophages perpetuate an inflammatory 
response that damages tissue non-specifically. A DTH response therefore represents 
a potential mechanism by which the infiltration of indirectly activated T cells, 
despite not recognising the antigenic determinants expressed on donor cells, could 
still effect graft damage. This is supported experimentally by the observation that the 
passive transfer, into Lewis (RT11) rats, of syngeneic T cell clones that are specific 
for allopeptide derived from the class II MHC (RTl.D pu) of the Wistar Furth rat 
strain (WF, RT1LI) augments the DTH response that occurs upon subcutaneous 
injection of both R Tl.D pu peptide, and more especially, WF splenocytes (249-251). 
Indirect T cell activation within the graft is dependent upon the initial infiltration and 
presentation of donor antigen by recipient APC. This process takes several days and 
the indirectly restricted DTH response is therefore unlikely to be a major effector of 
acute graft rejection.
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1.5.2.2 The Provision o fT  Cell Help fo r  Allocytotoxicity and Alloantibody responses.
Indirectly restricted T cells could provide help for the development of either an 
allocytotoxic or an alloantibody response. In general, CD4 T cell help is necessary 
for the development of both of these responses, although the exact mechanics o f this 
help, specifically the nature and degree of physical linkage that occurs between the 
helper and effector cell, has yet to be determined. It is possible that by secreting 
soluble cytokine factors, the helper cell provides sufficient help by simply being in 
close proximity, rather than by physically binding to, the effector cell (see Figure 
1.11 A). Such a model however, is unregulated and potentially damaging, as 
theoretically any activated CD4 T cell could provide help for the effector cell 
regardless of the antigenic determinants for which they are specific.
The provision of T cell help could be more strictly regulated if physical linkage 
between the helper T cell and the effector cell was instead necessary. Linkage could 
occur through two mechanisms. Firstly, the helper and effector cell may interact 
indirectly through a common APC (see Figure 1.1 IB). This would require the APC 
to present determinants that both the effector and helper cells recognise. Since these 
determinants would not necessarily be the same for each cell population, the helper 
cell would not recognise determinants that the effector cell presents. Nevertheless, 
the increased expression of costimulatory ligands on the surface of the donor cell, 
which its interaction with the helper T cell induces, would ultimately increase the 
activation state of the effector cell (252). A second form of linked help may occur 
through a direct cognate interaction between the class II MHC/peptide complex of 
the effector cell and the TCR of the helper cell (see Figure 1.11C). This arrangement 
may be especially advantageous in that T cell help would be restricted to T cells 
specific for the donor peptide fragments (as presented by the effector cell). By 
ensuring such specificity, the response may be more tightly regulated. Although 
fewer cells can participate in the provision of linked, as compared to unlinked, help, 
effector cell activation may nevertheless be unimpeded, due to additional signalling 
through costimulatory ligands.
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Figure 1.11 Diagrammatic representation of the varying degrees of physical 
linkage between helper (Th) and allo-specific effector cells (Eff).
Figure A Physical proximity only. The helper T cell is restricted for a third
party irrelevant antigen; there is no determinant sharing.
Figure B Physical linkage through third party linked determinants. The
helper T cell interaction with its determinant on the surface of the 
donor APC increases the latter’s expression of costimulatory 
ligands (CD28/B7, CD40/40L). Their increased expression results 
in more efficient activation of the alloreactive effector cell (252).
Figure C Cognate linkage through the MHC/peptide of the effector cell and
the TCR of the helper cell. Note that the provision of cognate help
for the allospecific effector cells can only be provided by T cells 
primed through the indirect pathway, and such helper cells will not 
be able to recognise the intact allogeneic determinants on the 
surface of the donor APC.
With specific regards to the alloimmune response, the mode of activation of the 
helper T cell population is fundamentally different for each of the above mechanisms 
of linked help. Using the cytotoxic CD8 T cell response as an example, cognate help 
(Figure 1.11C) is dependent upon the cytotoxic T cell additionally functioning as an 
APC and presenting the target donor antigen as peptide fragments. Such help would 
be limited to indirectly primed CD4 T cells that recognise self-restricted allopeptide 
fragments. In the alternative 3 cell cluster model (Figure 1.1 IB), dual linkage with 
the APC requires the APC to display the appropriate allogeneic class I and class II 
determinants for simultaneous recognition by recipient cytotoxic effector T cells and 
CD4 helper T cells. Since donor APC fulfil this criteria, this represents a mechanism 
by which directly restricted CD4 T cells can provide help. Elucidating the pathways 
by which T cell help is normally provided for the development of allocytotoxicity 
and alloantibody responses is therefore fundamental to establishing the relative 
contributions of the direct and indirect pathways to graft rejection.
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1.5.2.3 The Cytotoxic CD8 T Cell Response
Although the cytotoxic T lymphocyte (CTL) response is a major component of the 
alloimmune response, the precise nature o f the T cell help that is required for its’ 
development is poorly defined. CTL depend upon the presence of 11-2 for their 
maturation and CD4 T cells generally provide this (96, 97, 253, 254). Although in 
vitro studies suggest that there is no absolute requirement for linkage between the Th 
and the Tc (255-258), in vivo experiments contradict this (259, 260).
Both the three-cell cluster and the cognate Th/Tc interaction hypotheses (Figures
1.1 IB and 1.11C) appear capable of providing help for the development of an 
allocytotoxic response. In support o f the former, Mitchison and O ’Malley (261) 
demonstrated that target cells were more effectively lysed if they expressed the 
cytotoxic and helper determinants simultaneously (non-cognate linkage). They 
concluded that a three-cell cluster involving the donor APC, the CD4 Th cell, and the 
CD8 Tc cell was sufficient to induce cytolysis (Figure 1.1 IB). Shared MHC- 
restriction of the Th and Tc subsets did not increase cell lysis, indicating that help 
provided through a cognate interaction with the CD4 Th cell (Figure 1.11C) was 
unlikely to contribute to the development of CD8 Tc cell response.
Rosenberg reported similar results in vivo (262). In certain mouse strains, class I 
disparate skin grafts were still rejected after CD8 T cell depletion of the recipients. A 
subset of CD8 T cells resistant to the depleting antibody mediated graft rejection, 
and their development was dependent upon help provided by CD4 T cells. CD4 T 
cell activation was contingent upon the expression of additional helper determinants, 
which could be completely unrelated to the lymphocytotoxic target. These helper 
determinants had to be expressed in conjunction with the cytotoxic determinants, but 
could be co-expressed on a second ‘inducer’ graft (263). Similarly, the examination 
of a class I disparate strain combination, in which skin grafts were accepted 
permanently, revealed self-restricted CD4 Th cell proliferation in vitro to the donor 
MHC class I antigen (264, 265). These results suggest that help provided through the 
indirect T cell recognition of the disparate class I antigen was insufficient to 
stimulate rejection and that the development of an effective cytotoxic response 
required the expression of additional helper determinants.
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Rosenberg’s studies were performed on strains in which CD8 T cells produced their 
own T cell help and were able to reject skin grafts autonomously (266-269). The lack 
o f dependence upon the helper CD4 T cell subset may reflect deficiencies in the 
class II antigen processing pathways, preventing CD4 T cell activation through the 
indirect pathway. Similarly, whereas human CD8 T cells express MHC class II 
(270), the situation in the mouse remains undefined (271, 272). The above 
experiments may therefore not accurately reflect the extent to which indirectly 
primed CD4 T cells can provide cytotoxic CD8 T cell help. In the rat, for example, 
in vitro CD8 T cell proliferation, and the rejection of skin and vascularised grafts, 
are more heavily reliant upon CD4 T cells (273-276).
Evidence to support the cognate model of CD4 T cell help for cytotoxic T cell 
development was initially provided by the observation that certain accessory cells 
involved in the generation of an allocytotoxic response displayed self-MHC class II- 
restriction (265, 277, 278). Auchincloss recently validated these findings, as he 
noted that CD8 T cell-depleted mice rejected MHC class II-deficient skin grafts 
normally (279, 280). The absence of donor class II prevented CD4 T cell activation 
via the direct pathway and CD4 T cell help, necessary for the generation of CD8 
effector cells, was instead provided through the recognition of processed donor class 
I antigen, as presented by recipient APCs. Lee and Auchincloss proposed the 
incorporation of the recipient APC, specifically a recipient B cell, into a four-cell 
cluster model, which still permitted linkage for regulatory purposes (Figure 1.12A). 
He did not address the nature of the interaction of the self-restricted CD4 Th cell with 
the Tc cell, but linkage could equally be provided by assuming that the TCR of the 
indirectly primed CD4 T cell interacts with MHC class II of the CD8 T cell in a 
cognate fashion (Figure 1.12B) (281). Allocytotoxic CD8 T cell effector 
mechanisms have been traditionally viewed as typifying the direct T cell response, 
but Lee’s results suggest that the development of effector mechanisms may instead 
rely on directly and indirectly activated T cells cooperating in a synergistic fashion.
Both directly and indirectly activated T cells appear capable of providing help for the 
development of an allocytotoxic T cell response. The relative contribution of the 
indirect pathway is still a matter of conjecture, and will remain so until the nature of
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Figure 1.12 The provision of indirect CD4 T cell help for allo-cytotoxic T 
lymphocytes.
CD4 T cells that are activated through the indirect pathway provide help for the 
generation of an allo-cytotoxic CD8 T cell response through a four cell cluster (280) 
with the recipient APC most likely a B cell (Figure A). Regulatory linkage could also 
occur by assuming a cognate interaction between the class II MHC/peptide complex 
of the CD8 T cell and the TCR of the CD4 T helper cell (Figure B) (281).
the interaction between CD8 and CD4 T cells can be firmly established. It seems 
unlikely, given the strength of the direct response, that indirectly primed T cells 
would preferentially provide cytotoxic T cell help. That is, unless their ability to 
provide cognate help is, in terms of CD8 T cell activation, inherently advantageous. 
Recent evidence regarding 'cross-priming' of the CD8 T cell response to exogenous 
antigens, instead suggests that CD4 T cells provide help by modulating the APC, 
rather than the CD8 T cell (252, 282, 283) (Figure 1.13). This obviously requires the 
APC to express the helper and cytotoxic determinants simultaneously and is 
analogous to directly activated T cells providing non-cognate help by a three-cell 
cluster, as was originally suggested by Mitchison and O’Malley (261).
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Figure 1.13 The provision of T cell help for cross-reactive CTL responses.
The CD4 T cell provides help to the cytotoxic effector cell, by indirectly 
augmenting costimulatory molecules on the APC (282). This requires binding to the 
APC (left hand figures). For an alloimmune response in which the target APC is of 
donor origin, only allo-restricted CD4 T cells that directly recognise the allogeneic 
class II MHC, rather than those which are primed indirectly for self-restricted 
allopeptide, can fulfil this role (261).
1.5.2.4 The Alloantibody Response
The provision of T cell help for antibody production to nominal protein antigen is 
more defined. The transformation of ‘immature’ B cells into Ig-secreting activated 
plasma cells requires cognate help from T cells (284-287). CD4 T cells are similarly 
required for the development of an alloantibody response (288), and since 
alloreactive B cells will present donor allo-peptide, one would expect that only 
indirectly primed T cells would be capable of providing the necessary help. 
Confirmation that indirectly primed T cells are involved in the alloantibody response 
was initially established by Bradley and colleagues (289, 290). In an MHC class I- 
disparate rat renal allograft model, PVG-R8 (RT1.A3) to PVG-RT1U (RT1.AU), 
rejection was dependent upon CD4 T cells and, in contrast to Rosenberg’s findings 
(263), CD8 T cells were superfluous. Rejection was alloantibody mediated for 
passive transfer of hyperimmune serum was able to accelerate or restore rejection in 
nai've and nude rats respectively (289). In this model it is unlikely that CD4 T cell 
activation occurs through direct recognition of the disparate class I Aa antigen, but 
instead is contingent upon recipient APC processing the donor class I antigen and
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presenting it as peptide fragments in conjunction with self MHC class II. The 
exclusion of CD4 T cell activation via the direct pathway implies that indirectly 
restricted CD4 T cells are alone responsible for the development of an alloantibody 
response, through the provision of cognate B cell help. More recent experiments by 
MacDonald et al (246) have again highlighted that the recognition of processed 
donor allopeptide is integral to the rejection response in this strain combination, for 
subcutaneous injection of synthetic peptides derived from the hypervariable regions 
of the donor Aa molecule prior to grafting accelerated the rejection of subsequent Aa- 
bearing cardiac allografts. Furthermore, the administration of these peptides in a 
tolerogenic fashion, by targeting them to the resting recipient B cell population, 
downregulated the subsequent alloantibody response to the intact Aa antigen.
Fabre and colleagues have similarly found, in the DA (R T la) to Lewis (RT11) rat 
strain combination, that allopeptide priming can accelerate the subsequent 
alloantibody response to the intact donor MHC molecule (244, 247). This difference 
was most marked when interstitial dendritic cell-free grafts were used as donor 
organs (291). In this experiment, priming with peptide markedly accelerated both the 
alloantibody response and the kinetics of allograft rejection, seemingly confirming 
the importance of the indirect pathway in the provision of B cell help. However, the 
early alloantibody response was dependent upon the presence o f donor dendritic 
cells, which, as professional APCs, are capable of initiating a strong direct CD4 T 
cell alloresponse. Kelly et al further analysed this possibility that B cell help was 
provided by directly-restricted CD4 T cells (292). In PVG (RT1C) rats, the allo-class
I Aa antigen could only promote an antibody response when it was encountered on 
the surface of donor cells, in this case a vascularised allograft, and not when 
administered as a purified molecule. Furthermore, the MHC class I alloantibody 
response could be abrogated by the presence of antibodies reactive against the donor 
class II MHC molecule. Kelly concluded that T cells recognising the allogeneic class
II MHC directly were responsible for providing help for the early alloantibody 
response to a vascularised graft, in a manner similar to the three cell cluster model 
that Mitchison and O ’Malley had suggested governed the allocytotoxic T cell 
response (261). This concept is not unprecedented; earlier work with non-MHC 
antigens confirmed that activated T cells could provide non-cognate B cell help, 
although this help was contact dependent (293-295).
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The discrepancies between Fabre’s results and those of Bradley’s laboratory may be 
a result of analysing different aspects of an inherently complicated alloantibody 
response, which involves the separate processes of antigen induced activation, 
proliferation, antibody secretion and isotype switching. As the levels of T cell help 
for each of these processes may differ, so too may the relative requirement for help 
provided through either directly or indirectly restricted CD4 T cells. For example, 
Steele and Auchincloss (296) have noted that MHC class II-deficient mouse skin 
grafts are still rejected with a similar IgM and IgG response to the residual donor 
antigens as to controls receiving normal grafts. The absence of donor MHC class II 
restricts CD4 T cell activation to the indirect pathway and suggests, in concurrence 
with Bradley (297), that priming this pathway results in the development of a normal 
alloantibody response. In comparison, grafting skin from an unmodified donor to 
recipients deficient in MHC class II (but with a normal CD4 T cell repertoire), 
produced only a moderate titre of cytotoxic antibody, which was solely of the IgM 
isotype (296). In this latter model CD4 T cell activation is restricted to the direct 
pathway and Auchincloss concluded that the non-cognate B cell help provided by 
directly activated T cells is sufficient to initiate the primary IgM alloantibody 
response, but is insufficient to induce heavy chain class switching to IgG isotypes.
Fabre and Auchincloss’ data can therefore be reconciled by assuming that the 
antibody response in Fabre’s model was exclusively of the IgM class (in his 
experiments the isotype response was not analysed), for even an IgM-restricted 
alloantibody response (direct CD4 T cell help) will activate complement and may 
consequently be as detrimental to graft survival as a more differentiated IgG 
response (indirect CD4 T cell help). Two issues nevertheless require clarification. 
Firstly, as suggested by Fabre, is it only help from directly activated T cells that is 
responsible for the early alloantibody response? Secondly, as suggested by 
Auchincloss, is the capability to induce Ig heavy chain class switching restricted to 
only the indirectly primed subset of Th cells?
With regards to the nature of T cell help for the initial alloantibody response, 
Bradley’s results suggest that this can be adequately provided by indirectly restricted 
CD4 T cells (246, 289). The alloantibody response to the disparate MHC class I 
antigen in the PVG.R8 to PVG.RT1U strain combination is governed by indirectly
42
primed Th cells, yet it is detectable as early as four days after a vascularised cardiac 
allograft (Lovegrove et al, submitted). Certainly, within a few hours of encountering 
antigen, B cells can process and present it to T cells (298, 299).
One can also hypothesise that the required presence of donor dendritic cells to 
instigate an early alloantibody response simply reflects the migratory capabilities of 
dendritic cells, rather than a dependence on T cell activation via the direct pathway. 
Activation of B cells in a primary response occurs in T cell areas of the spleen (300) 
and dendritic cells may be uniquely proficient at trafficking antigen to this area 
(301). The migration of donor dendritic cells could therefore be responsible for an 
early alloantibody response, irrespective of whether alloantigen is recognised within 
the spleen predominantly via the direct or indirect pathways.
Finally, the three-cell cluster theory (292) was based on the observation that PVG 
rats mounted a much stronger alloantibody response to the Aa antigen when it was 
encountered as part of a completely mismatched graft. The indirect CD4 T cell 
response to this antigen, as judged by the inability to develop antibody against its 
purified form, is however weak. This may reflect strain-specific abnormalities in 
either antigen processing or the CD4 T cell repertoire and may not be typical o f the 
general immune response to allo-MHC in other strains or species. In other words, the 
indirect CD4 T cell response to MHC class I alloantigens may generally be sufficient 
to provide B cell help without the requirement for additional helper allo­
determinants.
With regards to Auchincloss’ hypothesis, that T cell help for Ig heavy chain class 
switching can only be provided by a cognate interaction with indirectly restricted 
CD4 T cells, recent advances in the understanding of the regulatory signals that 
govern the antibody isotype switch for nominal antigens, offer some insight. Rao’s 
group (302, 303) have confirmed that, as opposed to the initial IgM response, the 
class switch from IgM to IgG demands a higher frequency of primed Th cells. This 
may reflect a stringent requirement for an interaction between CD40 of the B cell 
and CD40L of the T cell for isotype switching (304-307). In turn, the T cell CD40L 
is upregulated by signalling via the TCR, as occurs through a cognate interaction 
with the MHC complex of a B cell, (308). This supports Auchincloss’ findings of the 
requirement for indirectly primed T cells to instigate class switching. However, there
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is also in vitro evidence of CD40L-induced class switching in the absence of TCR 
signalling (309, 310). In addition, Steele’s work was performed on a mouse skin 
graft model, and his findings may not apply to vascularised grafts, for the kinetics of 
the alloantibody response are much slower following skin grafting. This perhaps 
reflects an inherent bias for allo-activation to occur through the indirect pathway 
(281).
In summary, results to date suggest that either of the above mechanism for Th cell 
activation can provide B cell help. The relative contribution of each are likely to 
depend upon the particular characteristics of a given alloimmune response, but such 
characteristics remain poorly defined.
1.5.2.5 Targeting the Indirect Pathway to Achieve Tolerance
The use of tolerogenic protocols that specifically target the indirect pathway, provide 
an alternative means to study its’ role in effecting acute allograft rejection. Sayegh 
initially noted that feeding Lewis (RT11) rats with allopeptide derived from WF 
(RT1U) MHC class II, subsequently reduced the DTH response not only to the 
peptides, but also to intact donor splenocytes (311). More significantly, in the same 
strain combination, intrathymic injection of the same peptides resulted in prolonged 
cardiac allograft survival (312). Similar results with MHC class I allopeptide, but 
with the use of concomitant sub-therapeutic immunosuppression, have been more 
recently reported for the WF to ACI (R T la) and the PVG.R8 (R T la) to PVG.RT1U 
(RT1U) rat strain combinations (313-315). These results are startling for several 
reasons. The allopeptides administered were derived from only a single MHC 
molecule of the donor rat strain and yet had profound effects upon the survival of 
fully mismatched allografts. Furthermore, the synthetic peptides used represented a 
comparatively small percentage of the total allo-MHC sequence, and since the 
design of these peptides was somewhat arbitrary, they may not even be 
representative of the sequences that are presented upon processing of the donor 
MHC antigen by the recipient. Nevertheless, such studies not only provide the 
strongest evidence to date as to the importance of the indirect pathway of 
allorecognition in the process of graft rejection, they also suggest that tolerogenic 
strategies targeting this pathway may be clinically advantageous.
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1.6 Aims of Thesis. The Use of Soluble Class I Allo-MHC
1.6.1 Introduction
In the class I-disparate rat model of allograft rejection, PVG.R8 to PVG.RT1U, the 
assumption that CD4 T cell activation is dependent upon recognition of the 
processed donor R Tl.A 3 alloantigen, implies that the indirect pathway of 
allorecognition is solely responsible for graft rejection (297). Alternative 
explanations that rely on the direct pathway of allorecognition can however be 
postulated (297). Firstly, it is possible that the recombinant event that established the 
donor R8 strain translated not only the MHC class I locus, but also altered as yet 
undefined neighbouring antigens, such that the antigenic disparity between the two 
rat strains is not strictly limited to the RTl.A  locus. Such putative additional 
antigenic disparities may be able to activate Th cells directly, in an analogous fashion 
to the rejection of skin grafts in certain class I-disparate mouse skin allograft models 
(262). Alternatively, recipient CD4 T cells may recognise the disparate class I 
alloantigen directly. Although this appears to violate the basic laws of MHC- 
restriction, exceptional CD4 T cell clones have been described that are lytic towards 
MHC class I positive target cells (316, 317).
One way to test the hypothesis that recipient CD4 T cells are activated directly in the 
R8 to RT1U strain combination is to examine the effect that priming RT1U rats with 
purified donor RTl.A 3 antigen has upon the survival of subsequent R8 allografts. If 
this mode of immunisation has the same effect on graft survival as pre-immunisation 
with intact donor R8 cells, then one can reasonably exclude additional antigenic 
discrepancies as having a major influence on graft rejection. Sensitisation of RT1U 
rats with intact donor R8 cells in the form of a skin graft (246), an R8 blood 
transfusion (Lovegrove et al, manuscript in preparation) or subcutaneous injection of 
irradiated R8 splenocytes (245) leads to prompt rejection of subsequent R8 cardiac 
allografts (within one to two days of grafting). However, the effect of pre­
immunisation with purified R Tl.A 3 antigen is generally much more modest. For 
example, the administration of synthetic A3 antigen, either as complete heavy chain 
protein (248) or as allopeptides derived from the hypervariable regions of the A3 
molecule (245, 246), accelerates graft rejection by two days at most.
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Shirwan has similarly noted, in the same rat strain combination, that priming with 
donor cells results in a much more rapid rejection of a subsequent heart graft than 
priming with synthetic donor antigen (245). He too postulated that the accelerated 
rejection associated with donor cell priming is the result of the activation o f an 
additional subset of T cells via the direct pathway of allorecognition. It is notable in 
the above experiments, however, that the synthetic Aa antigen that was administered, 
either as misfolded heavy chain or as peptide fragments, did not display the same 
tertiary and quaternary conformations as the complete membrane-bound R Tl.A a 
MHC class I antigen. Consequently, in contrast to pre-immunisation with donor R8 
cells, prior exposure to the synthetic Aa antigens did not result in the development of 
an alloantibody response able to cross-react with intact Aa molecules on the cell 
surface of subsequent R8 allografts (245, 246). Rejection in PVG.R8 to PVG.RT1U 
rat strain combination is alloantibody-mediated (289, 290, 318). Pre-immunisation 
with intact Aa antigen, as on the surface of donor cells, may therefore cause rapid 
graft rejection simply because it displays the appropriate cross-reactive B cell 
epitopes to efficiently prime humoral immunity, rather than to any fundamental 
differences in the mode of T cell activation.
In summary, evidence to date does not permit definite conclusions as to the 
pathways of CD4 T helper cell allorecognition that initiate graft rejection in the 
PVG.R8 to PVG.RT1U rat strain combination, and in particular, whether indirectly 
restricted CD4 T cells are responsible for the accelerated rejection that results 
following priming with intact donor R8 cells. To clarify this, an experimental system 
was designed whereby T cell activation was restricted to the indirect pathway, but in 
which B cells could be simultaneously activated against the intact donor R Tl.A 3 
antigen. I reasoned, as discussed in section 1.6.4, that the use o f soluble R Tl.A 3 
antigen would achieve this objective. Soluble MHC class I alloantigen can however 
exert potent effects upon recipient CD8 T cells, which may complicate interpretation 
of the CD4 T cell response. For example, activated CD8 T cells can influence the 
pattern of cytokine secretion of CD4 Th cells (319) and can, under certain 
circumstances, provide help to B cells (320). Conversely, soluble MHC class I 
alloantigen can prevent the development of a cytotoxic CD8 T cell response by 
inducing apoptosis in alloreactive CD8 T cells (321). In using soluble MHC class I 
alloantigen to assess the influence of the indirect CD4 T cell response, one must
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therefore initially consider its direct effects, either inhibitory or stimulatory, on the 
cytotoxic CD8 T cell population.
1.6.2 The Tolerogenic Properties o f  Soluble Class I  Allo-MHC
Liver allografts are accepted more readily than other solid organ grafts, possibly 
because they are associated with the release of tolerogenic donor antigens (322). The 
search for these donor antigens resulted in the discovery that HLA could exist as a 
soluble serum factor. Van Rood and colleagues initially documented that soluble 
HLA could be detected in normal human serum (323), Kamada et al subsequently 
confirming the presence of donor MHC in the serum of liver recipients (324). 
Further studies suggested that soluble HLA was present in serum in three distinct 
biochemical forms (325). The largest, a 44kDa molecule, retains the transmembrane 
region and cytoplasmic tail, while these were absent in the smallest 35-37kDa 
molecule. The intermediate, 40kDa molecule lacks the transmembrane segment and 
is probably produced by alternate splicing (326, 327).
Shed soluble donor MHC was therefore proposed as the tolerogenic agent 
responsible for the relative ease with which liver allografts are accepted. This has 
not, however, been conclusively demonstrated experimentally, as several groups 
have evaluated the effects of the administration of purified soluble class I antigen 
and the results are contradictory. Sumimoto and Kamada (328) initially reported that 
the kinetics with which PVG (RT1.AC) rats rejected DA (RTl.Aa-bearing) cardiac 
allografts were slowed by the concurrent continuous infusion of naive DA rat serum. 
This effect was dependent upon the presence of the donor Aa antigen, since the 
administration of serum that had had the class I antigen removed by affinity 
chromatography did not prolong graft survival. Foster et al (329) performed similar 
experiments, but additionally examined the effects of the various physical forms of 
the R Tl.A 1 antigen. When the A1 antigen was administered to DA recipients as 
purified membrane-bound molecules, incorporated into protein micelles to form 
multivalent complexes, Lewis (A-bearing) renal allografts were accepted 
indefinitely. However, a water-soluble preparation of the purified R Tl.A 1 antigen 
was only able to prolong graft survival when administered in conjunction with a sub- 
therapeutic dose of cyclosporin.
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In contrast, neither Priestley (330) nor Spencer (331) were able to reproduce the 
tolerogenic effect of soluble donor class I in their rat allograft models. Even in 
combination with a sub-therapeutic dose of cyclosporin, the intravenous 
administration of RTl.A 3 antigen did not prolong the survival of either DA hearts in 
PVG recipients (331) or DA kidney grafts in PVG or Lewis recipients (330).
The discrepancies in the above studies reflect a limited understanding of the 
mechanisms responsible for the tolerogenic effects of soluble allo-MHC. Potential 
mechanisms involve binding to the TCR, or an interaction with other receptors 
(332), or downregulation of the indirect T cell response (333). The most likely 
mechanism of T cell tolerance is through interaction of the soluble MHC class I with 
the TCR of CD8 T cells. The ability of soluble MHC class I to prevent cytotoxic T 
cell development was first documented in the early 1990’s (334, 335). This 
coincided with the publication of the two-signal model hypothesis for T cell 
activation (336), whose principles could explain the tolerogenicity of soluble MHC. 
Specifically, soluble MHC, because it is not expressed upon a cell membrane, is 
unable to provide the second costimulatory signal required by T cells for activation, 
and that in its absence, the provision of signal one alone induces an anergic state in T 
cells.
This hypothesis does not however explain why larger aggregated forms of soluble 
class I alloantigen are more tolerogenic than shorter water-soluble versions (329). In 
vitro models of T cell activation suggest that this is due to the ability of multivalent 
soluble MHC aggregates to stably bind to several TCRs simultaneously on the 
surface of a CD8 T cell (321, 337-339). For example, McCluskey et al initially 
demonstrated that the molecularly engineered soluble counterpart of the MHC class I 
antigen, H-2Dd/Q10b was only able to stimulate 11-2 release from a T cell hybridoma 
when in a multivalent state (337). More recently, Dal Porto and colleagues 
genetically engineered a divalent MHC class I molecule by inserting the DNA 
sequence encoding the extracellular domains of H-2Kd into the 5' variable domain of 
a murine yl gene (339). This chimeric protein inhibited in vitro lysis of H-2K - 
bearing target cells when administered in nanomolar concentrations. Likewise, 
Abastado et al produced a recombinant divalent soluble H-2Kd antigen-peptide 
complex by using a specific anti-H-2Kd antibody to link the a3 domains. Whereas
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the unlinked monomers were unable to stimulate the relevant T cell hybridoma, 
dimers triggered the T cell hybridoma to secrete 11-2, and this was followed by an 
unresponsive state during which T cells were refractory to further stimulation (338). 
Zavazava and Kronke recently extended these observations and have established a 
mechanism by which polyvalent soluble antigen can prevent CD8 T cell activation. 
They reported that T cells that interact with hydrophobic soluble MHC, which is 
capable of forming multimers, undergo apoptosis as a result of Fas ligand 
upregulation (321). Shorter, hydrophilic, soluble MHC derived from the cytosol, and 
consequently unable to form aggregates, was less than 50% as efficient at inducing 
apoptosis. Cell death was prevented by the concurrent ligation of the T cell with 
CD28, and this explains why a third preparation of the class I antigen, which was 
derived from fragments of cell membrane, and therefore more likely to contain 
associated costimulatory molecules, did not induce apoptosis.
1.6.3 Can Soluble MHC Class I  Activate CD8 T Cells Directly?
Recent evidence has qualified the two-signal model of T cell activation. In vitro 
experiments suggest that the costimulatory requirement for T cell activation, 
particularly for CD8 T cells, is relative, rather than absolute (340-346). For example, 
Viola and Lanzavecchia (340) have demonstrated that CD4 T cell activation requires 
a defined number of signalling events to occur through the surface TCR. In the 
absence of costimulation, this threshold value is 8000, whereas concurrent 
costimulation lowers this value to 1500. CD4 T cell activation (as measured by 
calcium influx) also occurred, in the absence of costimulation, upon incubation with 
soluble class II tetrameric complexes (347, 348). By using a similar approach, Wang 
has recently confirmed the ability of soluble class I MHC tetramers to activate CD8 
T cells without additional signalling (349). Pardigon and Luxembourg (344, 345) 
have also verified that CD8 T cells can also be fully activated in the absence of a 
second signal, albeit with an efficiency of at least 20 times less than when 
costimulation is available (344). Although the studies employing class I and class II 
tetramers (347-349) noted that soluble, monovalent MHC did not induce T cell 
activation, in a different model using T cell hybridomas as responders, full activation 
was achieved using soluble MHC in monvalent form monovalent soluble class I
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MHC did induce full activation of a T cell hybridoma, but unlike activation induced 
by class I dimers, CD8 co-receptor expression by the hybridoma was required (350).
Results from in vitro experiments cannot necessarily be extrapolated to in vivo 
conditions, for in the above experiments the absence of costimulation may have been 
compensated for by either the addition of 11-2 (344, 346), or by immobilising the 
MHC class I protein into a non-physiological state by binding to plates (341, 347, 
348). Neither of these practices were used in Wang’s study (349), which is probably 
the most representative of the probable in vivo effects of soluble class I antigen. In 
his study, only tetrameric class I complexes could achieve CD8 T cell activation in 
vitro, and similar multivalent complexes are likely to be required to achieve the 
necessary in vivo cross-linking of the TCR.
1.6.4 The use o f  movalent soluble MHC class I  alloantigen.
One can postulate from the above experiments that the recipient CD8 T cell response 
to the in vivo administration of soluble MHC class I alloantigen will range from 
either no activation, to partial activation (anergy/inhibition), or to full activation, 
depending on whether monovalent, divalent, or multivalent complexes, are 
administered. As discussed in section 1.6.1, this thesis attempts, by administering 
soluble donor class I alloantigen, to explore the mechanisms resposible for 
accelerated rejection, and specifically, to assess whether the requirement for priming 
with donor cells reflects solely the presence of the appropriate B cell epitopes for the 
development of humoral alloimmunity, or whether direct T cell activation through 
recognition of determinants on the surface of donor cells additionally contributes. 
The principal tenet concerning the use of soluble class I allo-MHC is therfore that T 
cell activation occurs only through the indirect recognition of its processed 
fragments. The administration of soluble MHC class I alloantigen as a monomer that 
does not associate into multivalent complexes would be expected to fulfil this 
requirement.
To manufacture monovalent soluble MHC class I it is necessary to excise the 
transmembrane and cytoplasmic domains, since these are hydrophobic and 
responsible for self-aggregation. Soluble allo-MHC manipulated in this way has 
been used in vivo and the theoretical constraint that it would not result in CD8 T cell
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activation appears valid (351-354). For example, Geissler et al have reported that 
although intramuscular injection with a plasmid DNA vector encoding a membrane- 
bound form of the R Tl.A 3 molecule resulted in an anti-Aa cytotoxic T cell response, 
no such response was detected upon immunisation with a construct encoding a 
soluble version lacking the transmembrane and cytoplasmic domains (351). The
same constructs were subsequently used ex vivo to transfect Lewis (R T l1)
hepatocytes (352). Lewis rats injected into the portal vein with syngeneic 
hepatocytes that additionally expressed the membrane bound RTl.A 3 antigen 
demonstrated accelerated liver graft rejection, and showed CTL sensitisation. In 
contrast, injection of the soluble construct resulted in prolonged graft survival and 
was associated with a diminished anti-Aa cytotoxic T cell response. Furthermore, 
administration of the soluble MHC construct was able to prevent the immune 
activation and accelerated rejection that resulted from injection with the vector 
encoding the membrane-bound form of the antigen (353, 354).
Although these latter results suggest that monomeric soluble class I alloantigen may, 
as opposed to having no discernible effect, inhibit the direct CD8 T cell
alloresponse, this does not preclude its use to explore the indirect CD4 T cell
response in a model of accelerated, humoral' rejection. It in fact permits exploration 
of its potential to down-regulate the cytotoxic CD8 T cell response as a subsidiary 
objective.
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1.7 Summary and Objectives
The contribution of the indirect pathway to allograft rejection remains unclear, but it 
is probably as great as that of the direct pathway, particularly with respect to the 
provision of T cell help for the development of an alloantibody response. Although 
Kelly and Fabre (292) have suggested that the early, acute alloantibody response is 
dependent upon the provision of help from T cells activated exclusively via the 
direct pathway, antibody depletion studies suggest that in the MHC class I disparate 
PVG.R8 to PVG.RT1U rat strain combination, the alloantibody response mediating 
rejection is dependent upon CD4 T cell activation (290, 297, 355). Although this 
most plausibly occurs as a result of the indirect recognition of processed donor Aa 
antigen, it is impossible to exclude that, since pre-immunisation of RT1U rats with 
intact R8 cells accelerates the rejection of a subsequent R8 allograft to a greater 
degree than priming with purified forms of the Aa antigen (245, 246, 289), CD4 Th 
cells either respond to additional alloantigens expressed by donor APCs, or 
recognise the Aa alloantigen directly upon the surface of donor APC (297). 
Clarification of this issue has obvious implications for the understanding of the T 
cell recognition pathways involved in the rejection of class I disparate allografts. It 
also has a wider bearing on the nature of T-B cell collaborations during the 
development of an alloantibody response, since the allorecognition pathway of CD4 
T helper cells (indirect or direct) dictates whether T cell help for B cells is provided 
by cognate (antigen-specific) or non-cognate (antigen-non-specific) cell-cell 
collaboration (292, 296)
This thesis attempts, through the use of a soluble form of the donor R Tl.A 3 antigen, 
to explore more fully the role of indirectly primed T cells in the provision of help for 
the development of an alloantibody response, and in particular, to examine the 
ability of indirectly restricted T cells to effect accelerated humoral rejection. The 
three-dimensional structure of soluble MHC class I contains the appropriate B cell 
epitopes to generate an antibody response that would cross-react with the R Tl.A 3 
antigen as expressed on the surface of donor graft cells. Additionally, because it 
lacks both costimulatory ligands and, when administered in a monovalent form, the 
ability to induce TCR cross-linking, it is highly unlikely to result in the direct 
activation of either recipient CD4 or CD8 T cells. It is more contentious whether in
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this form the soluble class I antigen would actively inhibit the recipient CD8 T cell 
response, but since CD8 T cell depletion does not effect rejection in the R8 to RT1U 
strain combination (289), this will not influence the interpretation of the results.
The soluble MHC was manufactured using a molecular-based approach as this 
enabled the genetic sequence of the full-length RTl.A 3 antigen to be altered 
efficiently, such that a pure preparation of monovalent soluble class I antigen at 
physiological concentrations was assured.
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CHAPTER TWO
CLONING AND EXPRESSION OF R T l.A a HEAVY CHAIN ENCODING
PLASMID VECTORS
2.1 Introduction
In certain animal models the administration of soluble class I alloantigen tolerises 
the alloreactive CD8 T cell population, but in others no effect is observed (328- 
331). There are several possible explanations for these discrepancies. The first 
concerns the mode of administration o f the soluble class I alloantigen, for soluble 
MHC molecules have a short half-life (1.5 to 2.5 hours) (331). Physiological 
concentrations are perhaps therefore achieved only by its’ administration as a 
continuous infusion, as in Sumimoto’s experiments (328), rather than as a bolus 
injection, as favoured by Priestley and Fabre (330, 331). The method employed to 
purify the class I MHC (328) is equally important and results obtained using 
donor serum as a source of antigen may have been influenced by the presence of 
additional immunosuppressive serum factors (356, 357). Similarly, the protocol 
employed to purify the class I alloantigen will influence the precise physical 
conformation of the recovered MHC class I complexes, and in particular will 
dictate the relative concentrations of multivalent and monovalent complexes, that 
are recovered. These have markedly different effects on the CD8 T cell response 
(329).
To overcome the inconsistencies associated with purifying the RTl.A 3 antigen 
directly from the appropriate rat strain, I chose instead to administer it as a DNA- 
based plasmid vaccine. This approach ensures the absence of contaminating 
inhibitory factors, and permits the formation of a recombinant molecule that is 
lacking the transmembrane and cytoplasmic domains of the heavy chain. Without 
these domains, only monovalent complexes will be expressed, which, as discussed 
in section 1.6.4, are least likely to activate recipient CD8 T cells.
Plasmids are double stranded circular DNA molecules that range in size from lkb 
to more than 20kb and are found in a variety of bacterial species. They replicate 
and are inherited independently of the bacterial chromosome, but rely on protein
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encoded by the host for their replication and transcription. Plasmid-encoded genes 
are frequently advantageous to the bacterial host and, for example, confer 
resistance to antibiotics, and the ability to degrade sugars and aromatic 
compounds.
The use of plasmids as mammalian expression vectors is dependent upon the 
presence of prokaryotic sequences that facilitate the propagation of the vector in 
bacteria, and eukaryotic transcription units that control the expression of the insert 
within the mammalian cell. The prokaryotic sequences include a replicon; an 
origin of replication together with cis-acting control elements. Replicons dictate 
the extent to which plasmids replicate within the host and therefore the number of 
plasmids per cell (copy number). Plasmid vectors typically encode an ampicillin- 
resistance gene, enabling selection of successfully transformed bacteria. The 
essential eukaryotic modules consist of a promoter element, to mediate 
transcription of the insert within the mammalian cell, and signals required for the 
efficient 3' polyadenylation of the transcript. In commercially available plasmid 
vectors the promoter/enhancer region is typically derived from viruses, as these 
have a broader host range and are active in a wider variety of tissues. These 
include the human cytomegalovirus immediate/early promoter (358), the Rous 
sarcoma virus (359) and the SV40 early promoter (360). Post transcriptional 
modification of the nascent mRNA transcript, such as polyadenylation, is essential 
for subsequent translation. Polyadenylation signals consist of a highly conserved 
6-nucleotide sequence, AAUAAA, together with GU or U-rich sequences further 
downstream. The expression of certain mammalian genes is further increased by 
the presence of an intron sequence which provides functional splice donor and 
acceptor sites. These are frequently included in the vector design.
Plasmid vectors have been used to transfect mammalian cells in vitro for two 
decades. Their in vivo effectiveness at stimulating a T and B cell response has 
only recently been demonstrated (361, 362) and the plasmid characteristics that 
govern the nature and strength of the immune response remain poorly understood. 
This chapter describes the design of several R Tl.A 3 expressing plasmids, and the 
subsequent comparison of their ability to achieve in vitro and in vivo expression of 
the RT1 .Aa antigen.
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2.2 Results
2.2.1 Cloning o f  the RTl.Aa Heavy Chain Sequence into Plasmid Vectors
Figure 2.1 depicts the genetic sequences of the two forms of R Tl.A 3 a-chain that 
were kindly gifted by Simon Powis (Welcome Trust Building, University of 
Dundee, UK.). The full-length version is as described by Rada (39) and includes 
transmembrane and cytoplasmic domains. The soluble version was created by 
mutating the original full-length sequence to include a stop codon, followed by a 
Xba I restriction site, after the methionine residue at position 284 in the 
transmembrane region. The full-length and truncated sequences were inserted into 
the pcexvl-neo vector (pcexv-Aa and pcexv-tAa, respectively), which contains an 
SV40 early promoter upstream of the Eco RI cloning site, and an additional 
neomycin-resistance gene for the purposes of stable cell transfection (Figure 
2.2A).
Although the SV40 promoter is an eukaryotic promoter and can theoretically 
drive expression of the class I constructs upon intramuscular injection, the large 
size o f the pcexvl-neo vector is likely to substantially decrease the efficiency of 
in vivo expression. Consequently, the class I sequence^ were subcloned into 
several commercial expression vectors which offered characteristics more 
conducive to intramuscular expression. The pcDNAI-amp plasmid (Invitrogen, 
Carlsbarg, California) (Figure 2.2B) contains a polyadenylation sequence and a 
CMV early-late viral promoter which is generally the most effective 
commercially available promoter (358). It is also smaller than the pcexvl-neo 
vector and has a high copy bacterial origin of replication, which permits easier 
purification. The pCI-neo vector (Promega, Madison, USA) (Figure 2.2C) has 
similar features to the pcDNAI-amp plasmid but additionally contains a chimeric 
intron site upstream of the cloning site, comprising a 5' donor site from the first 
intron o f the human P-globin gene, and a 3' acceptor site from the intron of the 
sequence for the variable region of the immunoglobulin heavy chain. Chimeric 
intron sites can improve transcription of the insert by as much as 20-fold (363- 
365). However, the pCI-neo vector is larger in size as it also contains a 
neomycin resistance gene, which is unnecessary for the purposes of in vivo
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Figure 2.1 The nucleotide sequence of the MHC class I RTl.A3 a-chain.
The start and stop codons, the poly-adenylation signal, and the restriction digest 
sites involved in the subcloning procedures are shown in bold. The signal 
sequence is shown in italics (nucleotides 10-81). The soluble version was 
created by mutating the original sequence to incorporate the nucleotides for a 
stop codon and a Xba I digest site (taatctagacg) at position 934 (the methionine 
amino-acid residue at position 284 of the transmembrane region). Eco RI 
restriction sites are present at either end of the sequence for the purposes of 
cloning into the pcexvl-neo and pcDNAI-amp expression vectors. The sequence 
for the soluble antigen was subcloned into the pcmu-IV vector at the Not I and 
Xba I restriction sites, whereas cloning into the pCI-neo vector was achieved by 
using the Eco RI and the Xba I sites for the soluble antigen and the Eco Rl and 
PVU II sites for the full-length antigen.
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601 c t c g g g a a g g  a g a c a c t g c t  g c g c t c a g a t  c c c c c a g a g g  c a c a t g t g a c  c c t t c a c c c c
661 a g a c c t g a a g  g t g a t g t c a c  c c t g a g g t g c  t g g g c c c t g g  g c t t c t a c c c  t g c t g a c a t c
721 a c c c t g a c c t  g g c a g t t g a a  t g g g g a g g a c  c t g a c c c a g g  a c a t g g a g c t  t g t g g a g a c c
781 a g g c c t g c a g  g g g a t g g a a c  c t t c c a g a a g  t g g g c a t c . t g  t g g t g g t g c c  t c t t g g g a a g
841 g a g c a g a a t t  a c a c a t g c c g  t g t g g a g c a t  g a g g g g c tg c  c t a a g c c a c t  t t c c c a g a g a
901 t g g g a a c c t t  c t c c a t c g a c  t g a c t c c a a c  at< g a a a c c a  c t g t  
taatcta gacg
: a t t t a  t g t c a t c c t t
961 g g a g c t g t g g  c c a t g a t t g g  a g c t g t g g c c  a t c a t a g g a g  c t a t g g t g g c  t g t t g t g a g g
1021 agg a g g aag a g a a a c a c a g g tg g g a a a g g a g g a g a c t a c g c c c c t g c t c c ag g c ag g g ac
1081 a g c t c c c a g a g c t c c g a t g t g t c t c t c c c a g a t t g t a a a g  c a t g a a g a c a  g c t g c c t g g a  
stop Pvu II
1141 g t g g a c t g a g t g a c a g a c g a t g t g t t c a g g t c t c t c c t g t g a c a t  cc ag a g c c c t c a g t t
1201 c t c t t t a g a c a c c a g t g t c t g a a g t t c c c t g t g a t t c t a t g g c t t c a g t g t g a a g a a c t g
1261 t g g a g c c c a g c c t g c c c t g c a c t t c a g g a c c c t g t c c c t t c a c t g c c c g c t t t c c c t t c c
1321 a c a t t c a g c c t t g c t g g t c c ag c c t g g g g g t g g a g g g t g g g g a c a t c t g c a t c c t g t c c c
1381 c c t g t g c t a c c c t g a g c t t c a g c c c c t c a c t t c c a c c c t g a g a a t a a g a a t c t g a g t g t g
1441 a a c t t g a t t g t t c a c a t c c t t g a c a c a a g t g t a g a t g g c t t t t t a a a t t a c t g g a t t g a g
1501 a a t a c t t a g a g g t t t t t t g t t t t g g g t t t t g c t t t g t t t g a t t t t g t t t t t g a a a a a a a t
1561 a a a t g g c a g a t g g a g a a g c t t c c a a a a a a a .
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intramuscular injection. Finally, Etienne Joly (Babraham Institute, Cambridge, 
UK) kindly gifted the full-length RT1.A3 sequence which had been cloned into 
the pcmu-IV vector (366) Within this vector (Figure 2.2D), a human a-globin 
promoter and an SV40 enhancer control expression of the inserted MHC class I 
sequence. The stability of the mRNA is enhanced by the xenopus sequence, 
which adds an untranslated 5' cap (367). The untranslated 3' end of the rabbit (3- 
globin gene provides an intron acceptor site and the polyadenylation signal 
(368). This vector is not commercially available but this promoter and enhancer 
complex achieve high levels of expression of the downstream class I inserts 
(Etienne Joly, personal communication).
The class I sequences were subcloned into the pcDNAI-amp vector in two stages 
(Figure 2.3A). The full-length (Aa) and soluble RT1.A3 (tAa) heavy chain 
sequences were initially excised from the pcexvl-neo vector and reinserted into 
the pic20H cloning vector (Invitrogen, Carlsbarg, California) by digesting with 
Eco RI restriction enzyme (pic20H/Aa and pic20H/tAa, respectively). The 
sequences were then excised from the pic20H constructs by doubly digesting at 
the Bam HI and Xba I restriction sites, and religating into the pcDNAI-amp vector 
at the same sites (the RTl.A a-encoding pcDNAI-amp vectors are hereafter 
referred to as pcdna-Aa and pcdna-tAa) . The Bam HI and Xba I restriction digests 
cleave DNA to leave overhanging non-complementary ends, which increases the 
efficiency of the ligation reaction by ensuring that the pcDNAI-amp can only 
reform into double-stranded circular DNA by the inclusion of the class I sequence 
in the correct orientation. Control constructs were also created, in which the class 
I sequences were inserted in an anti-sense direction, firstly by doubly digesting the 
pic-20H/Aa construct with Bgl II and Sal I restriction enzymes, and then by 
cloning into the pcDNAI-amp vector at the Bam HI and Xba I sites (Figure 2.3B)
To create the pCI-neo class I constructs (pcineo-Aa and pcineo-tAa), Eco Rl/Xba I 
and Eco RI/Pvu II digests were performed to excise the truncated and full-length 
RT1.A3 sequences respectively from the pcexvl-class I vectors. The full-length 
sequence was inserted into the pCI-neo vector at the same digest sites, but the 
truncated sequence was inserted into the Eco RI and Sma I cloning sites
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Figure 
2.3 
D
iagram
s 
of sequential cloning 
of R
T
1.A
3 sequence 
into 
pcD
N
A
I-am
p 
in 
sense 
(A) 
and 
antisense 
(B) orientations.
(an Sma I digested end can religate onto a Pvu II digest as they are both class I 
restriction enzymes that cleave to leave blunt, rather than overhanging, ends).
To insert the sequence for the truncated, soluble version of the RT1.A3 sequence 
into the pcmu-IV vector, the pcmu-Aa plasmid was digested at the Xba I and Not I 
sites to excise the full-length sequence. The pcmu-IV vector was then re­
circularised by religating in the presence of the cDNA sequence for the truncated 
RT1.A3 antigen, which had been excised from the pcexv-tA3 vector using similar 
restriction digests. Empty control, pcmu-IV, plasmid was created by excising the 
full-length A3 insert at the Bam HI restriction site (Figure 2.4). Figure 2.5 depicts 
the series of DNA agarose gels that were performed in the creation and 
purification of the class I MHC containing pcmu-IV vectors.
■BamHl 
■ N otl ■LS LS
al a l
A pr a2 a2
pcmu-IV
a3 a3
Stop  
Xba] 
BamH 1TM
CD Stop
X bal
Bam Hl
Full length Aa Truncated Aa 
(pcmu-Aa) (pcmu-tAa)
Figure 2.4 Diagram of pcmu vector and RT1.A3 class I MHC inserts.
The pcmu-tAa vector was created by excising the full-length RT1.A3 sequence from 
the pcmu-A3 vector at the Not I and Xba I sites and inserting a similarly digested 
sequence for the truncated version (from pcexv-tA3) at the same sites. The first 14 
amino acids of the leader sequence (LS), upstream of the Not I site, are provided by 
the corresponding region of the mouse class I (H2-Db) sequence. The Xba I site 
directly downstream of the stop codon of the full-length sequence is not present in 
the original description of the RT1.A3 sequence (39) but had been previously 
incorporated by mutagenesis. The truncated A3 sequence encodes a soluble form of 
the class I a-chain resulting from the inclusion of a stop codon at nucleotide 934 in 
the transmembrane region (TM), thereby excising the cytoplasmic domain (CD).
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2.2.2 In Vitro Expression o f  the RTl.Aa Plasmid Constructs
Expression of MHC class I by the vector constructs was assessed by lipid- 
mediated, cell line transfection. Despite optimisation of transfection conditions 
(see section 2.5.2.2), there was neither expression of the R Tl.A a antigen on the 
cell surface nor in the cell culture supernatant following transient transfection of 
the rat myoblast cell line, L6, with the initial class I constructs, pcexv-Aa and 
pcexv-tAa (data not shown). Transient transfection, in which the plasmid does not 
integrate into the host genome, is a relatively inefficient, short-lived process. 
Transfection was therefore repeated but successfully transfected cells, which co­
express neomycin resistance, were selected by growing in geneticin (Sigma- 
Aldrich, Poole, UK). This permits incorporation of the plasmid into the genome, 
resulting in a population of stably transfected cells, in which every cell expresses 
the plasmid product. Only 2-3 cells per flask were initially resistant to geneticin, 
confirming that the efficiency with which the L6 cell line is transiently transfected 
is poor. Flow cytometric analysis of the stably transfected cell line confirmed that 
only the full-length, and not the truncated, RT1.A3 molecule was expressed on the 
cell surface (Figure 2.6). Conversely, soluble RT1.A3, as detected by an Aa- 
specific ELISA, was present in the supernatant of cells transfected with the 
truncated, but not the full-length, Aa molecule (Figure 2.7). Cells transfected with 
the control ‘empty’ vector expressed neither membrane-bound, nor water-soluble 
RT1.A3 protein (Figures 2.6 and 2.7). The L6 cell line was stably transfected on 
four occasions with identical results. Flow cytometric analysis of the pcexv-Aa 
transfectants invariably resulted in a bifid graph (Figure 2.6C), suggesting that 
two cell populations were present. The level of fluorescence in the left-hand 
population was no higher than the control line and this probably represents cells 
that have lost their plasmid on cell division.
To confirm that cloning of the RT1.A3 heavy chain into the pcDNAI-amp, pCI- 
neo and pcmu-IV vectors resulted in the translation and expression of a detectable 
cell surface protein, transient transfection of the L6 cell line was performed. 
Again flow cytometric analysis of the transfected cells did not reveal cell surface 
expression of the RTF A3 protein. As the pcDNAI-amp and pcmu-IV vectors 
don’t encode a selectable marker, stable transfection was not possible and
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A) Empty vector (pcexv)
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B) Truncated R Tl.A a (pcexv-tAa)
64
0
a3O
CJ
U
10 100 1000
C) Membrane bound R Tl.A a (pcexv-Aa)
64
0
10 100 1000
Fluorescence
Figure 2.6 Cell surface expression of R Tl.A a MHC class I.
The rat myoblast cell line L6 was stably transfected empty plasmid, pcexv (A), or 
plasmid encoding either the truncated (water-soluble) RT1.A3 molecule, pcexv-tAa 
(B), or the full-length, (membrane-bound) RT1.A3 molecule, pcexv-Aa (C). Flow 
cytometric analysis was performed after incubation of the cells with FITC- 
conjugated MN4-91-6 monoclonal antibody (mAb), which labels a polymorphic 
determinant of RT1. Aa.
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subsequent studies were performed using a human embryonal cell line, 293, which is 
transfected with approximately 90% efficiency using liposome-mediated transfer. 
Flow cytometric analysis of 293 cells that had been transiently transfected with the 
vectors encoding the full-length RT1.A3 heavy chain confirmed cell surface 
expression for all of the constructs (Figure 2.8 A-D). Transfection with the 
constructs encoding the truncated, water-soluble RTF A3 antigen resulted in cell 
surface expression similar to control non-transfected cells (Figures 2.8E and 2.8F). 
The pcdna-A3, pcineo-A3 and pcexv-A3 vectors were all associated with similar 
levels of RT1.A3 expression (Figure 2.9), which is unsurprising given the similarities 
in their promoter regions. Expression following transfection with the pcmu-Aa vector 
was significantly higher (Figure 2.9).
800 1
a©
pcexv-tAa pcexv-Aa pcexv
Figure 2.7 Soluble R Tl.A a protein in stable L6 culture supernatant.
Rat myoblast L6 cells were stably transfected with either the full-length RT1.A3 
construct (pcexv-A3), the truncated RT1.A3 construct (pcexv-tA3), or empty 
plasmid (pcexv). Undiluted samples of cell culture supernatant were assayed for 
the presence of soluble RT1.A3 protein by ELISA, using MN4-91-6 mAb as the 
capture antibody and biotinylated 0X18 mAb for detection. A detergent lysis of 
ACI splenocytes was used as a standard; the undiluted sample was arbitrarily 
assigned a concentration of 1000 units/ml. From serial dilutions of the standard, a 
standard curve was constructed using Biorad software and the concentration o f the 
test samples calculated. The results represent the mean and standard deviation of a 
minimum of four experiments.
An RT1.A3 specific ELISA was performed to confirm the presence of soluble 
RT1.A3 protein in the cell culture supernatant of the transiently transfected 293 
cells (Figure 2.10). There were significantly higher levels of RT1.A3 protein in the 
supernatant from cell lines that had been transfected with the vectors encoding the 
truncated, water-soluble RTF A3 class I sequence than in supernatant from the cell 
line transfected with the empty control vector. There was no detectable RTF A3 
protein in the supernatant from cells transfected with vectors encoding the full-
70
length RT1.A3 sequence (Figure 2.10, levels for pcmu-Aa depicted as example). 
O f the vectors encoding the truncated Aa antigen, the pcmu-tAa plasmid was 
associated with the highest mean level of expression, but this difference did not
32
0
32
0
.1 1 10 100 1000 .1 1 10 100 1000
C) pcineo-Aa
1 10 100 1000
D) pcexv-Aa
32
0
1 100010 1001
E) pcmu-tAs F) 293 cells
I I I I I I I  I I I II  Mil 
10 100 1000
Fluorescence
reach statistical significance (Figure 2.10).
0-1-1
Fluorescence
Figure 2.8 Cell surface expression of the R T l.A a MHC class I antigen.
The full-length RT1.A3 heavy chain sequence was cloned into the pcmu-IV, the 
pcDNAI-amp, the pCI-neo, and the pcexvl-neo vectors (as described in section 
2.2) to form respectively, pcmu-Aa, pcdna-Aa, pcineo-Aa and pcexv-Aa. The 
truncated RT1.A3 sequence was also inserted into the pcmu-IV vector (pcmu-tAa). 
The human embryonal kidney cell line 293 was transiently transfected with these 
constructs and flow cytometric analysis performed 48 hours later, by labelling 
with the FITC-conjugated MN4-91-6 mAb. The diagrams are representative o f a 
minimum of three experiments. The pcmu-Aa plasmid consistently resulted in 
higher levels of RT1.A3 expression (A). Of the truncated RT1.A3 constructs only 
the pcmu-tAa result is shown (E). Similar results were achieved with the 
remainder. Quantitative comparison of the levels of expression associated with 
each of the class I constructs was performed by gating separately on the 
transfected cell population, as depicted in the arrowed population in Figure A, and 
calculating its mean channel fluorescence (Figure 2.9).
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Figure 2.9 Quantitative comparison of cell surface R Tl.A a expression
293 cells were transiently transfected with the vectors encoding the R Tl.A a 
class I antigen using liposome-mediated transfection. 48 hours later cell 
surface expression of the RT1.A3 antigen was quantified by labelling cells 
with FITC-conjugated MN4-91-6 mAb and using flow cytometric analysis to 
calculate the mean channel fluoresence of the separately-gated transfected cell 
population (Figure 2.8). Values on the y-axis represent the mean channel 
fluorescence of this cell population. One way analysis of variation confirms 
the presence of separate populations (ratio of between group to within group 
variation: 35.7, p  < 0.001). Smilarly, there was no statistical difference 
between the levels of RTl.A a expression in control, non-transfected cells and 
cells transfected with pcmu-tAa vector, which encoded the truncated (water 
soluble) version of the RT1.A3 antigen (Mean +/- SD: 1.56 +/- 0.19 vs. 1.49 
+/- 0.094). There was no detectable surface RT1.A3 expression following 
transfection with any of the plasmid vectors that encoded the truncated A3 
cDNA (data not shown). The pcineo-A3, pcdna-A3 and pcexv-A3 vectors 
achieved comparable levels of A3 class I expression (Mean +/- SD: 2.2 +/- 
0.24, 2.2 +/- 0.28, 1.99 +/- 0.17), but this was significantly higher than the 
control cell line (95% Cl for the difference in means; 0.22 to 1.05; p  < 0.001). 
The pcmu-A3 vector induced the greatest levels of RT1.A3 expression (2.8 +/- 
0.27), which was significantly greater than the levels associated with the other 
class I-expressing constructs (95% Cl for the difference in means; 0.15 to 
1.06, p=0.003)
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Figure 2.10 Soluble RT1.A3 protein expression following 293 cell line 
transfection.
Human kidney embryonal 293 cells were transiently transfected with R Tl.A a 
class I vector constructs and undiluted cell culture supernatant analysed for the 
presence of the soluble RTl.A a protein 48 hours later by Aa specific ELISA. 
The results represent the mean and standard deviation of four experiments. A 
one way analysis of variance confirms that significantly different populations 
are present (ratio of between group to within group variation: 22.86, p<0.001). 
Cell lines transfected with the vectors encoding the truncated RT1.A3 sequence 
secrete significantly more RT1.A3 antigen into the cell culture supernatant than 
either the control, non-transfected lines (95% Cl for the difference of the means 
= 27 to 67 units/ml, p=0.002), or lines transfected with the full-length RT1.A3 
sequence (results for only the pcmu-Aa vector are shown). Although the mean 
secretion of RT1.A3 antigen was highest for the pcmu-tAa vector, this was not 
significantly different when compared to the other vectors encoding the soluble 
version of the A3 class I antigen (cf. pcineo-tAa; 95% Cl for the difference in 
the means = -4.3 to 35.3; p=0.246).
2.2.3 In Vivo Expression o f  the RTl.A a Plasmid Constructs
2.2.3.1 Local Expression o f  the RTl.Aa Antigen
Intramuscular expression of the RT1.A3 antigen was assessed by histological 
examination of the tibialis anterior muscle five days after PVG.RT1U rats were 
injected with lOOpg of the pcmu-IV vector encoding either the full-length or 
truncated RT1.A3 cDNA sequence. Three days prior to plasmid injection, the 
muscle was injected with 400pl of 0.5% Bupivicaine (l-butyl-N[2, 6-dimethyl 
phenyl] 2-piperidine-carboxamide) to induce myocyte regeneration, and thereby 
increase the efficiency of gene transfer. Figure 2.11 A depicts the typical 
histological appearance following bupivicaine injection. Areas of muscle 
regeneration containing numerous small myocytes are present and are arranged in
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tracts, consistent with injection sites. These tracts are surrounded by normal, non­
regenerating muscle that contains larger myoblasts.
Following injection with the pcmu-IV construct encoding the full-length Aa 
sequence (pcmu-Aa), peroxidase staining with MN4-91-6 mAb revealed that 
expression was confined to areas of regeneration (Figure 2.1 IB). No staining was 
present in muscle that had been injected with the control empty pcmu-IV vector 
(Figure 2.11C). Antibody against third party RT1.A antigen, which would have 
been the optimum control isotype antibody, was not available. Instead, the muscle 
was stained with the mouse IgG2a mAb, ESH8, which is directed against human 
factor VIII (Scottish Antibody Production Unit, Law, Scotland, UK). No 
expression was discernible (Figure 2.1 ID).
Muscle tissue, which had been injected with the vector encoding the truncated 
version of the RT1.A3 heavy chain sequence (pcmu-tAa), stained weakly upon 
labelling with MN4-91-6, with the results neither reliable nor convincingly higher 
than the levels of background staining (data not shown). Presumably the lack of 
cell surface tethering of the product of this plasmid prevented accurate fixation 
and staining.
2.2.3.2 Alloantibody Response to the Aa Product o f  the Pcmu Vectors.
Expression of the RT1.A3 antigen following intramuscular injection of plasmid 
was further confirmed by assessing the development of an anti-A3 alloantibody 
response. PVG.RT1U hosts injected intramuscularly on day 0 with the pcmu-IV 
vector encoding either the full-length (pcmu-A3) or truncated (pcmu-tAa) class L 
constructs developed a lymphocytotoxic alloantibody response, which could be 
detected by day 10 and was still present on day 26 following the plasmid injection 
(Figure 2.12). Injection of the control, empty pcmu-IV vector did not generate an 
alloantibody response. Although the alloantibody response to the product o f the 
pcmu-A3 vector displayed similar kinetics to the response against the pcmu-tA3 
vector, at all time points the magnitude of the response to the full-length RT1. A3 
antigen was smaller (Figure 2.12). Similar findings have been reported for 
plasmids that code for the retained or secreted forms of both the hepatitis C (369) 
and ovalbumin antigens (370). Although the genetic sequence for the soluble
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RT1.A3 protein lacks the transmembrane and cytoplasmic domains, the rate of 
translation of its product will be similar to that of the full-length antigen. The 
quantitative difference in the antibody response presumably reflects greater 
bioavailability of the water-soluble RT1.A3 antigen at the site of primary B cell 
activation within the T cell areas of secondary lymphoid tissues.
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Figure 2.12 Circulating lymphocytotoxic R T l.A a alloantibody response.
PVG.RT1U rats were immunised with the pcmu-IV vector encoding either the full- 
length (pcmu-Aa) or truncated (pcmu-tAa) nucleotide sequence of RT1.A3. Control 
animals were immunised with empty pcmu-IV plasmid. Animals received 400pl of 
0.5% bupivicaine intramuscularly followed 3 and 8 days later, by injection of 200pg 
of plasmid. Lymphocytotoxic antibodies in serum samples were detected by their 
ability to lyse 51Cr-labelled, Con A-transformed splenic blasts in the presence of 
guinea pig complement. Results are expressed as the mean and standard deviations 
of antibody titre (last dilution of serum that gave >=20% cytotoxicity) of a minimum 
of three animals. Values on the abscissa represent the time elapsed in days from the 
first injection of plasmid.
* p  < 0.05, Mann-Whitney U test (2-tailed).
The alloantibody response to the product of the pcmu-tA3 vector consisted of an 
early IgM response that was detectable by day seven, but heavy chain class 
switching, to the IgG2b isotype exclusively, was evident by day 10 (Figure 2.13). 
This confirms that plasmid injection results in an efficient T and B cell response 
to the RT1.A3 antigen since isotype switching is particularly T helper cell 
dependent (296, 303). The kinetics of the IgG2b response closely matched those 
of the allocytotoxic response (cf. Figure 2.12 to Figure 2.14). This is unsurprising,
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for in the rat, the IgG2b antibody subclass is the most effective mediator of 
complement-dependent lysis (371). The magnitude of the IgG2b response to the 
pcmu-tAa vector was significantly higher than to the pcmu-Aa vector (Figure 
2.14). No other isotype response was detected at later time points. No antibody 
was detectable in control animals (data not shown).
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Figure 2.13 Ig class and subclass of the anti-RTl.A3 antibody response.
PVG.RT1U rats were immunised with 400pl of 0.5% bupivicaine intramuscularly 
followed 3 and 8 days later, by injection of 200pg of pcmu-tAa. 7 days (Figure A) 
and 12 days (Figure B) later, sera were analysed for anti-Aa alloantibody by flow 
cytometric analysis, using PVG.R8 LNCs as targets and FITC-conjugated mouse 
anti-rat Ig subclass-specific mAb. Results (mean channel fluorescence) are shown 
as the mean and SD for a minimum of three animals.
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Figure 2.14 The allospecific IgG2b response following intramuscular injection 
with RT1.A3 encoding pcmu vectors.
PVG.RT1U rats were immunised with 400pg of the pcmu-IV vector coding for either 
the full-length RT1.A3 cDNA sequence (pcmu-Aa) or the truncated soluble version 
(pcmu-tAa). Serum samples taken on days 10, 12, 14, 19 and 26 after immunisation 
were assessed for IgG2b content by flow cytometry using naive PVG-R8 LNCs as 
target cells and a FITC-conjugated anti-IgG2b mAb. Results are expressed as the 
final dilution of serum at which antibody levels were greater than or equal to twice 
background values (level of fluorescence observed with cells and antibody alone). 
Control animals that received the empty pcmu-IV vector did not generate an anti-Aa 
IgG2b response (data not shown). Results represent the mean and standard 
deviations of 3 animals per group. Statistical analysis was performed using the 
Mann-Whitney U test; * p  < 0.05.
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2.3 Discussion
The cDNA sequence for the truncated water-soluble version of the RT1.A3 
antigen was created by inserting a stop codon after the a3 domain of the heavy 
chain, as initially described by Bjorkman (31). The transmembrane and 
cytoplasmic domains are responsible for tethering the RT1.A3 antigen to the cell 
membrane and their absence is equally advantageous in preventing aggregation of 
the soluble protein into multivalent complexes.
Transient in vitro transfection of the L6 rat myoblast cell line with either the full- 
length or truncated versions of the RT1.A3 antigen was unsuccessful and stable 
transfection was required. Expression in the rat myoblast cell line is important, as 
the in vitro model it represents most closely correlates with the proposed in vivo 
use of the plasmid. Equally, stable transfection provides the most strenuous 
examination of the potential for the soluble version of the RT1.A3 antigen to be 
expressed, even transiently, on the cell surface. If this were to occur, the central 
tenet of the experimental model, that the soluble A3 construct is unable to activate 
T cells directly, would be invalidated. Flow cytometric analysis of L6 cells stably 
transfected with the soluble A3 construct revealed levels o f cell-surface 
fluorescence identical to the control line (Figure 2.6B).
Subsequent in vitro expression experiments were performed on the human kidney 
embryonal cell line, 293, which is transiently transfected with much greater 
efficiency. Transfection with the pcmu-A3 vector resulted in a significantly higher 
level of cell-surface expression of the RT1.A3 antigen than was associated with 
the other A3-encoding vectors (Figure 2.9). Similarly, transfection with the pcmu- 
tA3 vector achieved greater levels of secreted soluble RT1.A3 antigen, though this 
did not reach statistical significance (Figure 2.10). The reason why the pcmu-IV 
vector was more efficient at expressing RT1.A3 protein than the commercially- 
available vectors (which contain generally powerful viral promoters and 
enhancers) is unclear; it presumably relates to the small size of the pcmu-IV 
vector and to an intrinsic ability of the human a-globin promoter to preferentially 
induce expression of MHC inserts.
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The quantities of plasmid required to assay the in vivo expression of each of the 
RT1.A3 constructs makes such an approach impractical and although the 293 cell 
line is of human derivation, it is reasonable to assume that Aa encoding pcmu-IV 
vectors would achieve the highest levels of expression of the RT1.A3 antigen in 
rat hosts. The pcmu-IV constructs were therefore chosen for subsequent in vivo 
experiments, although their small copy number is disadvantageous in that greater 
quantities of bacterial culture are required to purify a unit of plasmid and this 
potentially increases the concentration of bacterial contaminants. For this reason 
all plasmid that was used in vivo was prepared using Qiagen kits (Qiagen, 
Crawley, UK) that incorporated an Endotoxin Removal Buffer (section 2.5.1.5)
The in vivo use of DNA vectors generally involves either their incorporation into 
cationic lipids (see (372) for review), or the injection of the naked DNA 
intramuscularly. The latter technique results in the uptake of only picograms of 
the plasmid (373, 374), possibly through the T tubules and caveolae of skeletal 
muscle (375). Expression can be increased by pre-injection o f the muscle with 
either hypertonic solutions (376) or chemicals that stimulate muscle regeneration, 
such as bupivicaine (377). Plasmid DNA does not replicate in injected muscle 
cells, but can persist for years as an episome. Myoblasts do not, however, express 
costimulatory signals and one could consequently argue that their manipulation to 
express antigenic proteins would result in T cell tolerance, rather than stimulation 
(235). Nevertheless, intramuscular plasmid vaccination induces strong humoral 
and cellular immune responses (361, 362). It is now apparent that T cell activation 
following naked DNA injection intramuscularly is at least partly due to antigen 
presentation by dendritic, rather than muscle, cells (378). Dendritic cells are able 
to phagocytose protein antigen after it has been expressed by muscle cells, but are 
also capable of internalising and subsequently transcribing the plasmid DNA 
(379). Dendritic cells are professional APC and in theory only limited expression 
of the antigen would be sufficient to result in a powerful T cell response. 
Moreover, plasmid DNA of bacterial origin contains, unlike eukaryotic DNA, 
unmethylated CpG motifs, which have a strong adjuvant effect, promoting 
dendritic cell maturation, and migration to lymphoid tissue (380, 381).
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A consequence of the presentation of injected DNA antigen by dendritic cells is 
the preferential development of a Thl-biased T cell response (382). 11-12 is 
produced by the dendritic cells in response to unmethylated motifs present within 
the plasmid DNA. This in turn induces IFN-y production and creates the 
appropriate cytokine milieu to polarise towards a Thl response (383). The class 
and subclass of the antibody response is influenced by the nature of the T cell help 
(see (384) for review). In the rat a Th2 response favours the development of IgGl 
and IgG2a antibody subclasses, whereas the provision of help by Thl cells results 
in switching to the IgG2b and IgG2c subclasses (385). These observations may 
explain why the anti-Aa response in PVG.RT1U animals following injection of the 
Aa-encoding plasmid was of the IgG2b subclass (the IgG2c response was not 
assayed). This is in contrast to previous work in Bradley’s laboratory; PVG.RT1U 
animals that received either a PVG.R8 blood transfusion (246) or a kidney graft 
(386) developed an IgG response in which the levels of the subclass isotypes were 
comparable.
McPherson et al have recently demonstrated that dendritic cells are able to 
internalise and present intact protein antigen to B cells in conjunction with the 
necessary costimulatory signals to stimulate isotype switching (301, 387). This 
results in an abbreviated IgM response. The isotype response to the products of 
the plasmid vectors is similarly abbreviated, supporting the concept that the 
immune response to the plasmid vectors is the result o f dendritic cell presentation. 
For example, the IgM response to the Aa antigen following pcmu-tAa injection 
was detectable only on day 7 and had switched to an IgG2b response by day 10. In 
comparison, the IgM response to an R8 blood transfusion is detectable from day 7 
to day 14 (Lovegrove E., Ph.D. thesis).
Theorerical justification for using soluble class I alloantigen is reliant on it sharing 
similar B cell epitopes as the naturally-occuring antigen on the surface of donor 
PVG.R8 cells, such that a cross-reactive antibody response can develop. The 
formation of a stable, properly folded MHC class I molecule requires the presence 
of heavy chain, p2 -microglobulin (P2 M) light chain and bound peptide, but the 
injected plasmid encoded the heavy chain only. Expression of intact Aa antigen 
following plasmid injection is therefore reliant on the incorporation of
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endogenous P2 M and peptide. The P2 M subunit is highly conserved, as confirmed 
by the expression of RT1.A3 protein with the appropriate quaternary structure in 
human cells that were transfected with the heavy chain only. The RT1.A3 antigen, 
as expressed by plasmid-transfected PVG.RT1U muscle cells, is however, likely to 
present a different spectrum of peptide than the equivalent naturally-occuring 
antigen due to differences in both the pool of cytosolic proteins and in the nature 
of the TAP haplotype (130). Crucially, despite the differences in P2 M and in the 
spectrum of bound peptide, the alloantibody assays as used in these studies rely on 
the use of donor PVG.R8 target cells, and these confirm that the antibody 
response to the A3-encoding pcmu-IV vectors cross-reacts with the wild-type 
RT1.A3 antigen.
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2.4 Summary
Several plasmid constructs that expressed the full-length and truncated versions of 
the RT1.A3 antigen were created. These differed in size and in the nature o f the 
promoter/enhancer regions that controlled expression of the class I inserts. In vitro 
transfection studies confirmed that the constructs expressed either the membrane- 
bound or soluble RT1.A3 antigens with 100% purity and that the pcmu-IV vector 
achieved the highest levels of expression. The RT1.A3 antigen was detected by 
immunohistochemical staining of the muscle o f animals that had been injected 
with the pcmu-Aa construct. Both R Tl.A a encoding pcmu-IV vectors resulted in a 
strong lymphocytotoxic alloantibody response with heavy chain class switching 
predominantly to a Thl isotype subclass. The antibody response to the transgenic 
RT1.A3 molecule cross-reacts with the wild type antigen. Confirmation of the 
shared nature of the B cell epitopes is essential in fulfilling the theoretical 
requirements of the model.
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2.5 Materials and Methods
2.5.1 Construction and Purification o f the RTl.Aa Heavy Chain Encoding 
Vectors.
2.5.1.1 Restriction Digests
Restriction digests were performed using enzymes from Amersham Pharmacia 
Biotech Ltd (Bucks, UK). A common buffer, ‘One-Phor-All Buffer-plus’, applies 
to every enzyme, and this simplifies the use of two enzymes simultaneously. 
Generally, 0.5 to lpg  of target DNA in a total volume of 20pl was digested with 
one unit of enzyme at 37°C for 2-3 hours. The digest products were separated by 
agarose gel electrophoresis.
2.5.1.2 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used for purifying DNA and visualising the 
products of restriction digests. Gels were prepared and run according to the 
method of Aaij and Borst (388) with modifications by Sambrook (389) as follows: 
Agarose (0.8-1.5% (w/v)) was dissolved in TAE buffer (40mM Tris-base, 0.2% 
(v/v) glacial acetic acid, ImM EDTA, pH 8.0) by heating to 100°C. The solution 
was cooled to 60°C with gentle stirring to ensure even heat distribution and the gel 
poured around the required comb. The gel was left to set for 30 minutes at room 
temperature and then submerged in TAE buffer. Samples were mixed in a 6:1 
ratio with DNA gel loading buffer (40% (w/v) sucrose, 0.01% (w/v) bromophenol 
blue) and volume equivalents of no more than 0.5pg DNA added to each well of 
the gel. The gels were run horizontally using a Stratagene Minigel system 
(Cambridge, Cambridgeshire, UK) at 100V until the bromophenol blue tracking 
dye had advanced sufficiently down the gel. After staining with 1% ethidium 
bromide (Sigma-Aldrich Ltd , Dorset, UK), the gels were visualised on a ‘Biorad 
Gel Doc 1000’ UV transilluminator (Biorad, Hemel Hempstead, UK) and 
analysed using associated Biorad ‘Molecular Analyst Software’. Molecular weight 
markers VII (0.37 to 8.0 kbp), or VIII (0.67 to 1.114 kbp) (Boehringer Mannheim, 
Boehringer, Germany) were used to distinguish fragment sizes.
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2.5.1.3 Subcloning
The appropriate digest products were eluted from the agarose gel by using either 
‘Geneclean II’ (BIO 101, La Jolla, California) or ‘Wizard DNA Clean-Up’ 
(Promega, Southampton, UK) purification kits. Although the specific protocols 
for these kits differ, they rely on the addition of a high osmolar buffer solution to 
dissolve the DNA from the agarose gel block, while simultaneously inducing the 
preferential binding of the DNA to silica particles. The liquid phase containing the 
impurities is then exchanged with wash buffer, before the DNA is finally eluted 
from the silica with either TE buffer or water. The final products were re-run on 
an agarose gel, enabling quantitation of the recovered DNA.
Cloning of DNA inserts was generally designed so that the parent vector was 
digested with two restriction enzymes simultaneously, resulting in non-cohesive 
termini that could only be re-ligated by the addition of an insert with reciprocal 
digests at either end. This increases the efficiency o f the ligation reaction; as much 
as 80% of the linearised vector will be converted to monomeric plasmid/insert 
DNA chimeras (389). Ligation involves the formation of new bonds between the 
phosphate residues located at the 5' termini of double-stranded DNA and adjacent 
3'-hydroxyl moieties and is catalysed by the addition of T4 DNA ligase (Gibco 
BRL Life technologies, Paisley, UK). Calculation of the vector to insert DNA 
ratio was performed according to the equation:
Vector (ng) x size of insert (kbp) Moles of insert
---------------------------------------------- X   = Insert (ng)
Size of vector (kbp) Moles of vector
Generally, lOOng of vector was ligated using 1 Weiss unit of T4 DNA ligase in 
ligase buffer (66mM Tris-HCl, 5mM magnesium chloride, ImM dithioreitol, 
lOmM ATP, pH 7.5) in a volume of 10pl, at a temperature of 16°C overnight. A 
control ligation reaction without the DNA insert was invariably performed.
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2.5.1.4 Bacterial Transformation
Successful re-ligation of the plasmid vectors and subsequent transformation into 
E. coli bacteria confers ampicillin-resistance, due to the inclusion of the gene- 
sequence for p-lactamase within the plasmid vector. Before E. coli bacteria could 
be transformed with plasmid DNA they were made competent with CaCh 
treatment, as first described by Cohen (390). Briefly, under aseptic conditions, a 
freshly grown colony was transferred from an agar plate into 100ml of Luria broth 
(Gibco BRL, Life Technologies) and incubated for 3 hours at 37°C, ensuring that
o
the number of viable cells were not greater than 10 /ml. The bacteria were then 
cooled and resuspended in 0.1 M CaCU, and a volume equivalent to no more than 
50ng of the re-ligated DNA added. Following incubation on ice for 30 minutes the 
tubes were rapidly heat-shocked at 42°C. 800pl of broth was added and the 
mixture plated on ampicillin-containing agar plates and left overnight at 37°C. E. 
coli cells that had been successfully transformed grew as single colonies on the 
plate. Controls included competent bacteria that received either 50ng of standard 
preparation of plasmid DNA, or no plasmid. The E. coli strain, DH5a, was chosen 
for transformation as this grows rapidly, contains minimal amounts of 
carbohydrate, and does not exhibit significant levels of endonuclease activity 
(391).
2.5.1.5 Plasmid Purification 
Miniprep
A freshly grown colony of transformed DH5a E. coli bacteria was transferred to 
lOmls of Luria Broth (Gibco BRL), containing ampicillin at lOOpg/ml (Penbritin, 
SmithKline Beecham, UK) and expanded overnight in a shaking incubator at 
37°C. After centrifugation at 4000rpm for 4mins, plasmid was extracted from the 
bacterial pellet by either performing a boiling miniprep (392) or by using a 
commercially available Wizard Plus Minipreps DNA Purification System 
(Promega). The purified plasmid DNA was resuspended in TE buffer.
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Maxiprep
For in vivo animal use, larger quantities of plasmid were purified using a Qiagen 
Plasmid MegaKit, incorporating Endotoxin Removal Buffer (Qiagen, Crawley, 
UK). This purification procedure is based on the optimised alkaline lysis method 
of Birnboim and Doly (393), and involves the selective capture of plasmid DNA 
in anion-exchange columns in 1M salt solution, pH 7. Plasmid DNA is recovered 
from the column by eluting with 1.25M NaCl/Tris buffer at pH 8.0. The presence 
of endotoxin in standard DNA preparations may influence in vivo responses to 
plasmid DNA (394) and typical endotoxin levels in DNA purified using the 
endotoxin removal buffer are <50 endotoxin units per mg of DNA (395).
The pcmu-IV vector has a low copy number, which complicates its purification 
from E. coli cells, since the larger volumes of bacterial culture that are required 
per unit of plasmid purified increase the concentration of bacterial contaminants. 
Plasmid yield was improved by adding chloramphenicol (180mg/ml)(Pharmacia 
and Upjohn, Surrey, UK) to the bacterial culture at mid-log phase. The 
bacteriostatic effect of chloramphenicol increases the copy number of plasmid per 
bacterial cell. To optimise its use, chloramphenicol was added at various times to 
10ml miniprep cultures of the pcmu-Aa vector, and plasmid purified using the 
Wizard Plus minipreps, as described above. Purified DNA was quantified against 
standards by agarose gel electrophoresis, using Biorad software (section 2.5.1.2). 
The highest yield of plasmid was achieved when the chloramphenicol was added 
3 to 4 hours after culturing was commenced, when the optical density at 
wavelength 600nm was approximately 0.35 (Figures 2.15A and 2.15B).
2.5.2. In Vitro Expression o f the Products o f  R Tl.Aa-Encoding Plasmid
2.5.2.1 Cell Lines
A rat thigh muscle cell line, L6 (396) and a human embryonal kidney line, 293 
(397) (both from ECACC, Salisbury, UK) were used. L6 cells were grown as a 
monolayer in Dulbecco’s modified eagle medium (DMEM) (Gibco BRL), 
supplemented with 2mM glutamine (Gibco BRL) and 10% foetal calf serum 
(FCS) (Sigma Biosciences, Dorset, UK). They were subcultured when semi­
confluent to a seeding density of 1.5 -  2.0 x 103 cells/cm2 using trypsin/EDTA 
(Gibco BRL); 5% CO2 ; 37°C. 293 cells were grown as a monolayer in Minimal
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Figure 2.15 Optimisation of conditions for bacterial culture.
lOOjul of freshly grown pcmu-Aa transformed E. coli bacteria were transferred into a 
series of 10ml aliquots of Luria Broth and expanded in a shaking incubator at 37°C, 
200rpm. A single aliquot of 1.8mg of chloramphenicol was added at different time 
points (from 0 to 6 hours) after culture initiation and bacterial growth quantified by 
serial spectrophotometric analysis at 600nm.
A) Bacterial growth as measured at 600nm.
B) After 16 hours of culture, plasmid was purified using Promega Wizard 
Minipreps, linearised by digestion with Xba I, and quantified against standards 
on gel electrophoresis, using Biorad software. The graph represents the mean and 
standard deviation of each experiment performed in triplicate.
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Essential Medium (MEM) with Earle’s salts (Gibco BRL), supplemented with 2mM 
glutamine and 10% FCS. Cells were subcultured when 90% confluent and seeded at 3 -  5 
x 103 cells/cm2 using 0.25% trypsin.
2.5.2.2 Cell Transfection
Transfection of the rat myoblast cell line, L6 and the human embryonal kidney 
cell line, 293 was performed using DOTAP (N-[l-(2,3-Dioleoyloxy)propyl]- 
N,N,N-trimethylammonium methylsulphate) (Boehringer Mannheim). DOTAP is 
a cationic liposome-mediated transfection agent that forms stable complexes with 
negatively charged DNA. These complexes are able to adhere to the cell surface, 
fuse with the cell membrane and release DNA into the cytoplasm. The 
DNA:DOTAP ratio that achieved optimum transfection was established by 
initially transfecting the L6 cell line with the plasmid, pcDNA-CAT. (Invitrogen,
UK). The product of this plasmid expresses chloramphenicol acetyl transferase 
(CAT), which was quantified using a specific ELISA (Boehringer Mannheim). 
Optimum transfection of L6 cells in a 25cm2 flask was achieved with a mixture of 
5 jag of DNA and 25pl of DOTAP (Figure 2.16). Similar data was obtained for 
transfection of 293 cells (data not shown). Cells were re-plated 24 hours prior to 
transfection in order to achieve a cell density of 70% at the time of transfection.
For stable transfection the number of cells re-plated was reduced to achieve a cell 
density of 50% at the time of transfection. The DNA/DOTAP mixture was added 
to the cell culture medium and was replaced with fresh medium after 4 hours in 
culture. Transient expression of the product was assayed after a further 72 hours 
in culture. For stable transfection, geneticin (Sigma-Aldrich) was added, which in 
pilot experiments inhibited cell division at a concentration of 30mg/ml (data not 
shown).
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Figure 2.16 Optimising DOTAP transfection conditions
Optimum DNA and DOTAP concentrations for transfection of the L6 line were 
established by transfecting 1 x 106 cells with the pcDNA-CAT plasmid (Invitrogen), 
which expresses the reporter protein, chloramphenicol acetyl transferase (CAT). The 
expression of CAT was quantified 48 hours after transfection using a CAT-specific 
ELISA (Boehringer, Germany). The value on the x-axis represents the concentration of 
DOTAP used. It is expressed relative to the plasmid concentration; the amount of 
DOTAP added in pg is the factor of the value on the x-axis and the plasmid 
concentration. Points represent the mean and standard deviation o f three experiments.
2.5.2.3 Monoclonal Antibodies
The mouse monoclonal antibodies (mAb), MN4-91-6, specific for a polymorphic 
determinant of the rat RT1.A3 MHC class I molecule (398), and 0X18, which 
recognises a monomorphic determinant of the RT1.A MHC class I molecule (399) 
were used to detect expression of the product of the class I encoding plasmid 
vectors. These antibodies were produced by intraperitoneal injection of the 
appropriate hybridoma cell line into pristane-primed Balb/c mice (Harlan, UK) to 
produce ascites, from which IgG was purified by protein A column 
chromatography (ProSep, Fisher Scientific, Loughborough, UK). The 
concentration was determined by UV spectrophotometry. Biotinylation of the 
0X18 was performed by the N-hydroxysuccinimide method using a commercially 
available kit (Boehringer Mannheim) followed by overnight dialysis against PBS 
at 4°C. The mouse IgG2a mAb, ESH8, which is directed against human factor 
VIII (Scottish Antibody Production Unit, Law, UK), was used as isotype control 
(400).
W)c
a 6 #o
«u
E 44>CJao(J O
H<
U
91
2.5.2.4 Flow Cytometric Analysis o f  RTl.Aa Cell Surface Expression
Cell surface expression of the RT1. A3 antigen was quantified by flow cytometric 
analysis. 5 x 105 transfected cells were washed in washing medium (2.5.3.2), 
resuspended in 1 OOpil of PBS/0.2% BSA/0.1% sodium azide (PBA) and incubated 
for 30 mins at 4°C with FITC-conjugated MN4-91-6 mAb. The cells were then 
washed twice, resuspended in PBS and flow cytometry performed using a Coulter 
Epics XL flow cytometer (Coulter Ltd., Luton, UK) with associated software. To 
compare the levels of RT1.A3 expression induced by the different vectors, the 
transfected cell population was gated and the mean channel fluorescence of this 
sub-population noted. A one-way analysis of variation was performed to confirm 
that the levels of RT1.A3 expression induced by the various class I constructs 
represented different statistical populations. Modified T tests according to the 
Bonferroni method were then performed to interpret the significance of the 
variation for each specific construct.
2.5.2.5 Development o f  the ELISA against Soluble RTl.Aa
An RT1. A3 specific ELISA was developed according to the protocol described by 
Pockley AG et al. (401), with minor modifications. A control standard was 
prepared from the detergent lysates of rat ACI spleen (RT1.A) and was arbitrarily 
assigned a concentration of a 1000 units/ml. For the assay a 96 well, Immulon IV 
microtitre plate (Dynatech Laboratories, Billinghurst, UK) was bound overnight at 
4°C with 100pl of MN4-91-6 (5pg/ml) in carbonate/bicarbonate buffer, pH 9.6. 
The plate was washed with 0.05% Tween in PBS (washing buffer), and non­
specific binding blocked by incubation with 10% BSA for one hour at 37°C. A 
series of tripling dilutions of the RT1.A3 standard in cell culture medium were 
prepared. 1 OOjul of the standards or test samples (neat cell culture supernatant 
from the RT1.A3 transfected L6/293 cell lines) were added to the wells of the 
plates incubated for one hour at 37°C. Following washing, bound soluble class I 
was detected by the addition to each well of 1 OOptl biotinylated OX18 (5pg/ml) in 
PBS/0.2%BSA. After incubation for one hour at 37°C plates were washed and a 
lOOql of a 1:1000 dilution of extravidin/peroxidase conjugate (Sigma) in 
PBS/0.2%BSA added to each well and incubated for a further hour at 37°C. Plates
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were re-washed and lOOpl of TMB (KPL Ltd., Guildford UK) substrate added. 
The reaction was stopped by the addition of lOOpl of 0.2M H 2 O4  and the 
absorbance determined at 450nm using a Dynatech MR500 plate reader and 
associated ‘Biorad’ software (Dynatech Lab, Billinghurst, UK). A standard curve 
for the dilutions of the standards was constructed, from which the concentrations 
of the test samples were calculated. The presence of statistically distinct 
populations was assessed by performing a one-way analysis of variation. 
Intergroup variation was calculated using modified T tests (Bonferroni method).
Initial results were limited by high backgrounds. A variety of blocking agents 
were tested, 10% FCS, 10% BSA, 5% ‘marvel’ (Premier Bands Ltd, UK) or 
‘Megga-block III’ (Bionostics), and the latter was consistently associated with 
lowest background values (data not shown). However, acceptable background 
values (OD450 <0.1) were only achieved when commercially-obtained 
biotinylated 0X18 (Cedarlane Laboratories Ltd, Ontario, Canada) was used, 
suggesting that there had been non-specific biotin-binding associated with the 
biotinylated OX-18 batch that had been prepared in the laboratory.
2.5.3. In Vivo Expression o f  the Products o f  RTl.Aa Encoding Plasmids
2.5.3.1 Animals.
PVG.RT1U (AUB/DUCU) congenic rats and PVG.R8  (AaB/DuCu) recombinant rats, 
whose derivation is cross-referenced elsewhere (402), were obtained from Harlan 
Ltd., (Bicester, Oxon, UK). DA (R T lavl), PVG (RT1C), and Lewis (RT11) rats 
were obtained from the same source. All animals were maintained under standard 
animal house conditions at the University of Glasgow Central Research Facility 
and were used when 8 - 1 2  weeks old.
2.5.3.2 Tissue Culture Medium 
Washing Medium
Hanks Buffered Salt Solution (HBSS) (Gibco BRL) supplemented with 2% heat- 
inactivated (HI) Foetal Calf Serum (FCS) (Sigma), lOOU/ml Penicillin, lOOpg/ml 
Streptomycin and lOmM Hepes solution (all Gibco BRL), was used in all 
preparative procedures for cells, unless otherwise stated.
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Culture Medium
RPMI 1640 (Gibco BRL) supplemented with 2mM L-glutamine (Gibco BRL), 
lOOU/ml Penicillin, lOOpg/ml Streptomycin, and 5pM 2-Mercaptoethanol (Fischer 
Scientific, Loughborough, Leicestershire, UK) was used as culture medium for cells, 
supplemented with HI normal syngeneic rat serum or FCS as stated.
2.5.3.3 Cell preparations
Lymph Node Cells
Cervical, mesenteric and popliteal lymph nodes were removed from sacrificed rats under 
sterile conditions. Pooled lymph nodes were finely chopped with a scalpel blade, and 
gently pushed through a fine stainless steel mesh, using a sterile 5ml syringe plunger, to 
yield a single-cell suspension in lOmls of washing medium.
The cell suspension was transferred into a conical based test-tube (Sterilin, Stone, 
Staffs, UK), and left to stand on ice for a few minutes to allow the debris to settle. 
Cells were transferred to a clean test-tube, centrifuged at 1200 rpm for 7 minutes, re­
suspended, and washed a further 3 times. Cells were counted using a 
haemocytometer, and viability was determined by trypan blue exclusion.
Splenocytes
Spleens were removed under sterile conditions, and gently teased apart in washing 
medium using plastic forceps. The resulting cell suspension was transferred to a 
10ml conical based test-tube, and left on ice for a few minutes, to allow cell debris to 
settle out. Cells were transferred to a fresh test-tube and centrifuged at 1200 rpm for 
7 minutes. The cell pellet was re-suspended and erythrocytes removed by hypotonic 
lysis, by the addition of 5mls distilled water followed immediately by the addition of 
5mls 1.8% NaCl. Splenocytes were washed twice more, and counted with trypan 
blue exclusion.
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Concanavalin A-Transformed Lymphoblasts
5'Chromium (51Cr)-labelled Concanavalin A (ConA)-stimulated lymphoblasts were 
used as target cells in antibody-mediated cytotoxicity assays.
Splenocytes from donor-strain rats were prepared as described but were not depleted 
of erythrocytes. Cells were adjusted to a concentration of 2 - 2.5 x 106 cells/ml in 
50mls of culture medium enriched with 10% HI FCS, and incubated with 5pg/ml of 
ConA (Sigma) in a 75cm3 tissue culture flask (Nunclon, Denmark) for 48 hours at 
37°C in 5% C 0 2.
2.5.3.4 Plasmid Administration
Gene transfer of the DNA sequences encoding the RT1.A3 heavy chain was achieved 
by directly injecting plasmid DNA into the skeletal muscle o f adult rats (374). To 
induce regeneration of plasmid DNA into skeletal muscle and thereby increase the 
efficiency of gene transfer (403, 404), 400pl of 0.5% Bupivicaine (l-butyl-N[2, 6- 
dimethyl phenyl] 2-piperidine-carboxamide) (Astra, King's Langley, UK) was first 
injected into each tibialis anterior muscle using a 28-gauge needle. Three and eight 
days later, 200jig of pcmu-IV encoding either the full-length or truncated nucleotide 
sequence of the RT1.A3 heavy chain was injected into each tibialis anterior muscle. 
As control, empty pcmu-IV plasmid was administered. The amount of plasmid 
injected was decided empirically, based upon the equivalent concentrations that 
achieved T cell activation in mice (362).
2.5.3.5 Detection o f  Cytotoxic Alloantibody
The lymphocytotoxic RT1.A3 alloantibody response was determined in serum 
samples from modified PVG.RT1U rats by assessing the ability to lyse target 51Cr- 
labelled donor strain PVG.R8 ConA-transformed splenoblasts (section 2.5.3.3) in 
the presence of guinea pig complement. Briefly, PVG.R8 splenocytes were 
adjusted to a concentration of 2 x 106 cells/ml in 50mls of culture medium 
enriched with 10% HI FCS, and incubated with 5p.g/ml of ConA (Sigma) in a
3 075cm tissue culture flask (Nunclon, Denmark) for 48 hours at 37 C in 5% C 0 2. 
The target cells were then suspended in 1ml of serum-free culture medium and 
incubated with 5.0MBq 5lNa-Chromate (CJS11, Amersham International pic.) for
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90 minutes in a water-bath at 37°C with regular agitation. Cells were washed once 
with washing medium (section 2.5.3.2), re-suspended, and erythrocytes removed 
by hypotonic lysis. Cells were washed a further 3 times to remove excess sodium 
chromate, counted by trypan blue exclusion, and re-suspended at a concentration 
o f 1 x 106 cells/ml in RPMI 1640 + 5% HI FCS.
Serum samples were triply diluted in RPMI 1640 + 5% HI FCS to produce 
dilutions of 1:3, 1:9, 1:27, 1:81, 1:243, 1:729, 1:2187 and 1:6561. Triplicate 50pl 
aliquots of diluted serum samples were incubated in 96-well V-bottomed plates 
(Serowell, Bibby Sterilin Ltd., Stone, Staffs, UK) with 50pl of target cells at 37°C 
in 5% CO2 for 45 minutes. lOOpl of guinea pig complement (Harlan Sera Labs, 
Bicester, Oxon, UK) was added to each well, and the plates incubated for a further 
60 minutes.
Spontaneous cellular release of chromium was determined using target cells 
incubated without complement or serum, and maximum release was determined 
using cells incubated with Triton X 100 (Sigma).
Plates were centrifuged for 7 minutes at 1200 rpm, and lOOpl of supernatant was 
harvested from each well. Released 51Cr was determined using either a 
Compugamma Counter (LKB Pharmacia, Milton Keynes, UK).
Percent specific 51Cr-release was calculated by the formula:
Experimental Release -  Spontaneous Release
----------------------------------------------------------------- X 100
Maximum Release -  Spontaneous Release.
The serial antibody response was assessed by calculating, for a given time-point, 
the mean and SD of the lowest antibody titres that resulted in a cytotoxicity of 
>=20%. This was an arbitrary cut-off value, chosen on the grounds that 
background levels were invariably less than 10%. Statistical analysis on these 
time points was performed by Mann-Whitney U tests (2-tailed).
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2 .5 .3 .6  Determination o f Class and Subclass ofAnti-Aa Alloantibody
IgM and IgG2b anti-Aa alloantibodies were detected by flow cytometry in serum 
samples from experimental RT1U rats using R8 lymph node target cells (2.5.3.3) at 
a concentration of 1 x 106 cells/ml in PBS/0.2% BSA/0.1% sodium azide (Sigma).
Serum samples were triply diluted in PBS/0.2% BSA/0.1% sodium azide (PBA) 
to produce dilutions of 1:3, 1:9, 1:27, 1:81, 1:243, 1:729, 1:2187 and 1:6561. 50pl 
aliquots of diluted serum samples were incubated in 96-well U-bottomed plates 
with 50pl o f target cells for 30 minutes at 4°C. Cells were then washed by adding 
lOOpl of PBA, and plates centrifuged for 7 minutes at 1800 rpm. The supernatant 
was discarded, and the plates washed again with 200pl of PBA.
FITC-conjugated mouse anti-rat IgM (Harlan Sera Labs) and IgG2b (Sigma) 
monoclonal antibodies were used to detect IgM and IgG2b alloantibodies 
respectively. Each antibody was diluted 400-fold in PBA, and lOOpl added to 
experimental wells. Cells were re-suspended using a pipette, and plates incubated 
for 30 minutes at 4°C in the dark. Plates were washed twice as before, and cells 
re-suspended in lOOpl of PBA.
IgM and IgG2b alloantibodies were detected using a Coulter Epics XL flow 
cytometer (Coulter Ltd, Luton, UK) with associated software. The serial antibody 
response was assessed by calculating, for a given time-point, the mean and SD of 
the lowest antibody titres that resulted in a mean channel fluorescence greater than 
twice background. Statistical analysis on these time points was performed by 
Mann-Whitney U tests (2-tailed).
2.5.3.7 Preparation o f  Cry os tat Sections
Muscle samples from rats that had been injected with the RT1.A3 encoding pcmu 
vectors were harvested upon sacrifice of the animals. Preservation of muscle 
tissue was achieved using an isopentane freezing bath. The muscle was dissected 
and placed transversely on a cork card and embedded in OCT compound (Tissue- 
Tek, BDH Ltd). This was then frozen by placing in isopentane that had been 
cooled to freezing point in liquid nitrogen. Samples were stored at -70°C. 5pm
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crytostat sections were cut at -20°C onto gelatinised multispot slides (C.A. 
Hendley, Essex, UK)
2.5.3.8 Immunoperoxidase staining
Sections were fixed in acetone at room temperature for 10 minutes and then 
washed in PBS. Excess moisture was dried from around each section, then the 
slides were incubated for 5 minutes with 0.6% hydrogen peroxide in methanol to 
quench endogenous peroxidase activity. The sections were washed in PBS and 
then treated with avidin solution (0.01%) (Sigma) for 5 minutes, followed by a 
biotin solution (0.001%) (Sigma) for a further 5 minutes. This blocks endogenous 
avidin-binding activity (405). Slides were rewashed, excess moisture removed, 
then 50pl (lOpg/ml) of primary biotinylated monoclonal antibody (either MN4-9- 
16 or OX18) applied to each section. Slides were incubated for 45 minutes at 
room temperature in a humidified chamber. Slides were thoroughly washed then 
incubated for 30 minutes with StreptABCComplex (Dako, Glostrup, Denmark), a 
solution containing biotinylated horseradish peroxidase and streptavidin that binds 
peroxidase to the primary antibody at a higher ratio than conventional, 
peroxidase-conjugated secondary antibodies, thereby increasing the detection 
sensitivity. Slides were washed and incubated for 5 minutes with 0.6 mg/ml 3,3’- 
diaminobenzidine tetra-hydrochloride (peroxidase substrate) (Sigma) plus 0.01% 
hydrogen peroxide. Slides were re-washed, counterstained in Harris’ 
haematoxylin for one second, dehydrated and cleared in aclohols and xylene, then 
mounted in DPX (BDH Ltd., Poole. UK).
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CHAPTER THREE
THE INFLUENCE OF Aa-PRIMING ON THE ALLOANTIBODY 
RESPONSE TO, AND THE REJECTION OF, CLASS I MHC DISPARATE
HEART GRAFTS
3.1 Introduction
Several mechanisms have been proposed to explain the rejection of MHC class I 
disparate grafts by CD4 T cells (406). These differ fundamentally as to whether 
CD4 T cell activation is restricted to the recognition of processed allo-class I 
MHC peptide as presented by recipient APC and consequently, whether the 
indirect pathway of allorecognition is solely responsible for effecting acute graft 
rejection. For example, recipient congenic PVG.RT1U (AUB/DUCU) rats differ from 
donor recombinant PVG.R8 (AaB/DuCu) rats at the classical class I RT1.A locus 
only, but rejection is CD4 T cell dependent (289, 290). Although Bradley has 
proposed that CD4 T cells are indirectly restricted and effect rejection through the 
provision of B cell help for the development of an alloantibody response, the 
possibility that CD4 T cells instead recognise antigen directly on the surface of 
donor cells has not been excluded (297). As discussed in section 1.6.1, recent 
evidence from Shirwan supports the hypothesis that T cells directly restricted for 
antigenic determinants on the surface of PVG.R8 cells are pivotal in effecting 
rejection. He noted that immunising PVG.1U (PVG.RT1U) rats with peptides 
corresponding to the hypervariable region of the donor RT1.A3 antigen, which in 
theory achieved maximal stimulation of the indirect pathway, achieved only a 
modest acceleration in the rejection of subsequent PVG.R8 heart grafts, whereas 
immunising with intact donor cells resulted in rejection within 48 hours (245).
Clarification of the mechanisms responsible for accelerated rejection in the 
PVG.R8 to PVG.RT1U strain combination are of obvious importance in the 
understanding of the T cell allorecognition pathways involved in the rejection of 
MHC class I disparate grafts. It is equally relevant to the nature of T-B cell 
collaboration during alloantibody production to MHC class I, since the 
allorecognition pathway of CD4 T helper cells (indirect or direct) dictates whether
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T cell help for B cells is provided by cognate (antigen-specific) or non-cognate 
(antigen-non-specific) cell-cell collaboration (292, 296). The experiments in this 
chapter report the effects that priming PVG.RT1U rats with donor RT1.A3 antigen 
have on the subsequent rejection of PVG.R8 hearts. Different forms of the RT1 .Aa 
antigen were administered; a series of 15-mer allopeptides corresponding to the 
a l  and a2  domains of the RT1.A3 antigen, PVG.R8 skin grafts, or pcmu-IV 
plasmids encoding the R Tl.A a heavy chain (either the full-length or the truncated, 
water-soluble form). These antigens were chosen on their respective ability to 
prime the direct or the indirect T cell response and on their display of the 
appropriate conformational B cell epitopes to stimulate an alloantibody response 
directed against intact RT1.A3 antigens on donor graft cells. Immunising with the 
different forms of the R Tl.A a antigen resulted in marked differences in the 
kinetics of rejection of subsequent PVG.R8 heart grafts, but as will be discussed, 
these differences relate primarily to the presence of cross-reactive B cell epitopes, 
rather than to any intrinsic difference in the mode of helper CD4 T cell activation.
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3.2 Results
3.2.1 The Alloantibody Response to Priming with R Tl.Aa antigen
PVG.RT1U rats were immunised with a full-thickness PVG.R8 skin graft, or 
900pg of pooled Aa peptide corresponding to the a l  and a2 domains o f the 
RT1.A3 antigen (see section 3.5.3), or 400pg of pcmu-IV plasmid (see section 
3.5.4) encoding either the full-length (pcmu-Aa) or truncated (pcmu-tAa) sequence 
for the RT1.A3 heavy chain. Serum was sampled 12 days later and the presence of 
anti-A3 allocytotoxic alloantibody detected by assaying against chromium-labelled 
PVG.R8 lymphoblasts in the presence of guinea-pig complement (Figures 3.1 and 
3.2). PVG.RT1U recipients sensitised by the application of a full thickness 
PVG.R8 skin graft developed high levels of circulating cytotoxic anti-A3 
alloantibody (Figure 3.1). In contrast, immunising PVG.RT1U rats with synthetic 
allopeptides corresponding to the hypervariable regions of the A3 MHC class I 
molecule did not stimulate the development of cytotoxic antibody recognising 
intact RT1.A3 on donor cells (Figure 3.1). Concurrent experiments in our 
laboratory have demonstrated that an antibody response can be generated to 
several of the individual allopeptides, confirming their immunogenicity 
(Lovegrove E, submitted) but, as Benham has also demonstrated (291), anti­
peptide antibody does not cross-react with the intact RT1.A3 antigen. The product 
of the pcmu-tA3 vector also stimulated a strong allocytotoxic alloantibody 
response, and this was of the same magnitude as the antibody response that 
developed following PVG.R8 skin grafting (Figure 3.2). The magnitude of the 
antibody response to the product of the pcmu-A3 vector was, as noted in section
2.3.2.2, lower than to the product of the pcmu-tA3 vector (Figure 3.2).
3.2.2 The Kinetics o f  Heart Graft Rejection following Priming with RTl.Aa 
Antigen
PVG.RT1U rats were primed with an R8 skin graft, or with RT1.A3 peptide, or 
with the R Tl.A a-encoding pcmu-IV plasmids, twelve days before receiving a 
PVG.R8 heterotropic cardiac allograft. PVG.RT1U rats respond strongly to 
RT1.A3 class I MHC alloantigen for, as shown in Table 3.1 (group 1), naive 
animals rejected Aa-bearing PVG.R8 heart grafts rapidly (MST 7 days). Prior
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Figure 3.1 Cytotoxic alloantibody response upon RT1.A3 immunisation.
The circulating lymphocytotoxic RTl.A a antibody response of PVG.RT1U rats was 
assessed 12 days after application of a full thickness PVG.R8 skin graft or 
immunisation with Aa allopeptide. Allopeptide-immunised animals received 900pg 
of pooled Aa peptides emulsified in CFA and given subcutaneously into each hind 
footpad. Control animals received adjuvant alone. Sera were assayed against 51Cr- 
labelled PVG.R8 ConA blasts in the presence of guinea-pig complement (section 
2.5.3.5). Values shown are the mean and SD of four animals per group. 
* Skin graft vs. allopeptide, p<0.02, Mann-Whitney U test (2-tailed).
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Figure 3.2 Cytotoxic alloantibody response to Aa encoding pcmu-IV vectors.
The circulating lymphocytotoxic R Tl.A a antibody response of PVG.RT1U rats was 
assessed 12 days after immunisation with pcmu-IV plasmid vectors encoding either 
the full-length RT1.A3 antigen (pcmu-Aa) or the truncated, water soluble version 
(pcmu-tAa). Control animals were immunised with empty pcmu-IV plasmid. 
Animals received 400pi of 0.5% Bupivicaine intramuscularly followed 3 and 8 days 
later, by injection of 200pg of plasmid. Values shown are the mean and SD of four 
animals per group. Shown also for comparison is the cytotoxic antibody response in 
animals sensitised 12 days earlier with an R8 skin graft (data from Figure 3.1). 
* Pcmu-tAa vs. pcmu-Aa p<0.02, Mann-Whitney U test (2-tailed).
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exposure to the Aa antigen is effective at inducing accelerated rejection as 
PVG.RT11 recipients that were sensitised by the application of a full-thickness 
PVG.R8 skin graft, 12 days before heart transplantation, consistently rejected 
PVG.R8 heart grafts within 1 day of transplantation (Table 3.1, group 2).
Immunisation of PVG.RT1U rats with the synthetic allopeptides was less effective at 
promoting accelerated rejection of Aa-bearing heart grafts (Table 3.1, group 4). 
Compared to control animals immunised with CFA only or with irrelevant peptide 
emulsified in CFA, rejection times were faster (MST 4 vs. 6.5 days, p<0.02), but 
heart graft rejection in allopeptide-primed animals was still markedly slower than 
that observed in animals primed by a PVG.R8 skin graft (p<0.02). These findings are 
consistent with a recent study by MacDonald, who instead studied the effects of 
immunising with individual allopeptides (246). She noted that priming PVG.RT1U 
rats subcutaneously with an emulsion of CFA and a single allopeptide corresponding 
to the hypervariable regions of either the a l  (amino acids 57-80) or the a2  domains 
(amino acids 143-163) of the RTl.A a molecule achieved a similar modest 
acceleration in the rejection of PVG.R8 hearts (MST 5 vs. 6 days).
Table 3.1. Rejection of R Tl.A 3 class I disparate PVG.R8 heart grafts by 
PVG.RT1U recipients.
Group Immunisation protocol na Heart graft Survival 
(daysb)
MST
(days6)
l d None 4 6,7,7,7 7
2d PVG.R8 skin graft6 5 1,1,1,1,2 1
3d CFAf 4 6,6,7,8 6.5
4d CFA/peptidef 5 4,4,4,5,5 4
5 CFA/irrelevant peptidef 3 6,7,7 7
a Number of animals in group.
b Grafts were assessed by daily palpation, and rejection was defined as complete 
cessation of myocardial contraction. 
c Median survival time.
d Groups 1 vs. 2, groups 2 vs. 4, and groups 3 vs. 4, p<0.02, Mann-Whitney U test. 
e Animals were immunised by the application of a full-thickness PVG.R8 skin graft 
12 days before heart transplantation. Skin grafts were rejected on days 6 or 7. 
f Animals were immunised with 900pg of pooled Aa allopeptides (50mg of each 
15-mer), emulsified in CFA, and given s.c. into each hind footpad 12 days before 
heart transplantation. Control animals received either adjuvant alone (group 3) or 
lOOpg of irrelevant peptide emulsified in CFA (group 5).
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To assess whether the difference in the rejection kinetics between skin-grafted and 
peptide-immunised animals was due to more effective priming of the humoral 
immune response, rather than to differences in the T cell activation pathways, the 
rejection kinetics of R8 heart grafts were assessed in PVG.RT1U rats, which had been 
immunised 12 days earlier with the plasmid vectors encoding the sequence for either 
the full-length or truncated RT1.A3 antigen. All animals rejected PVG.R8 heart 
grafts rapidly, with similar kinetics to those animals that had received a skin graft 
(Table 3.2, groups 1 and 2 and cf. Table 3.1 group 2). Although animals immunised 
with the truncated RT1.A3 antigen rejected their grafts slightly more quickly than 
those immunised with the full-length antigen (group 2 vs group 1), this difference 
was not significant (MST 1.5 vs. 2 days,/? = 0.49). Control recipients immunised 
with the ‘empty’ pcmu-IV plasmid rejected PVG.R8 heart grafts at the same rate as 
naive PVG.RT1U recipients (cf. Table 3.1 group 1 and Table 3.2 group 3). 
Immunising with the plasmid encoding the truncated RT1.A3 antigen did not effect 
the rejection of third party PVG.RT1C heart grafts (Table 3.2, group 4).
Table 3.2. Rejection of R Tl.A a class I disparate PVG.R8 heart grafts 
by PVG.RT1U recipients after immunisation with DNA 
encoding RT1.A3 antigen.
Group Immunisation protocol n3 Heart graft Survival (days) MST
(days)6
l d pcmu-Aa ^ 5 1,2,2,2,3 2
2d pcmu-tA3 (e) 7 1,1,1,2,2,2,2 1.5
3d pcmu (control)6 4 6,1,7,7, 7
4 pcmu-tA3 (e) 3 5,6,7 (PVG.RT10) (E) 6
5 Immune serumf 3 5,6,6 6
3 Number of animals in group.
b Grafts were assessed by daily palpation, and rejection was defined as complete 
cessation of myocardial contraction.
c Median survival time.
d Groups 1 vs. 3,p  <0.02. Groups 2 vs. 3,/?<0.01. Groups 1 vs. 2,/?=0.49 
e PVG.RT1U rats were immunised with 400pg pcmu-IV plasmid encoding full- 
length, membrane bound A3 class I MHC (pcmu-A3), truncated A3 class I MHC 
(pcmu-tA3), or empty plasmid control (pcmu). 12 days later, rats received a 
heterotopic PVG.R8 (or third party PVG.RT1C) cardiac allograft. 
f 1.5mls of immune serum (harvested from PVG.RT1U animals 12 days after 
injection with 400pg of pcmu-tA3 plasmid) was administered to unmodified 
PVG.RT1U recipients on days 0, 1, and 2 relative to a PVG.R8 cardiac allograft.
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3.2.3 The Anti-Aa Antibody Response to an R8 cardiac Allograft following  
Priming with RT1.AU Antigen
Although immunisation with Aa allopeptide failed to stimulate an alloantibody 
response to the intact RTl.A a molecule (Figure 3.1), class I allo-peptide priming 
has been previously noted to accelerate the subsequent alloantibody response to 
the intact class I molecule, as displayed by a vascularised allograft (244, 247, 
291). To assess whether the more rapid rejection in peptide primed animals was 
the consequence of the development of a more rapid anti-Aa antibody response, 
sera from PVG.RT1U rats primed with the R Tl.A a antigen were sampled for the 
presence of cytotoxic alloantibody four days after R8 heart grafting. Initial 
experiments demonstrated that sera from rats that had developed an anti-Aa 
antibody response following priming with either an R8 skin graft or the plasmid 
encoding the truncated RT1.A3 heavy chain (pcmu-tAa) unsurprisingly contained 
higher levels of alloantibody four days after, rather than at the time of, secondary 
challenge with an R8 cardiac allograft (Figure 3.3).
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Figure 3.3 Progression of the anti-Aa antibody response in R T l.A a-primed 
PVG.RT1U rats following PVG.R8 heart transplantation.
Animals received either a full thickness PVG.R8 skin graft or were injected 
intramuscularly with 400pg of plasmid encoding the truncated RT1.A3 antigen 
(pcmu-tAa). Heart transplantation was performed 12 days later. Sera were sampled 
for cytotoxic anti-Aa antibody at the time of transplantation (day 0) and four days 
later (day 4). Samples at day 0 correspond to the data depicted in Figure 3.2. Results 
shown are the mean of four animals per group.
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More importantly, the anti-Aa alloantibody response developed more rapidly in those 
animals that had been primed with the allopeptide mixture than in those animals 
primed with adjuvant only (Figure 3.4). Peptide immunisation therefore appears to 
accelerate rejection by priming T cells to provide cognate help for the generation of 
a humoral immune response directed against intact R Tl.A a antigen on the surface of 
donor graft cells.
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Figure 3.4 Cytotoxic anti-Aa antibody response of PVG.RT1U rats to an R8 
cardiac allograft following allopeptide immunisation
Recipients were pre-immunised with either 900pg of pooled Aa allopeptides 
emulsified in CFA, or CFA alone, 12 days before heart transplantation. Serum was 
sampled four days after cardiac transplantation and analysed for the presence of 
cytotoxic alloantibody. Results shown are the mean and SD of four animals per 
group.
* p  < 0.05, Mann-Whitney U test (2-tailed).
3.2.4 The Cytotoxic CD8 T cell Response to RTl.Aa Antigen
As discussed in section 1.6.4, the plasmid construct for the truncated version of 
the RT1.A3 heavy chain (pcmu-tAa) was designed to ensure that its’ soluble class I 
protein product would not engender a direct CD8 T cell response. The assumption 
that the full-length R Tl.A a product of the pcmu-Aa vector would be expressed by 
professional recipient APC (378, 379, 407) implies, by comparison, that an anti- 
Aa cytotoxic CD8 T cell response may develop. To assess the cytotoxic CD8 T 
cell response, spleen cells were obtained from PVG.RT1U rats 12 days after 
immunisation with either pcmu-Aa or pcmu-tAa and assayed against 51Cr-labelled 
PVG.R8 Con A blasts. Splenocytes harvested from RT1U recipients 12 days after
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PVG.R8 skin grafting, were used as a positive control. Although lymphoid cells 
from PVG.RT1U recipients primed with PVG.R8 allografts do not generally 
display very high levels of in vitro cytotoxic T cell activity (290), spleen cells 
from animals grafted with PVG.R8 skin showed significant levels of CTL activity 
(Figure 3.5). CTL activity was also detected in animals immunised with the full- 
length Aa vector, pcmu-Aa, but crucially, the levels of cytotoxicity in animals 
immunised with the truncated Aa vector, pcmu-tAa, were similar to control 
animals immunised with the empty vector (Figure 3.5).
50
*  40
CJ• mXX o
U
30
20
10
0
skin graft 
pcmu-Aa 
pcmu-tAa 
pcmu (control)
100 50 25 12
Effector: target ratio
Figure 3.5 Analysis of the CTL response to R Tl.A a alloantigen
PVG.RT1U rats were grafted with PVG.R8 skin or immunised with 400jug of the 
plasmid vectors encoding the full-length RT1.A3 heavy chain (pcmu-Aa), the 
truncated heavy chain (pcmu-tAa), or empty control plasmid (pcmu). The animals 
were sacrificed after 12 days and spleen cells were assayed against 51Cr-labelled R8 
Con A blast target cells in a 6-hour cytotoxicity assay. Values shown are the mean 
and SD of three animals per group. This experiment was repeated on two occasions 
with similar results.
* Skin graft vs. pcmu-tAa groups, p<0.02, Mann-Whitney U test, 2-tailed.
Additional experiments were performed in which LNC obtained from PVG.RT1U 
rats immunised as above were further stimulated in vitro for 5 days with irradiated 
fully allogeneic (R T la) spleen cells (Figure 3.6). The secondary in vitro challenge 
with RT1.A3 antigen permits a more rigorous assessment of the ability of DNA 
encoding soluble Aa to induce a CTL response. It also provides a means of 
examining whether immunisation with soluble MHC class I results, by inducing 
apoptosis in alloreactive CD8 T cells (321), in inhibition of the cytotoxic T cell 
response. After in vitro stimulation, the level of CTL activity observed in LNC
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from animals primed with pcmu-tAa were comparable to those seen in T cells 
from control animals immunised with empty plasmid (Figure 3.6), suggesting that 
neither augmentation nor inhibition of the cytotoxic CD8 T cell response had 
occurred.
30-1
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pcmu (control) 
pcmu-tAa plasmid
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100 650 12 325
Effector: target ratio
Figure 3.6 The CTL response following in vivo and in vitro challenge with 
R Tl.A a antigen.
LNC were obtained from PVG.RT1U rats 12 days after immunisation with 400jug 
of pcmu-tAa (or pcmu control plasmid) and used as responders (4 x 107 in 20ml) 
in a bulk MLR. Stimulators were fully allogeneic (R T la), irradiated (20Gy) spleen 
cells (2 x 107). After 5 days of in vitro stimulation, responders were tested for 
their ability to lyse 51Cr-labelled PVG.R8 Con A blast targets in a 6-hour 
cytotoxicity assay. Values shown are the mean and SD of three animals per group. 
There was minimal lysis of third-party Lewis (RT11) lymphoblast target cells (data 
not shown).
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3.2.5 Elucidation o f  the Effector Mechanisms Responsible fo r  Accelerated 
Rejection Followingpcmu-tAa Priming
The lack of a discernible cytotoxic CD8 T cell response following immunisation 
with the pcmu-tAa vector provides indirect evidence that its’ soluble R Tl.A a 
product accelerates the kinetics of rejection of subsequent PVG.R8 heart grafts by 
priming humoral immunity. To confirm this, 1.5ml of immune serum (harvested 
from PVG.RT1U animals 12 days after injection with the pcmu-tAa plasmid) was 
administered to naive PVG.RT1U animals at the time of a PVG.R8 cardiac 
allograft, and everyday thereafter. A similar protocol using hyperimmune serum 
from PVG.RT1U rats challenged with a PVG.R8 skin graft has been previously 
demonstrated to accelerate the rejection of R8 heart grafts to within 24 hours 
(246). In this instance, rejection times were not significantly different than control 
animals (Table 3.2 group 5). A limitation in the quantity of available immune 
serum prevented the administration of more than 3 doses to each rat. In two of the 
recipients the hearts beat appreciably weaker directly after the administration of 
the immune serum and perhaps increasing the total volume of serum that was 
administered may have accelerated rejection.
By comparison, histological examination of the rejected hearts was suggestive of 
humoral rejection (Figures 3.7 and 3.8). Control unmodified PVG.RT1U recipients 
of PVG.R8 hearts reject their grafts on day 7 (Table 3.1 group 1). Low power 
examination of the rejected hearts (Figure 3.7A) reveals a marked cellular 
infiltrate, consistent with diffuse cellular rejection. High power views confirm that 
myocytes are separated by a severe infiltration of mononuclear cells (Figure 
3.7B), consisting of lymphocytes and macrophages. There are multiple scattered 
foci of myocardial fibre necrosis (Figure 3.7B) and thrombus is present within the 
lumen (Figure 3.7A), indicating severe rejection. There is also a dense endocardial 
and subendocardial monocyte infiltrate (Figure 3.7D). Priming PVG.RT1U 
recipients with the plasmid encoding the truncated RT1 .Aa heavy chain resulted in 
rapid rejection of a PVG.R8 heart graft (MST 1.5 days, Table 3.2 group 3). 
Histological examination of hearts that were removed at the time of rejection is 
consistent with humoral rejection (Figure 3.8). At low power magnification, there 
is little cellular infiltrate but the atrial and ventricular orifices are occluded with
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thrombus indicating that the heart had stopped beating (Figure 3.8A). Although 
the ultrastructure of the heart muscle appears relatively normal, high power 
magnification (Figure 3.8B) reveals that virtually every myocyte has lost its 
striatal pattern (c.f. control muscle, Figure 3.8D). This is the earliest indicator of 
myocyte death. Other features consistent with humoral rejection include 
haemorrhage into the muscle fibres (Figure 3.8B) and extravasation of neutrophils 
from capillaries (Figure 3.8C). Sections of heart grafts from PVG.RT1U rats that 
had initially been primed with an R8 skin graft revealed similar findings (data not 
shown).
3.2.6 T cell Depletion Studies
To determine whether the ability of immunisation with pcmu-tAa to promote 
accelerated rejection of PVG.R8 heart grafts was CD4, and not CD8, T cell- 
dependent, pcmu-tAa plasmid-immunised animals were simultaneously treated 
with mAbs directed against T cell subsets. As shown in Table 3.3, the rapid 
rejection associated with immunisation with pcmu-tAa was not prevented by 
treatment with the anti-CD8 mAb, MRC 0X8, either at the time of plasmid 
injection or at the time of the heart graft (MST 1 day, groups 3 and 4 
respectively). Treatment with 0X8 mAb results in >99% CD8 T cell depletion 
(355) as determined by flow cytometric analysis (data not shown). Confirmation 
that this phenotypic depletion corresponded to an in vivo depletion of functional 
cytotoxic T cells was provided by the observation that LNC obtained from 
PVG.RT1U rats during the first week after in vivo treatment with 0X 8 mAb, and 
that had undergone culture in vitro for 5 days against fully allogeneic R Tl.A a 
irradiated splenic stimulators (as described in the legend to Figure 3.5) did not 
develop a measurable CTL response (<10% cytotoxicity at an effector: target cell 
ratio of 100:1). In comparison high levels of cytotoxicity were detected using 
LNC from unmodified PVG.RT11 rats (>50% cytotoxicity at an effector: target 
cell ratio of 100:1).
In vivo treatment of pcmu-tAa-immunised PVG.RT1U rats with the anti-CD4 mAb 
MRC 0X38 not only prevented accelerated graft rejection, but extended graft 
survival beyond that observed in naive PVG.RT1U recipients (MST 13 days, Table 
3.3, group 5). MRC-OX38 treatment results in approximately 50% CD4 T cell
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depletion (289) and it is likely that recovery of the residual CD4 T cell population 
was responsible for eventual rejection of the heart grafts.
The ability of the mAb treatments to influence heart graft survival in pcmu-tAa 
primed animals closely mirrors their effect on the development of a cytotoxic 
RTl.A a Ab response. The administration of anti-CD4 mAb completely abrogated 
the early alloantibody response, whereas there was no discernible difference, as 
compared to control isotype antibody-injected injected animals, in the cytotoxic 
alloantibody response following CD8 T cell depletion (Figure 3.9).
Table 3.3. Rejection of R8 heart grafts following T cell subset depletion of 
pcmu-tAa plasmid primed PVG.RT1U recipients.
Groupd DNA
vaccination3
mAb
Treatment
n Heart graft 
survival (days)
MST (days)
1 pcmu (control) - 4 6,7,7,7 7
2 pcmu-tAa - 7 1,1,1,2,2,2,2 1.5
3 pcmu-tAa Anti-CD8b 4 1,1,1,1 1
4 pcmu-tAa Anti-CD8° 3 1,1,1 1
5 pcmu-tAa Anti-CD4° 4 8,12,14,17 13
a PVG.RT1U rats were immunised with 400 pg pcmu-IV plasmid encoding either a 
truncated Aa class I MHC (pcmu-tAa), or empty plasmid as control. Twelve days 
after the first DNA injection, rats received a heterotopic PVG.R8 cardiac 
allograft.
b Animals in group 3 received 2mg anti-CD8 mAb (0X8) on days -1 , 0, and 1 
relative to heart transplantation.
0 Animals in groups 4 and 5 were treated with anti-CD8 (2mg 0X 8 on days -1 , 0 
and 1) or anti-CD4 (5mg 0X38 on days -3 , 0, 3, 6, and 9) relative to plasmid 
injection.
d Group 1 vs. group 5,p <  0.02. Group 2 vs. group 5,p  < 0.02.
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Figure 3.9 Lymphocytotoxic anti-Aa alloantibody response in pcmu-tAa 
immunised PVG.RT1U rats following T cell subset depletion.
PVG.RT1U rats were immunised with 400pg pcmu-tAa, and treated with anti-CD4 
(5mg 0X38 (or isotype control, ESH8) given i.p. on days -3 , 0, 3, 6, and 9 
relative to plasmid injection) or anti-CD8 antibody (2mg 0X 8 on days -1 , 0, and 
1). Levels of cytotoxic antibody were assessed by assaying sera (four animals per 
group) against 51Cr-labelled PVG.R8 Con A blasts in the presence of guinea pig 
complement. Results are expressed as mean and SD of antibody titre (last dilution 
of serum that gave > 20% cytotoxicity).
3.2. 7 Immunisation o f Lewis Rats (RT11) with RTl.Aa-Encoding pcmu-IV Vectors
The Lewis rat strain (RT11) is a high responder towards the RT1.A3 antigen; 
completely mismatched DA (R T la) hearts are rejected rapidly and priming with 
donor strain blood results in accelerated, rather than prolonged, graft survival. To 
examine whether priming with soluble class I allo-MHC resulted in a similar 
acceleration in the rejection of Aa-bearing heart grafts as in the PVG.RT1U strain, 
Lewis rats were immunised with 400pg of the Aa-encoding vectors (pcmu-Aa and 
pcmu-tAa) and 12 days later transplanted with a DA (R T la) cardiac allograft. 
Animals immunised with either the plasmid encoding the full-length RT1.A3 
antigen, pcmu-Aa, or the soluble version, pcmu-tAa, rejected their grafts only 
modestly more rapidly than control animals injected with the ‘empty’ plasmid 
(Table 3.4). Rejection times in the group immunised with pcmu-Aa were slightly 
more rapid than in the group immunised with pcmu-tAa, but this difference was 
not statistically significant (MST 4.5 vs. 5,p  = 0.286). The alloantibody response 
did not, however, correlate with rejection, since the antibody response in the 
pcmu-Aa animals was minimal, whereas a significant titre developed in the pcmu- 
tAa immunised animals (Figure 3.10).
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Table 3.4 Rejection of DA heart grafts by Lewis recipients after 
immunisation with DNA encoding Aa class I MHC
Group Immunisation protocol n Heart graft 
Survival (days)
MST
(days)
l a pcmu (control) 4 6,6,7,7 6.5
2a pcmu-Aa 4 4,4,5,5 4.5b
3a pcmu-tAa 4 5,5,5,6 5b
a Lewis animals were injected with 400pg of the pcmu plasmid vectors encoding 
either the full-length RTl.A a antigen (pcmu-Aa) or the truncated, water-soluble 
version (pcmu-tAa). Control animals were immunised with empty pcmu 
plasmid. Twelve days after plasmid immunisation, rats received a heterotopic 
DA cardiac allograft. Grafts were assessed by daily palpation and rejection was 
defined as complete cessation of myocardial contraction.
b Group 1 vs. group 2 and 3,p  < 0.03 and p = 0.09, respectively.
Group 2 vs. group 3 ,p  = 0.286.
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Figure 3.10 Development of the cytotoxic anti-Aa alloantibody response in 
Lewis rat recipients.
Lewis animals were injected with 400pg of the pcmu plasmid vectors encoding 
either the full-length RT1.A3 antigen (pcmu-Aa) or the truncated, water-soluble 
version (pcmu-tAa). Control animals were immunised with empty pcmu plasmid. 12 
days after plasmid immunisation, the presence of serum cytotoxic anti-Aa antigen 
was measured by the ability to lyse 51Cr-labelled DA (R T la) Con A splenoblasts in 
the presence of guinea pig complement. Values shown are the mean and SD of four 
animals per group. Shown also for comparison is the cytotoxic Ab response in RT1U 
animals (dashed) sensitised 12 days earlier by injection of the pcmu-tAa vector (from 
Figure 3.2). * Pcmu-tAa (Lewis recipient) vs. pcmu-Aa (Lewis recipient), p<0.02, 
Mann-Whitney U test, 2-tailed.
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3.3 Discussion
PVG.RT1U animals primed with an R8 skin graft rejected a subsequent R8 heart 
graft rapidly (Table 3.1). This was associated with the development of a strong 
anti-Aa cytotoxic alloantibody response. Animals primed with allopeptide did not 
generate an anti-Aa antibody response, and grafts were rejected only modestly 
more rapidly than controls (Figure 3.1, Table 3.1). Since the passive transfer of 
hyperimmune serum into naive PVG.RT1U recipients results in the rejection of an 
R8 heart graft within 24 hours (246), the most likely explanation for the difference 
in the rejection times between skin-grafted and peptide-primed animals is that the 
intact RT1.A3 antigen on the surface of donor R8 skin cells provides the 
appropriate conformational epitopes for the generation of an antibody response 
that cross-reacts with the subsequent heart graft.
The antibody response to alloantigen is, however, T helper cell dependent, and the 
indirect CD4 T cell recognition of certain class I alloantigens does not provide 
sufficient help for the generation of an effective alloantibody response; the 
expression of additional T helper cell determinants on donor graft cells are 
required (292). The ability of an R8 skin graft, rather than allopeptide 
immunisation, to prime the development of an alloantibody response responsible 
for accelerated heart graft rejection may therefore not only reflect the presence of 
the appropriate B cell epitopes, but may also be due to more efficient helper T cell 
activation.
A number of reasons may be postulated as to why skin grafting generates more 
efficient T cell help. Firstly, the intact RTl.A a antigen, as presented by an R8 skin 
graft, may be processed to generate more optimal Aa-peptide T helper cell 
determinants than occurs upon immunising with the allopeptide mixture. In an 
attempt to encompass all potential determinants involved in the indirect response to 
the RT1.A3 antigen, a series of 18 peptides that spanned the a l  and a2 domains were 
administered. Sequential peptides however, differed by five, rather than one amino 
acid, and it is it is conceivable that the optimum T cell epitope is not contained 
within any individual immunising peptide but instead corresponds to an amino acid 
sequence that spans two consecutive peptides. Nevertheless, all studies that have
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examined the effects of allopeptide immunisation to date (244-246, 291) have 
consistently reported a similarly modest acceleration in vascularised allograft 
rejection. In particular, PVG.RT1U rats immunised with the full-length RT1.A3 heavy 
chain protein, which presumably did result in optimal peptide epitope presentation to 
T helper cells, accelerated rejection of PVG.R8 heart grafts to day 4 (248). The 
allopeptide mixture used in this thesis achieved a similar acceleration in rejection, 
suggesting that maximal stimulation of the indirect pathway was achieved. This is 
further supported by the observation that similar peptides have been targeted to 
abrogate the anti-Aa antibody response (246). Further refinement of the administered 
peptides would be consequently unlikely to alter the kinetics of graft rejection and 
the difference in rejection times between peptide-primed and skin-grafted animals is 
therefore the result of activation of either T cells via other allorecognition pathways 
or alternative effector mechanisms.
One such alternative allorecognition pathway by which skin grafting may generate 
more efficient T cell help for alloantibody production is through activation of a CD8 
T cell subset that directly recognises the intact class I RT1.A3 antigen. This is equally 
unlikely, for although there are examples whereby the CD8 T cell response can 
directly influence the antibody response (319, 320), in the model employed in this 
thesis, CD8 T cell depletion influences neither the alloantibody response nor the 
kinetics of heart graft rejection (355).
A more difficult explanation to refute is that skin grafting results in CD4 T cell 
activation via the direct pathway. Possible antigenic determinants for direct CD4 T 
cell recognition are either the intact donor RT1.A3 antigen or additional disparities 
carried over in the recombinant event that created the PVG.R8 strain (297). The 
recognition of the donor class I antigen by recipient CD4 T cells appears to break the 
rules of MHC restriction, but exceptional CD4 T cell clones that recognise class I 
MHC have been described (316, 317). Similarly, although there is no direct evidence 
to confirm that additional antigenic discrepancies influence CD4 T cell activation in 
this strain combination, in an analogous class I disparate mouse model, additional, 
undefined antigens are responsible for the activation of T cells which provide help 
for the generation of an anti-alloMHC class I cytotoxic T cell response (263).
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If the above hypothesis, that accelerated rejection is a manifestation of direct T 
cell allorecognition, is correct, it has important implications for the nature of T-B 
cell collaboration, for it provides support for the three-cell cluster model (292). 
According to this model, the direct allorecognition pathway dominates the initial 
alloimmune response and is uniquely responsible for the provision of help for the 
early alloantibody response. Moreover, since directly activated CD4 T cells are 
able to recognise intact donor antigen on the graft, they could theoretically 
additionally effect rejection through either a direct cytotoxic response, or through 
the initiation of a DTH response.
Immunising with the plasmid vector encoding the full-length membrane bound 
R Tl.A a antigen resulted in the development of an anti-Aa antibody response and 
subsequent heart grafts were rejected in a similar time scale to those animals that 
had initially been primed with a skin graft (Tables 3.1 and 3.2). By administering 
only the appropriate nucleotide sequence, a DNA-based approach ensures that the 
RT1.A3 antigen is expressed with complete purity, and this result therefore 
obviates the need to invoke the recognition of additional putative alloantigens as 
being responsible for accelerated rejection. It does not preclude direct T cell 
recognition of the RT1.A2 antigen influencing the alloantibody response for, as 
discussed in section 2.3, professional APCs can internalise the pcmu-Aa vector 
and express the RTl.A a antigen on their cell membrane, in conjunction with 
appropriate costimulatory molecules.
The influence that the vector encoding the soluble class I alloantigen has on the 
alloantibody response is the most critical result. T cell recognition of the product 
of the pcmu-tAa vector is expected to be restricted to the indirect pathway. This 
hypothesis is the principal tenet governing the design and interpretation of the 
experiments described in this thesis and requires further consideration. It is based 
on the two signal model for T cell activation (336); that naive T cell activation 
requires not only an interaction with the appropriate MHC/peptide complex via 
the T cell receptor, but also signalling through costimulatory receptors. In the 
absence o f costimulation, an interaction with the TCR results in partial activation, 
or anergy. Since the costimulatory signals are provided by professional APC the 
two-signal model provides a means of preventing potentially deleterious
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responses developing to peripheral self-antigens. Although soluble MHC, released 
from transfected cells in vivo, could interact directly with the TCR of alloreactive 
T cells, the absence of costimulatory signals delivered by APC would in theory 
prevent T cell activation.
It has more recently been suggested, however, that the costimulatory requirement 
for T cell activation, particularly for CD8 T cells, is relative rather than absolute 
(340-345). Viola and Lanzavecchia (340) have demonstrated that in vitro CD4 T 
cell activation requires a defined number of signal events to occur through the 
surface T cell receptor. In the absence of costimulation, this threshold value is 
8000, whereas concurrent costimulation lowers this value to 1500. Several recent 
studies have also verified that CD8 T cells can be activated in the absence of a 
second signal (344-346, 408), albeit with an efficiency of at least 20 times less 
than when costimulation is present (344). Similarly, Delon (350) has 
demonstrated that Ca2+ mobilisation in CD8 T cells can be triggered with soluble 
peptide/MHC class I complexes in the absence of a costimulatory signal. These in 
vitro studies may nevertheless not accurately represent in vivo CD8 T cell 
activation. Delon’s studies examined calcium influx rather than differentiation of 
the CD8 T cells into effector cells (350), and in the other studies the absence of 
CD4 T cell help was compensated for by either the addition of 11-2 (344, 346) or 
by immobilisation of the class I protein by binding to plates (345, 408). 
Immobilisation effectively increases the ligand density of the class I MHC 
complex, and this presumably results in more effective cross-linking of the TCR 
and CD8 co-receptor complex. Recent evidence suggests that to achieve similar 
cross-linking in vivo, physiological soluble MHC class I (i.e. non-immobilised) 
has to be aggregated into multivalent complexes; whereas tetrameric class I MHC 
resulted in T cell activation (348, 349), monovalent and divalent complexes were 
non-stimulatory (348).
The exact physical conformation of the soluble class I MHC product used in this 
thesis was not formally assessed and should have ideally been verified by SDS- 
PAGE analysis under non-reducing conditions. Nevertheless, it was constructed 
by excising the hydrophobic transmembrane and cytoplasmic domains of the full- 
length RT1.A8 heavy chain. In their absence it is likely that soluble MHC class I
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resulting from gene transfer is released in monomeric form and consequently 
unable to activate T cells directly. This assumption receives strong support from 
the analysis of the CTL responses (Figures 3.5 and 3.6) and from the inability of 
CD8 T cell depletion to influence either the alloantibody response to, or the 
rejection kinetics of, heart grafts (Figure 3.9 and Table 3.3). RT1.A3 plasmid 
constructs have also been assessed in Lewis rats by Geissler (351), who similarly 
demonstrated that a cytotoxic T cell response developed following vaccination 
with the vector encoding the full-length heavy chain, but not with the soluble 
version. More recently, the transfer of hepatocytes that were transfected with the 
soluble antigen was associated with downregulation of the cytotoxic T cell 
response (352-354).
In summary, T cell recognition for either the allopeptide mixture or the soluble 
class I MHC product of the pcmu-tAa vector is restricted to the indirect pathway. 
This infers that soluble MHC class I alloantigen is a more effective immunogen 
solely because its tertiary protein structure provides the conformational B cell 
epitopes necessary for generation of pre-transplant antibodies directed against 
target graft cells expressing intact allogeneic MHC class I. My results therefore 
offer an alternative explanation to that proposed by Shirwan (245) as to why 
priming with donor R8 splenocytes results in rapid rejection; that, in an analogous 
fashion to priming with soluble class I alloantigen, the immunogenicity o f donor 
cells resides in their ability to prime humoral immunity that may nevertheless be 
solely dependent on help from indirectly-restricted CD4 T cells. Shirwan did not 
assess the anti-Aa antibody response that followed splenocyte infusion, but the 
results from my experiments and others (246, 290, 355) suggest that a strong 
lymphocytotoxic alloantibody response would have developed.
The corollary, that the accelerated rejection is mediated by humoral, rather than 
cellular mechanisms, is confirmed by the histological examination of the rejected 
hearts, but was not supported by the experiments involving passive transfer of 
immune serum. This discrepancy can be explained by the observation that 
plasmid-primed animals frequently did not reject their heart grafts until day two. 
The levels of pre-formed anti-Aa antibody were presumably not enough to cause 
immediate rejection, and if so, the transfer of a 1.5ml sample of this serum could
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hardly be expected to be any more effective. In two of the rats, however, the 
hearts beat perceptively less strongly following hyperimmune serum 
administration, but had recovered by the next day. This approach may have 
induced accelerated rejection if serum had been taken from RT1U animals that had 
been administered several pcmu-tAa plasmid injections, such that a secondary 
alloantibody response was sampled.
Implicit to the hypothesis that T cell help for the development of an anti-Aa 
antibody response is restricted to the indirect pathway is of course the assumption 
that the alloantibody response is T cell dependent. By using MHC class II 
deficient recipients, Steele has demonstrated that a limited IgM alloantibody 
response can develop in the absence of help from recipient CD4 T cells, but that 
isotype switching required cognate T cell help (296). Agarwal has similarly 
documented that the process of isotype switching is determined by T cell 
availability (302, 303). Nevertheless, an alloantibody response restricted to the 
IgM isotype can still theoretically activate complement to the extent necessary to 
compromise graft survival. The results from my experiments, that an IgG2b 
response developed to the soluble RT1.A3 protein and, most importantly, that CD4 
T cell depletion abrogated the alloantibody response (Figure 3.9) confirms the 
CD4 T cell-dependent nature of the alloantibody response. Anti-CD4 T cell 
treatment results in depletion of approximately only 50% of peripheral CD4 T 
cells (289) and the eventual rejection of heart grafts and the development of an 
alloantibody response presumably reflects recovery of the residual population. In 
contrast anti-CD8 treatment resulted in profound CD8 T cell depletion (-99% ) but 
had no discernible effect on graft survival.
Whereas rapid rejection (within 1 to 2 days) is generally considered to be antibody 
mediated, the mechanisms responsible for the modest acceleration following 
allopeptide priming were not assessed. Peptide immunisation accelerated the 
kinetics of the antibody response to the heart graft (Figure 3.3). This suggests that 
peptide primed T cells (recognising the same peptide/self MHC class II complex 
as presented by R Tl.A a-specific B cells) provide cognate B cell help for the 
generation of an alloantibody response, and that the availability of T cell help is 
the rate limiting factor in the development of this response. Although the more
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rapid cytotoxic alloantibody response following peptide priming (first detectable 
by day four after heart grafting) correlated with the kinetics of accelerated 
rejection (MST day 4, Table 3.1) histological examination of the rejected hearts 
was not performed.
Nevertheless, a feature of the experimental work of this thesis is how closely the 
alloantibody response to the RT1.A3 antigen corresponds to the rejection of 
PVG.R8 heart grafts, whether in the accelerated rejection following pcmu-tAa 
plasmid priming, or in the delayed rejection following anti-CD4 mAb treatment. 
Consequently, rejection in unmodified, and not just peptide-primed recipients, is 
possibly alloantibody-mediated. This has been previously suggested, based on 
experiments involving the passive transfer of immune serum (289), and more 
recently, on the observation that B cell tolerance is involved in the prolongation of 
graft survival (409). If so, the histological appearances of cellular rejection in 
PVG.R8 heart grafts from unmodified PVG.RTT recipients (Figure 3.7) are 
simply a marker for activation of the alloimmune response, but are not 
representative of the alloantibody response that is main effector mechanism 
responsible for rejection. Certainly, the presence of cellular infiltrates within a 
graft does not necessarily correlate with rejection (410). However, the possibility 
that indirectly primed CD4 T cells may effect the rejection of PVG.R8 grafts in 
PVG.RT1U recipients through other mechanisms, such as the initiation of a DTH 
response within the graft (249-251), has not been excluded.
The alloantibody response to the product of the vector encoding the truncated 
RT1.A3 heavy chain (pcmu-tA3) was of a similar magnitude in Lewis and 
PVG.RT1U rats (Figure 3.10), but the kinetics of graft rejection were markedly 
different (Table 3.2 vs. Table 3.4). Knechtle et al have also administered RT1.A3 
encoding plasmid to Lewis recipients and have found a similarly modest 
acceleration in the rejection of A3-bearing heart grafts (411). The difference in 
rejection times is surprising, for the passive transfer of anti-A3 hyperimmune 
serum to Lewis recipients has been previously documented to result in hyperacute 
rejection of DA (R T l3) hearts (412). In this latter study hyperimmune serum was 
prepared by performing three serial skin grafts and 6mls of serum was 
administered, which presumably represents a much greater antibody titre than was
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achieved with the protocol for plasmid injection used in my experiments. A 
possible explanation therefore for the differences between plasmid-primed 
PVG.RT1U and Lewis rats in the rejection kinetics of Aa-bearing heart grafts is 
that for a given alloantibody concentration, the antibody-dependent effector 
mechanisms are triggered less efficiently in Lewis rats. In support of this 
hypothesis, complement, which is the most likely mediator through which 
alloantibody effects rejection, has been demonstrated to have inherently different 
levels of activity in different rat strains (413). For example, the passive transfer of 
lml hyperimmune serum into the naive recipient of a high responder strain 
combination resulted in hyperacute rejection, whereas in a low responder 
combination (Lewis recipient) led to graft enhancement. In the low responder 
strain combination, however, hyperacute rejection was restored if guinea pig 
complement was administered along with the hyperimmune serum. It would be 
interesting to examine whether the concurrent administration of guinea pig 
complement to those Lewis recipients that had been primed with the plasmid for 
the soluble R Tl.A a antigen would result in as rapid a rejection as occurred in the 
Aa-plasmid primed PVG.RT1U recipients of PVG.R8 heart grafts.
The results from my experiments and those of Knechtle (411) suggest that the 
rejection o f DA hearts by Lewis recipients is instead effected by the cytotoxic 
CD8 T cell, rather than by the humoral response. Lewis recipients primed with the 
plasmid construct for the full-length, membrane bound RTl.A a antigen failed to 
develop a strong alloantibody response, yet rejection was if  anything more rapid 
than in those animals that expressed high levels of anti-Aa alloantibody following 
priming with the plasmid for the truncated antigen (Table 3.4 and Figure 3.10). 
The cytotoxic CD8 T cell response to the product of the Aa-encoding pcmu 
plasmid constructs was not assessed but Geissler has used similar Aa plasmids and 
in his experiments an anti-Aa cytotoxic CD8 T cell response was detectable only 
in Lewis rats immunised with the plasmid construct for the full-length R Tl.A a 
antigen (411), and not in those immunised with the truncated version. The 
hypothesis that the cytotoxic CD8 T cell response is more pivotal in the Lewis rat 
could be tested by antibody depletion studies and one would expect that, in 
contrast to the R8-RT1U strain combination, CD8 T cell depletion would abrogate 
the accelerated rejection associated with plasmid priming.
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3.4 Summary
The physical nature of the R Tl.A a antigen with which PVG.RT1U rats were 
immunised significantly influenced the rate of rejection of PVG.R8 heart grafts. 
Priming with a PVG.R8 skin graft stimulates an IgG2b cytotoxic alloantibody 
response and resulted in rejection of an R8 heart graft within 24 hours. Priming T 
cells for indirect recognition with allopeptides corresponding to the a l  and a2 
domains of the RT1.A3 heavy chain did not result in the development of an anti- 
Aa antibody response and R8 hearts were rejected only modestly more rapidly. 
Crucially, intramuscularly injection with plasmid encoding a water soluble 
version of the R Tl.A a heavy chain (pcmu-tAa) was associated with a strong anti- 
Aa alloantibody response and similar rejection kinetics of PVG.R8 heart grafts as 
occurred in animals primed with a skin graft. T cell recognition of soluble class I 
allo-MHC is theoretically restricted to the indirect recognition of allopeptide 
fragments presented by recipient APC. The absence of a direct CD8 T cell 
response was confirmed by T cell antibody depletion studies and the lack of in 
vitro cytotoxic killing. Histological examination of the heart grafts from pcmu- 
tAa-primed recipients verified that rejection was antibody mediated. These results 
suggest that soluble class I allo-MHC is a more effective immunogen than 
allopeptide because it displays the appropriate conformational B cell epitopes for 
the development of humoral immunity directed against intact MHC on donor 
cells, and not because of any inherent differences in the nature of helper T cell 
recognition. Surprisingly, although Lewis animals that had been similarly primed 
with pcmu-tAa plasmid developed an equally strong anti-Aa alloantibody 
response, rejection of Aa-bearing heart grafts was much less rapid. This possibly 
reflects strain-specific differences in the levels of complement activity.
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3.4 Materials and methods
3.5.1 Animals
Animals were purchased and maintained as described in Section 2.5.3.1
3.5.2 Antibodies
MRC 0X8 (anti-rat CD8) (254) and MRC 0X38 (anti-rat CD4) (414) monoclonal 
antibodies were used for in vivo T cell depletion studies. These were produced by 
intraperitoneal injection of the appropriate hybridoma cell line into pristane- 
primed Balb/c mice (Harlan, UK) to produce ascites, from which IgG was purified 
by protein A column chromatography (ProSep, Fisher Scientific, Loughborough, 
UK). The antibody concentration was determined by UV spectrophotometry. The 
0X 8 and 0X38 mAb treatment regimens used to induce blockade of the CD8 and 
CD4 T cell subsets, respectively, were based on experience with these Abs in 
previous studies (290, 355). The mouse IgG2a mAb, ESH8, which is directed 
against human factor VIII (Scottish Antibody Production Unit, Law, Scotland, 
UK), was used as an isotype control (400).
3.5.3 Allopeptides and Allopeptide Immunisation
A series of 18 synthetic 15-mer peptides, overlapping by 5 amino acids, and 
spanning the otl and a2 domains of the rat classical class I MHC molecule RTl.A a 
(residue 28 [glycine] to residue 212 [phenylalanine] inclusive, (39)), were purchased 
from Immune Systems Ltd. (Paignton, UK). A control peptide (designated 
irrelevant) was also manufactured. This contains the same amino acids as peptide 
number 7, which corresponds to the hypervariable region of the a l  domain, but in a 
random order. All peptides were synthesised by FMOC chemistry, purified by 
HPLC, and assessed by Mass Spectrometry for purity. All peptide preparations were 
shown to be greater than 80% pure. The peptide sequences are depicted in Table 3.5.
PVG.RT1U rats were immunised subcutaneously in each hind footpad with a single 
injection of 900pg of allopeptide (comprising a mixture of 50pg of each of the 18 
individual allopeptides), dissolved in 50pl of water and emulsified with a
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comparable volume of CFA (Sigma). lOOpg of irrelevant peptide emulsified in CFA 
was administered as control.
P E P T I D E S E Q U E N C E P O S I T I O N
PI G S H S L R Y F Y T A V S R P 25-39
P2 A V S R P G L G E P R F I A V 35-49
P3 R F I A V G Y V D D T E F V R 45-59
P4 T E F V R F D S D A E N P R M 55-69
P5 E N P R M E P R A R W M E R E 65-79
P6 W M E R E G P E Y W E Q Q T R 75-89
P7 E Q Q T R I A K E W E Q I Y R 85-99
P8 E Q I Y R V D L R T L R G Y Y 95-109
P9 L R G Y Y N Q S E G G S H T I 105-119
P10 G S H T I Q E M Y G C D V G S 115-129
Pll C D V G S D G S L L R G Y R Q 125-139
P12 R G Y R Q D A Y D G R D Y I A 135-149
P13 R D Y I A L N E D L K T W T A 145-159
PI 4 K T W T A A D F A A Q I T R N 155-169
PI 5 Q I T R N K W E R A R Y A E R 165-179
PI 6 R Y A E R L R A Y L E G T C V 175-189
P17 E G T C V E W L S R Y L E L G 185-199
P18 Y L E L G K E T L L R S D P P 195-209
Irrelevant Y A Q W E I Q K E R E R Q T I N/A
Table 3.5 The amino acid sequences of the 15-mer synthetic peptides
Peptide sequences begin at amino acid residue number 25, as the amino acids 
preceding this represent the signal sequence, which is cleaved during final transit of 
the nascent MHC through the endoplasmic reticulum.
3.5.4 Plasmid Administration
Gene transfer of the DNA sequences encoding the RTl.A a heavy chain was 
achieved by directly injecting plasmid DNA into the skeletal muscle of adult rats 
(374). To induce regeneration of plasmid DNA into skeletal muscle and thereby 
increase the efficiency of gene transfer (403, 404), 400pl of 0.5% Bupivicaine (1- 
butyl-N[2, 6-dimethyl phenyl] 2-piperidine-carboxamide) (Astra, King's Langley, 
UK) was first injected into each tibialis anterior muscle using a 28-gauge needle. 
Three and eight days later, 200pg of pcmu-IV encoding either the full-length or 
truncated nucleotide sequence of the RTl.A a heavy chain was injected into each 
tibialis anterior muscle. As control, empty pcmu-IV plasmid was administered.
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3.5.5 Cardiac Transplantation
Donor Heart Retrieval
The donor rat was anaesthetised by continuous halothane inhalation. A midline 
incision was used to expose the inferior vena cava (IVC), into which 400 units of 
heparin (CP Pharmaceuticals Ltd., Wrexham, UK) was injected using an insulin 
syringe (Becton Dickinson). The aorta was transected and the animal 
exsanguinated. A thoracotomy was immediately performed, and cardioplegia 
achieved by packing the thoracic cavity with ice. The operating field was 
visualised using an operating microscope (Wild Heerbrug, Switzerland) at xlO 
magnification, and the heart and great vessels were dissected free from the 
surrounding connective tissue, and the aorta, pulmonary artery and great veins 
were identified. The right superior vena cava (SVC) and IVC were ligated with 5° 
silk sutures (Ethicon Ltd., UK) and divided flush at their junction with the right 
atrium. Similarly, the left SVC and the azygous vein were ligated and divided at 
their common insertion into the left atrium. The ascending aorta was divided 
proximal to its first division. Finally, the pulmonary veins draining into the back 
of the heart were ligated as a pedicle, and the heart removed by dividing between 
this tie and the posterior mediastinal structures.
Recipient Transplantation
Heterotopic cardiac transplantation was performed using the modified technique 
of Ono and Lindsey (415). Recipient rats were anaesthetised by continuous 
halothane inhalation. A midline abdominal incision was made, and the intestines 
displaced and wrapped in a saline-soaked swab. The aorta and IVC were exposed, 
cleared of surrounding connective tissue, and a length of approximately 5mm of 
each vessel cleared of any tributaries or branches, to allow haemostatic control by 
the application of a proximal and distal occlusion clamp. The operating field was 
visualised through an operating microscope at x l6  magnification, and a 3mm 
arteriotomy and venotomy were fashioned in the recipient’s aorta and IVC 
respectively. Thereafter, continuous end to side anastomosis of the donor aorta to 
the recipient aorta was performed using a 9° nylon suture (Ethicon Ltd.). A similar 
technique was used to anastomose the donor pulmonary aorta to the recipient
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IVC. During anastomosis, the donor heart was kept cool by the application of a 
gauze swab to which cold saline was intermittently applied. Upon completion, the 
clamps were slowly removed and any haemorrhage from the suture line controlled 
by a combination of pressure and the application of haemostatic alginate 
(Surgicel, Ethicon Ltd). Cold ischaemic times for the heart ranged from 30 to 40 
minutes. On confirmation that the heart had begun to beat, the intestinal contents 
were replaced, and the wound closed in two layers with continuous 3° vicryl 
sutures (Ethicon Ltd.). Grafts were assessed daily by palpation, and rejection was 
defined as the complete cessation of myocardial contraction.
3.5.6 Skin Transplantation
Recipients were grafted on the flank with full thickness PVG.R8 skin allografts as 
previously described (275). Briefly, anaesthetised RT1U animals were grafted onto 
the flank with 1cm2 full thickness R8 abdominal skin, secured by four 4° sutures 
(Ethicon Ltd) applied at the corners of the graft. Wounds were dressed with a 
saline-soaked swab, held in place with sleek tape. Dressings were removed after 4 
days, and the grafts assessed daily. Rejection was defined as 50% necrosis of the 
graft.
3.5. 7 Cytotoxic Alloantibody Determination
Lymphocytotoxic antibodies were determined by assaying test serum against 51Cr- 
labelled R8 ConA blasts in the presence of guinea pig complement as described in 
section 2.5.3.5.
3.5.8 Cell-Mediated Cytotoxicity Assays
PVG.RT1U rats were grafted with PVG.R8 skin (Section 3.5.5) or immunised with 
plasmid vectors (Section 3.5.4) encoding either of the RT1.A3 heavy chain 
constructs (pcmu-A3 or pcmu-tA3) or with pcmu-IV (empty vector). After 12 days, 
purified spleen cells (Section 2.5.3.3) were used as effector cells and assayed 
against 5ICr-labelled allogeneic R8 Con A blast targets in a standard 6 hour Cr- 
release assay (416). Briefly, two fold serial dilutions of effector cells were made 
to give effector: target cell ratios of 100:1, 50:1, 25:1, 12.5:1, 6:1, and 3:1. Equal 
volumes (75pi) of effector and target cells were mixed in wells of 96 V-well
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microtitre plates (Sterilin, Teddington, UK), with each combination set up in 
triplicate. Spontaneous release was determined using target cells incubated 
without effector cells, and maximum release was determined using target cells 
incubated with 10% Triton x 100 (Sigma). The plates were centrifuged briefly, 
then incubated for 6 hours at 37°C in 5% CO2  in air. From each well, 75pl of 
supernatant was harvested and the amount of released isotope determined using a 
Compugamma counter (LKB, Milton Keynes, UK). Specific 51Cr release was 
calculated by the formula:
Experimental Release -  Spontaneous Release
----------------------------------------------------------  X 100
Maximum Release -  Spontaneous Release.
4 x 107 LNC from RT1U animals immunised with either an R8 skin graft or the 
truncated RT1.A3 plasmid vector were additionally cultured for a further 5 days in 
vitro against 2 x 107 irradiated (20Gy) DA splenic lymphocytes in 20mls tissue 
culture medium in 25cm2 tissue culture flasks (Nunclon). The influence of the 
initial in vivo challenge with Aa antigen on the in vitro generation of cytotoxic T 
cells was assessed by assaying against 5lCr-labelled allogeneic Con A blasts as 
described above.
3.5.9 Histological Examination o f  Rejected Hearts
Upon rejection, the animals were sacrificed and the hearts excised and preserved 
in 10% formal saline solution. After embedding in paraffin wax, the grafts were 
sectioned (5p,m), and stained with haemotoxylin and eosin by the Department of 
Pathology, Western Infirmary, Glasgow.
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CHAPTER FOUR
DISCUSSION
Transplant models in which the donor and recipient share either class I or class II 
MHC loci have been pivotal in the elucidation of the principle that CD8 and CD4 
T cells effect rejection through the recognition of MHC class I and class II 
antigens respectively. The role however, of CD4 T cells in the rejection of class I 
MHC disparate grafts has not been clarified, as different models have 
demonstrated that their participation is variable. This ranges from having no 
involvement (262, 266, 268), to providing essential help for the generation of a 
cytotoxic CD8 T cell response (275, 417), and to even effecting graft rejection 
autonomously (269, 290, 418).
The ability of the CD4 T cell population alone to effect rejection of MHC class I 
disparate grafts remains a particular puzzle and several mechanisms have been 
proposed (406). These include MHC class II restricted CD4 CTL (418), MHC 
class I restricted CD4 CTL (316, 419), the activation of eosinophils (420), the 
initiation of a DTH response within the graft (250), and finally, the provision of B 
cell help for the development of an alloantibody response (290, 297, 399). In the 
latter model, Bradley and colleagues proposed that B cell help is provided by self­
restricted CD4 T cells that recognise peptide epitopes of the MHC class I 
alloantigen. Their observations thus highlight the importance o f the indirect 
pathway of allorecognition in effecting graft rejection. Nevertheless the 
hypothesis that CD4 T cells recognise additional antigenic disparities has not been 
conclusively disproved (297), and is supported by the observed discrepancies in 
the rejection kinetics of heart grafts following priming with either allopeptide or 
donor cells (245). The experiments detailed in this thesis therefore provide 
conclusive evidence that rejection can occur when T cell activation is restricted to 
the indirect pathway and demonstrate for the first time that this is equally 
applicable to the process of accelerated rejection.
Of the proposed mechanisms by which indirectly restricted CD4 T cells mediate 
allograft rejection autonomously, it is likely that the provision o f B cell help is 
unique in effecting rapid rejection since the generation of alloantibody directed
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against intact alloantigen permits donor cells to be targeted specifically. 
Otherwise, since indirectly restricted CD4 T cells cannot respond to intact donor 
antigen, they can only damage graft cells through non-specific bystander 
mechanisms. Priming indirectly-restricted CD4 T cells to accelerate graft rejection 
through, for example a DTH response, is dependent upon the recipient APC first 
infiltrating the graft and then processing and presenting donor antigen. Recipient 
APC infiltration into the graft is likely to take several days and perhaps explains 
why in all studies to date allopeptide priming results in either no, or in only 
modest, acceleration of graft rejection (244-246, 248).
CD4 T cells can also effect the rejection of MHC class I disparate grafts by 
providing help for the development of an alloMHC class I-restricted cytotoxic 
CD8 T cell response. Although it was initially suggested that the presence of 
additional helper determinants on the surface of the donor cell was required for 
CD4 T helper cell activation (the direct pathway) (263), Auchincloss, using MHC 
class II-deficient donors, has unequivocally demonstrated that effective help can 
also be provided by indirectly restricted CD4 T cells (279, 280). The provision of 
such indirect T cell help for priming allocytotoxicity is therefore analogous to the 
priming of humoral effector mechanisms as described in this thesis, in that an 
optimum response relies on a synergistic relationship between the direct 
recognition of intact allogeneic MHC class I by the effector cell (either the CD8 T 
cell or B cell) and the indirect recognition of the allogeneic MHC class I by the 
CD4 helper T cell. Auchincloss’ (279, 280) and my experiments therefore 
emphasise that the requirement for the presence of intact allo-MHC to prime 
potent effector mechanisms does not preclude a pivotal role for the indirect 
pathway in their development.
The experimental work of this thesis was modelled on the PVG.R8 to PVG.RT1U 
rat strain combination as this is ideal for studying the T cell allorecognition 
pathways responsible for the provision of B cell help. It nevertheless remains an 
anomaly and it is necessary to explain why, in comparison to other MHC class I 
disparate models, the alloantibody, and not the cytotoxic CD8 T cell, response 
predominates. The conventionally-held view that CD8 T cells alone were 
responsible for the rejection of class I disparate grafts was, however, based on
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studies examining skin graft rejection in class I mutant mouse strains (262, 263, 
266) and this model is no longer considered representative. The CD8 T cell subset 
in the class I mutant mouse strains secretes 11-2 and is consequently capable of 
providing endogenous help for the generation of a cytotoxic T cell response. CD8 
T cells in most other species, particularly in humans, do not display this property, 
and the requirement for CD4 T cell activation, at least to provide CD8 T cell help, 
is more stringent (270). The lack of contribution of the CD4 T cell subset to 
rejection in the mutant mouse strains is alternatively explained by the observation 
that the donor and recipient class I alleles differ by only a few amino acids. 
Processing of the allogeneic class I MHC molecule by recipient APC may not 
therefore result in the presentation of immunogenic class II restricted peptide 
epitopes (406).
The amino acid differences between the donor RT1.A3 allele and the recipient 
RT1.AU allele are comparatively more extensive. Immunisation with the RT1.A3 
antigen results in the development of a self-restricted CD4 T cell response 
directed against epitopes derived from these differences (E. Lovegrove 
submitted). In this model indirectly restricted CD4 T cells appear to effect 
rejection through the provision of B cell, rather than CD8 T cell help. That 
cytotoxic T cell killing was detected following either skin grafting or 
immunisation with the plasmid construct for the full-length, membrane-bound 
RT1.A3 antigen (Figure 3.5) suggests that a CD8 T cell response does occur 
during allograft rejection, but that its contribution is masked by the strength of the 
alloantibody-mediated effector mechanisms.
It is nevertheless possible that the predominance of the alloantibody response, 
rather than being an intrinsic feature of the PVG.R8 strain’s immune system, 
reflects particular characteristics of the DNA-based immunisation protocol, that 
the adjuvant effect of DNA polarises the T cell response to favour the provision of 
help for B cells, and not cytotoxic CD8 T cells (382). As discussed in Section 3.3 
however, the mechanisms responsible for accelerated rejection in plasmid- 
immunised Lewis rats appear to centre on the cytotoxic T cell response, rather 
than the alloantibody response. This suggests that rejection in the R8 strain is 
antibody-mediated either because of a relative ineffectiveness of the CD8 T cell
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response or because of more efficient complement activity (413, 421), and that 
this is a strain-specific, rather than a plasmid-specific, effect.
There is yet a further explanation as to why the CD4 T cell and alloantibody 
responses appear so strong in the PVG.R8 to PVG.RT1U strain combination and 
this concerns the shared nature of the MHC class II antigen. This theoretically 
permits CD4 T cell help to be generated by a unique 3-cell cluster model, which 
differs from the original description by Kelly (292), in that CD4 T cells 
recognising the peptide/class II MHC complex on the surface of the donor APC 
may provide cognate B cell help (Figure 4.1). This could only occur if the class II 
MHC on donor cells were to present a similar spectrum of RT1.A3 peptide 
epitopes (derived from endogenous processing) as would be presented by the 
recipient APC upon exogenous processing of the RT1.A3 antigen. Certainly, 
membrane proteins are recycled into the class II processing pathway (185) and 
peptides derived from self MHC class I antigen have been eluted from MHC class 
II (228), but the recombinant PVG.R8 strain in particular may display a 
preponderance of MHC class II-associated RT1.A3 peptides as a result of 
incompatibilities at the TAP transporter. The RT1.A3 antigen has a high binding 
affinity for peptides with an hydrophobic C-terminal residue, but the TAP2-B 
haplotype of the PVG.R8 rat is particularly poor at transporting such peptides into 
the endoplasmic reticulum (130). The resulting surfeit of empty, unstable RT1.A3 
molecules would undergo degradation in the endoplasmic reticulum and could 
enter the class II processing pathway either through transfer into the lysosomal 
system (422) or by re-routing from the cytoplasm (230, 231). The strongest 
argument against such a cognate 3-cell cluster model is provided by the 
beneficial, not detrimental, influence that class II MHC sharing has on human 
allograft survival. This hypothesis could nevertheless be tested by assessing the 
influence on the alloantibody response that altering, by perhaps incorporating a 
permissive TAP haplotype, the spectrum of peptides that is presented by donor 
PVG.R8 class II MHC.
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Figure 4.1 Cognate three-cell cluster due to shared class II MHC
The presence o f shared MHC class II on the recipient B cell and donor APC 
permits the formation of, assuming that both cells present similar class I 
allopeptide, a unique cognate 3 cell cluster that incorporates the recipient CD4 T 
helper cell (Th)
BCR B cell receptor.
TCR T cell receptor.
Thus, despite the strong alloantibody response that characterises the rejection of 
PVG.R8 grafts in PVG.RT1U hosts being dependent upon CD4 T cell recognition 
of allo-MHC class I peptide fragments, the possibility that T cell activation occurs 
through recognition of the shared MHC class II on the surface of donor APC 
prevents definitive conclusions as to the precise mechanisms by which T cells 
provide B cell help. Similarly, although the results from my thesis highlight the 
role of indirect T cell activation in the development of an alloantibody response, 
they do not necessarily infer that T cell help for the development of the initial 
alloantibody response to a vascularised allograft is exclusively provided by 
indirectly restricted CD4 T cells co-operating in a four cell cluster (296). The 
alternative three-cell cluster model, involving directly-restricted T cells, was 
proposed to explain why the initial anti-MHC class I alloantibody response was 
dependant upon the presence of donor MHC class II antigens (281, 292); the two 
models are distinguished not on their exclusive ability to provide B cell help but 
rather on the kinetics of the alloantibody response that they are responsible for 
generating. This difference was not addressed in this thesis because priming with 
soluble MHC class I alloantigen polarised available T cell help to the indirect 
pathway and animals were only challenged with a heart graft after the
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alloantibody response to the soluble protein had developed. Nevertheless, the 
kinetics of the alloantibody response to the product of the soluble, pcmu-tAa 
vector were similar to the response to a PVG.R8 heart graft (cf. Figures 2.12 and 
3.4), which suggests that indirectly restricted CD4 T cells can mediate the 
development of the early alloantibody response. Uncertainties regarding the rate 
at which protein is expressed following plasmid DNA injection, however, prevent 
definitive comparison. It is more reasonable to conclude that indirectly restricted 
CD4 T cells can effect accelerated rejection, not that they are necessarily 
responsible for the initial alloantibody response. Additional experiments, such as 
the use of class II deficient recipients or reconstitution of nude animals with 
peptide-specific T cell clones, would have to be performed in order to assess the 
contribution of each model to the development of the primary alloantibody 
response to a vascularised allograft.
A valid criticism of the experimental work of this thesis is the difference in the 
physical characteristics of the immunising agents that were administered; i.e. the 
soluble RT1.A3 protein was administered as a DNA vaccine, whereas the Aa 
peptides were administered as synthetic protein. They should have ideally been 
administered either both as DNA vectors or both as recombinant protein. Indirect 
T cell priming to the RT1.A3 alloantigen could have been achieved using a DNA- 
based approach by excising the leader signal of the DNA sequence for the RT1.A3 
heavy chain. This would prevent trafficking through the endoplasmic reticulum to 
the cell surface (423), and instead the nascent class I protein would be degraded to 
peptide fragments within the cell. Likewise heavy chain, P2 M and peptide could 
have been produced using recombinant techniques and folded ex vivo to produce 
MHC class I alloantigen that displayed the appropriate conformational B cell 
epitopes (424). The availability of isolated heavy chain would also permit its 
administration as a means of fully priming the indirect pathway, for it would 
contain the necessary amino acid sequences for the generation of optimum CD4 T 
cell epitopes but its tertiary structure would not display the appropriate B cell 
epitopes for the development of humoral alloimmunity. It is however unlikely, as 
discussed in section 3.3, that either of these approaches would have altered the 
results or their interpretation.
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One may also contend that the experiments in this thesis are ultimately no more 
informative than the earlier demonstration that the passive transfer of 
hyperimmune serum results in accelerated rejection (246, 355), since 
immunisation with soluble MHC class I alloantigen would be expected to result in 
the development of an alloantibody response. Surprisingly, the results in this 
thesis are the first to demonstrate an unequivocal primary alloantibody response to 
soluble allo-MHC. To date the responses have been undetectable (330, 331), 
unpredictable (351), or fail to develop until the eighth week (292). Although the 
effect on graft survival is similar, immunising with soluble protein moreover 
differs, from the administration of hyperimmune serum, in that it additionally 
permits examination of the T cell allorecognition pathways that are involved in 
the provision of B cell help.
The uniquely strong alloantibody response also explains why my experiments are 
the first to demonstrate accelerated rejection following priming with soluble MHC 
class I alloantigen. Soluble MHC has in fact generally been proposed as a potent 
immunoregulatory agent. In vitro experiments demonstrate that it exerts its effects 
by interacting directly with the alloreactive CD8 T cells to block cytotoxic activity 
and induce apoptosis (321, 333, 338). These effects appear to be dependent on the 
ability of multimeric forms of MHC class I to cross-link the TCR (321, 333, 338) 
and earlier conflicting reports on the in vivo use of soluble MHC class I 
alloantigen probably reflect differences in the physical characteristics of the class 
I alloantigen that was administered (328-331). More recent in vitro experiments 
have, however, demonstrated that monomeric soluble MHC class I can induce 
apoptosis in alloreactive CD8 T cells, albeit at a concentration five times greater 
than that required with multimeric forms (321, 425). In addition, the injection of 
syngeneic hepatocytes expressing monomeric soluble MHC class I alloantigen has 
now been reported to prolong allograft survival (352). In my experiments 
injection of the pcmu-tAa vector had no demonstrable influence on the cytotoxic 
CD8 T cell subset (Figure 3.6). This is probably a consequence of the monomeric 
nature of its’ product (the hydrophobic transmembrane and cytoplasmic domains 
have been removed) and of the relatively limited levels of RT1.A3 protein that are 
released following naked DNA injection, such that effective cross-linking of the 
TCR of the CD8 T cell did not occur. CD8 T cell inhibition may perhaps have
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occurred if an alternative vector system, that achieved higher levels of soluble 
class i protein expression, had been used. Nevertheless, my results demonstrate 
that the potential benefits of administering soluble alloMHC class I, even with its 
dose and valency optimised to achieve maximal inhibition of the direct CD8 T cell 
response, may be negated by the associated indirect T cell response, which in the 
presence of intact donor class I MHC may generate powerful effector mechanisms 
directed against donor graft cells.
In summary, the results from this thesis suggest that the indirect pathway may be 
more important in effecting graft rejection than is currently appreciated. This may 
be clinically relevant, for although the indirect pathway has become increasingly 
prominent over the last decade, it is currently perceived as being more relevant to 
the process of chronic rejection, because in this situation allorecognition occurs 
predominantly through the recipient APC. The demonstration that the indirect 
pathway may be an integral component in the development of effector 
mechanisms that directly target intact donor antigen suggests that it may be 
equally pivotal in effecting acute graft rejection. This is especially so, given that 
the role of alloantibody in effecting acute and chronic rejection has probably been 
undervalued (426). The recent inclusion of alloantibody-mediated rejection as a 
separate classification of the Banff criteria for renal allograft rejection (427) 
suggests that its contribution to clinical transplantation, and consequently, that of 
the indirect pathway’s, will be reassessed. This has practical, and not just 
theoretical, implications in that tolerogenic strategies specifically targeting the 
indirect pathway may have a useful clinical role. Intrathymic injection of 
allopeptide has, in animal models, achieved indefinite survival o f completely 
mismatched grafts (312), suggests that tolerance induced to the indirect pathway 
may be powerful enough to overcome the influence o f T cell activation via the 
direct pathway. Moreover, only limited donor allopeptide sequences may need to 
be administered, for the indirect T cell response appears to focus upon only one or 
two dominant determinants (428). Antigen-specific tolerance remains the ultimate 
goal of transplantation, because this would avoid the complications of infection 
and malignancy that are associated with current clinical immunosuppressive 
protocols. Strategies that target the indirect pathway may represent a novel means 
of achieving this goal.
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